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Abstract 
 
Neuroblastoma is a cancer of the sympathetic nervous system derived from neural 
crest cells that fail to differentiate during development. Neuroblastoma tumours and 
cell lines are heterogeneous, comprised of ‘neuroblastic’ N-type cells, precursors to 
a neuronal neural crest cell lineage and ‘substrate-adherent’ S-type cells, precursors 
to a non-neuronal neural crest cell lineage. Retinoids, such as retinoic acid (RA), 
cause both N- and S-type cells to switch from proliferation to differentiation. This 
underlies the use of RA in the treatment of neuroblastoma disease. The aim of this 
study was to investigate the role of Ca
2+
 signalling in the process of differentiation. 
 
N- and S-type cell populations were enriched from the SH-SY5Y neuroblastoma 
cell line to allow characterisation of Ca
2+
 signalling and differentiation within the 
two cell phenotypes. The RA-induced switch from proliferation to differentiation 
was accompanied by a down-regulation in store-operated Ca
2+
 entry (SOCE) in N-
type cells but not in S-type cells. In N-type cells expression of the ER Ca
2+
 sensor 
protein STIM1 and the channel protein Orai1 also became down-regulated, whilst 
expression of the channel protein TRPC1 became up-regulated. Knockdown of 
STIM1 and Orai1 in proliferating N-type cells down-regulated SOCE. Knockdown 
of Orai1, but not STIM1, induced differentiation and also enhanced differentiation 
induced by RA. Overexpression of STIM1 and Orai1 in RA-differentiated cells 
restored SOCE and reduced the extent of differentiation. Knockdown of TRPC1 had 
no effect on SOCE or differentiation in proliferating N-type cells but reduced the 
extent of SOCE down-regulation and differentiation induced by RA. These 
observations suggest that Orai1 may be a negative regulator of differentiation in N-
type cells whereas STIM1 down-regulation may be required to maintain the 
differentiated state. TRPC1 expression may be required for a fully functional 
differentiated phenotype. These proteins could represent putative drug targets in the 
multi-modal treatment of neuroblastoma disease. 
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1.1 Neuroblastoma 
Neuroblastoma is a cancer of the sympathetic nervous system (SNS) derived from cells 
of the neural crest (Brodeur et al., 1997; Goodman et al., 1999). Neuroblastoma is the 
most common cancer in infancy (Gurney et al., 1999) and accounts for 15% of all 
paediatric oncology deaths (Maris et al., 2007). 90% of neuroblastoma cases are 
diagnosed in patients under the age of 5 (Maris et al., 2007). 
 
In the developing embryo neural crest cells migrate and separate into several distinct 
cell lineages (Ciccarone et al., 1989; Ross et al., 2003; Nakagawara et al., 2004; Walton 
et al., 2004). The sympathoadrenal cell lineage of the neural crest gives rise to 
sympathetic neurones of the SNS and neuroendocrine chromaffin cells of the adrenal 
medulla (Ciccarone et al., 1989). In neuroblastoma, for unknown reasons, cells derived 
from the sympathoadrenal cell lineage fail to differentiate. Tumours predominantly 
consist of immature nerve cells (i.e. neuroblasts) and are most commonly found in the 
adrenal gland, though they can also be found in the nerve tissues of the spine, chest, 
neck and pelvis (Ishola et al., 2007). 
 
One of the most significant prognostic factors in neuroblastoma is age. The 5-year 
survival rate from diagnosis in infants (under the age of 1) is 83%, in patients 1-4 years 
old is 55% and in patients aged 5 years and above is 40% (Goodman et al., 1999). 
Neuroblastoma is unique as advanced metastatic disease can spontaneously regress or 
mature into benign ganglioneuromas, particularly in infants (Brodeur, 1995).  
 
50% of neuroblastoma patients are classed as high-risk (Maris et al., 2007). The 5-year 
survival rate for high-risk patients is only ~30% (Cotterill et al., 2001; Mertens et al., 
2001). High-risk patients may receive chemotherapy with the retinoid 13-cis-retinoic 
acid (Matthay et al., 1999, 2009). RA treatment of neuroblastoma induces 
differentiation and inhibits proliferation (Sidell, 1982). This effect underlies the use of 
RA in the treatment of neuroblastoma today (Matthay et al., 1999, 2009; Reynolds et 
al., 2003).  
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1.2 Heterogeneity in neuroblastoma tumours and cell lines 
Cellular heterogeneity is a characteristic of both neuroblastoma tumours and their 
derived cell lines (Biedler et al., 1973, 1975; Ross et al., 1983, 1995, 2003, 2007; 
Ciccarone et al., 1989; Walton et al., 2004). Three morphologically and biochemically 
distinct cellular phenotypes have been identified; these are N-type, S-type and I-type 
cells (Ciccarone et al., 1989; Ross et al., 1995, 2003).  
 
The ‘neuroblastic’ N-type cells have small round cell bodies, scant cytoplasm and 
several short neuritic like processes. They are weakly substrate adherent in culture and 
attach better to each other than to substrate and therefore form cell aggregates 
(pseudoganglia) (Biedler et al., 1973; Walton et al., 2004). The N-type cells display 
neuronal properties such as expression of neurotransmitter enzymes (Biedler et al., 
1973, 1978; Ross et al., 1983), catecholamine uptake and the presence of neurofilament 
proteins (Ciccarone et al., 1989). They also display neuroendocrine properties as they 
contain chromogranin A which is characteristic of adrenal medulla cells (Ciccarone et 
al., 1989; Ross et al., 2003). The presence of neuronal and neuroendocrine properties is 
consistent with the concept that N-type cells are multipotent precursor cells of the 
sympathoadrenal cell lineage of the neural crest (Ross et al., 1995, 2003, 2007). In 
culture N-type cell lines have been described as ‘immortal’ (Ciccarone et al., 1989). 
 
The ‘substrate-adherent’ S-type cells, originally named E-type for epithelial-like 
(Biedler et al., 1975), are larger and more flattened in appearance with abundant 
cytoplasm and no neuritic processes. These cells are strongly substrate adherent and 
show contact inhibition of growth and therefore grow as monolayers (Biedler et al., 
1973; Walton et al., 2004). S-type cells do not display neuronal properties and instead 
display properties of glial cells, Schwann cells and melanocytes (Ciccarone et al., 1989; 
Ross et al., 1995). The presence of tyrosinase is indicative of melanocytes; stromal 
collagen of glial and Schwann cells and fibronectin and vimentin of all three (Ciccarone 
et al., 1989). The S-type cells display properties of a number of different cell types 
which is consistent with the concept that they are multipotent precursor cells of a non-
neuronal neural crest cell lineage (Ross et al., 1995). In culture S-type cells appear to 
have a limited lifespan and begin to grow extremely slowly and/or stop proliferating 
(Ciccarone et al., 1989; Ross et al., 2007).  
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The ‘intermediate’ I-type cells are intermediate with respect to N- and S-type cells, 
displaying morphological and biochemical features of both cell phenotypes (Ciccarone 
et al., 1989; Ross et al., 1995). As such I-type cells are more difficult to identify and 
were not identified until over ten years later than N- and S-type cells (Cicarrone et al., 
1989). I-type cells are small in appearance, may or may not have neuritic processes and 
have intermediate levels of cytoplasm. They are moderately substrate adherent and grow 
as multilayers that are able to form cell aggregates (Walton et al., 2004).  
 
I-type cells have been hypothesised to be a cancer stem cell as they display the property 
of self renewal and are potentially progenitors of the N- and S- cell phenotypes as they 
express both N- and S- markers (Ross et al., 1995). I-type cells would therefore have 
the capacity to give rise to at least two distinct neural crest cell lineages. In contrast N- 
and S-type cells, although multipotent, appear to be committed to a specific cell lineage 
of the neural crest (Ross et al., 2007). I-type cells could also represent an intermediate 
stage in the transdifferentiation process between N- and S-type cells. N- and S-type cells 
can also transdifferentiate into one another without an intermediate (Ross et al., 1983, 
2003, 2007; Ciccarone et al., 1989) (Figure 1.1).  
 
It has been shown that there is a strong correlation between cell phenotype and 
malignant potential (Piacentini et al., 1996; Matthay et al., 1999). The N-type cell line 
SH-SY5Y has a tumour frequency of 22% in athymic mice while the S-type cell line 
SH-EP1 has a tumour frequency of 0%. In contrast the I-type cell line BE-2-M17 has a 
tumour frequency of 81% and therefore displays the greatest malignant potential. This is 
consistent with the hypothesis that I-type cells are cancer stem cells (Ross et al., 2003). 
It has also been shown that aggressive tumours have higher levels of I-type cells 
(Walton et al., 2004). 
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Figure 1.1 Transdifferentiation between cell phenotypes (Ciccarone et al, 
1989) 
Three possible models explaining the process of cellular transdifferentiation as 
proposed by Ciccarone et al., 1989. A) N- and S-type cells transdifferentiate into one 
another directly (as shown by Ross et al., 1983). B) N- and S-type cells 
transdifferentiate into one another via a transient intermediate, the I-type cell. C) I-type 
cells are progenitors of both N- and S-type cells and N- and S-type cells can 
transdifferentiate into one another directly. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 - Introduction
 
6 
 
1.3 The SH-SY5Y neuroblastoma cell line 
The SK-N-SH neuroblastoma cell line was established in 1970 from a bone marrow 
aspiration of a 4 year old female with metastatic neuroblastoma (Biedler et al., 1973). 
The SK-N-SH cell line is comprised of N- and S-type cells (Biedler et al., 1973) and 
was thrice cloned (SH-SY, SH-SY5, SH-SY5Y) to produce the N-type neuroblastoma 
cell line SH-SY5Y (Biedler et al., 1975; Ross et al., 1983). Evidence of the neuronal 
origin of N-type cells is that cells express tyrosine hydroxylase and dopamine-β-
hydroxylase activity, enzymes that are specific to noradrenergic neurons (Ross et al., 
1983). Although predominately composed of N-type cells, the SH-SY5Y cell line 
remains heterogeneous in nature as N-type cells are able to give rise to S-type cells 
(Biedler et al., 1975; Ross et al., 1983). Neuroblastoma cell lines have been identified 
as prime cell lines for the study of neuronal differentiation (Abemayor & Sidell, 1989). 
The SH-SY5Y cell line was used in the study of Ca
2+
 signalling and RA-induced 
differentiation in this thesis. 
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1.4 Differentiation 
In 1982 Sidell first reported that the retinoid, all-trans-retinoic acid (ATRA), could 
induce growth arrest and differentiation in human neuroblastoma cells. The ability of 
RA to inhibit proliferation and induce differentiation of neuroblastoma cells underlies 
the use of retinoids in the treatment of high-risk neuroblastoma patients (Matthay, 
1999).  
 
1.4.1 Retinoic acid  
Vitamin A (retinol) and its derivatives (retinoic acid) play an important role in the 
regulation of many biological processes, including differentiation, growth, vision, and 
gene transcription (Niles, 2000). RA plays a prominent role in regulating the transition 
of cells from proliferation to differentiation (Reynolds, 2000, 2003). Several naturally 
occurring RA isoforms exist; ATRA, 13-cis-retinoic acid (13cRA) and 9-cis-retinoic 
acid (9cRA) (Lovat et al., 1994, 1997a, 1997b; Miller et al., 1998) (Figure 1.2).  
 
RA works by binding to two families of retinoid receptor; the retinoic acid receptors 
(RARs) and the retinoid X receptors (RXRs), each family has an α, β and γ isoform 
(Miller et al., 1998; Ponthan et al., 2001). Receptors are members of the steroid/thyroid 
family of receptors and are located within the cell nucleus (Reynolds et al., 2003). RA 
is transported to the cell nucleus via cytoplasmic retinoic acid-binding proteins 
(CRABPs). ATRA, 13cRA and 9cRA all bind to RARs whereas only 9cRA can bind to 
RXRs (Redfern et al., 1995). Binding of RA to RARs and RXRs activates the receptors 
which form heterodimers that bind to regions of the chromosome known as retinoic acid 
response elements (RAREs). RAREs are linked to RA responsive genes and binding of 
these regions allows regulation of gene transcription thus enabling RA to regulate 
biological processes such as differentiation (Reynolds et al., 2003).  
 
In vitro RA has been shown to induce differentiation of the immature neuroblastic cells 
that form the bulk of most tumours into a mature non-proliferating neuronal phenotype 
(Lovat et al., 1994, 1997a, 1997b; Miller et al., 1998; Matthay et al., 1999; Reynolds et 
al., 2003). Clinical trials therefore began integrating RA as a part of the treatment 
process for high-risk patients (Matthay et al., 1999, 2009). The 13cRA isomer is used in 
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the treatment of high-risk neuroblastoma patients due to the lower levels of toxicity it 
displays in comparison to the other retinoids (Lovat et al., 1997a; Ponthan et al., 2001). 
13cRA has a very low affinity for RAR receptors but in vivo isomerises to ATRA, 
which is thought to be the main biologically active isomer (Redfern et al., 1994; Lovat 
et al., 1997a). 9cRA has been shown to be the most effective isoform for the induction 
of cellular differentiation and inhibition of proliferation which may be attributed to its 
differential binding of RXR receptors (Lovat et al., 1997a; Miller et al., 1998; Ponthan 
et al., 2001). Although 9cRA would appear to be more effective for neuroblastoma 
treatment the levels of toxicity it displays are too high for use in a clinical setting 
(Ponthan et al., 2001). 
 
13cRA is currently only used as a treatment option for high-risk neuroblastoma patients 
(Matthay et al., 1999, 2009). These patients have already gone through intensive 
treatments including surgery, chemotherapy, radiotherapy and/or bone marrow 
transplants (Matthay et al., 1999). Although tumour responsiveness to RA treatment 
was less than anticipated (Lovat et al., 1997a, 1997b), a significant increase in 3-year 
event-free survival was observed in patients administered 13cRA (46±6%) following 
primary treatment (autologous bone marrow transplantation or chemotherapy) compared 
to patients who were not (29±5 %) (Matthay et al., 1999) (Figure 1.3). The results have 
since been followed up and show that overall survival was significantly higher for 
patients administered 13cRA than for those who were not (Matthay et al., 2009). 
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Figure 1.2 RA exists in several naturally occurring isoforms (adapted from 
Redfern et al., 1994) 
RA exists in several naturally occurring isoforms; all-trans (ATRA), 9-cis (9cRA) and 
13-cis (13cRA) isomers being the most widely studied.  The 9cRA isoform was used to 
induce neuronal differentiation of SH-SY5Y neuroblastoma cells in this thesis.    
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Figure 1.3 Treatment with 13cRA (Matthay et al., 1999) 
The 3-year event-free survival probability for high-risk neuroblastoma patients was 
significantly higher in patients who received 13cRA treatment compared to those who 
did not, P=0.027. The first randomisation was whether the patients received 
continuation chemotherapy or bone marrow transplantation. The second randomisation 
was whether or not patients received 13cRA treatment.  
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1.4.2 Bcl-2 
The proto-oncogene Bcl-2 is expressed throughout the nervous system, particularly in 
sympathetic and sensory neurones (Garcia et al., 1992; Merry et al., 1994). As a cancer 
of the SNS, cells from neuroblastoma tumours express Bcl-2 (Hanada et al., 1993; 
Lasorella et al., 1995). The level of Bcl-2 expression in neuroblastoma cell lines is 
related to how neuronal the cell line is. For example, the N-type neuroblastoma cell line 
SH-SY5Y expresses high levels of Bcl-2 whereas the S-type neuroblastoma cell line 
SH-EP has no detectable Bcl-2 expression. SK-N-SH, the parental cell line of SH-
SY5Y and SH-EP, comprised of both N- and S-type cells shows intermediate levels of 
Bcl-2 expression (Reed et al., 1991). Furthermore, RA-induced differentiation of SH-
SY5Y cells is associated with a further increase in Bcl-2 expression as the cells become 
more neuronal-like (Hanada et al., 1993; Lasorella et al., 1995; Riddoch et al., 2007). It 
is unknown whether changes in Bcl-2 expression are due to the direct action of RA or to 
neuronal differentiation itself. However, as Bcl-2 expression correlates with neuronal 
phenotype Bcl-2 was considered as a biochemical marker of differentiation in this 
thesis. 
 
Cells expressing high levels of Bcl-2 are more resistant to apoptosis in response to 
cytotoxic agents which has implications in the treatment of neuroblastoma (Hanada et 
al., 1993; Lasorella et al., 1995). Bcl-2 expression is thought to inhibit apoptosis by 
interfering with p53 expression (Lasorella et al., 1995). Conversely p53 may regulate 
Bcl-2 expression and it is the low expression of p53 in neuroblasts that increases Bcl-2 
expression (Miyashita et al., 1994). Differential expression of Bcl-2 and p53 has been 
identified in N- and S-type cells enriched from the parental neuroblastoma cell line SK-
N-BE(2); in N-type cells high Bcl-2 expression and barely detectable p53 expression 
was associated with a low apoptotic index, whereas in S-type cells low Bcl-2 expression 
and p53 expression was associated with a high mitotic index (Piacentini et al., 1996). 
The complete role of Bcl-2 in apoptosis is not yet fully understood (Pinton et al., 2000).  
 
Bcl-2 may also play a role in store-operated Ca
2+
 entry (SOCE) where increased Bcl-2 
expression has been associated with inhibition of SOCE (Pinton et al., 2000; Riddoch et 
al., 2007).   
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1.5 Ca
2+
 signalling 
Ca
2+
 is a ubiquitous intracellular second messenger that controls a diverse range of 
cellular processes, such as proliferation, differentiation, apoptosis and gene transcription 
(Berridge et al., 1998, 2000; Bootman et al., 2001). Cells possess a Ca
2+
 signalling 
‘toolkit’ comprised of Ca2+ ‘on’ mechanisms and Ca2+ ‘off’ mechanisms that enables 
cells to generate Ca
2+
 signals that vary in space, time and amplitude (Berridge et al., 
1998, 1999, 2000; Bootman et al., 2001).  
 
The equilibrium between Ca
2+
 ‘on’ and ‘off’ mechanisms maintains the resting level of 
cytosolic Ca
2+
 at ~100nM. Ca
2+
 sensitive processes are activated when cytosolic Ca
2+
 
rises to ~1µM (Berridge et al., 2000; Bootman et al., 2001). Cells generate Ca
2+
 signals 
with the use of extracellular and intracellular Ca
2+
. Extracellular Ca
2+
 enters cells across 
the plasma membrane (PM) and intracellular Ca
2+
 is released from internal endoplasmic 
reticulum (ER) stores, or the sarcoplasmic reticulum (SR) in muscle cells (Berridge et 
al., 2000; Bootman et al., 2001). These sources are often used simultaneously or 
sequentially (Putney et al., 2001). An additional intracellular Ca
2+
 store is found in 
endosomes and lysosomes (Calcraft et al., 2009; Galione et al., 2010). 
 
1.5.1 Ca
2+
 ‘on’ mechanisms 
Channels that mediate Ca
2+
 entry into the cell cytosol are referred to as Ca
2+
 ‘on’ 
mechanisms, as they allow the cytosolic Ca
2+
 level to increase, thus generating Ca
2+
 
signals. Ca
2+
 ‘on’ mechanisms are balanced with Ca2+ ‘off’ mechanisms which serve to 
reduce cytosolic Ca
2+
 levels and thus remove the signal (Bootman et al., 2001). 
 
Ca
2+
 ‘on’ mechanisms located at the PM include, voltage-operated Ca2+ channels 
(VOCs), receptor-operated Ca
2+
 channels (ROCs), and store-operated Ca
2+ 
channels 
(SOCs) (Berridge et al., 2000; Bootman et al., 2001). VOCs are Ca
2+
 entry channels 
that open in response to depolarization (Bootman et al., 2001). There are several 
channel types; L, T, N P/Q and R, grouped accordingly due to differences in kinetics 
and pharmacological properties. VOCs are commonly present in excitable cells 
(Berridge et al., 2000). ROCs are Ca
2+
 entry channels that open in response to binding 
of extracellular agonists, such as the neurotransmitters glutamate, ATP and 
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acetylcholine (Berridge et al., 2000; Bootman et al., 2001). ROCs are commonly 
present in secretory cells and at nerve terminals. SOCs are Ca
2+
 entry channels that open 
in response to ER store depletion. The link between ER store depletion and SOC 
activation is the focus of much current research (see section 1.6 for more detail). Ca
2+
 
‘on’ mechanisms located on the ER/SR membrane include, ryanodine receptors (RYRs) 
and inositol 1,4,5-trisphosphate receptors (IP3Rs) (Berridge et al., 2000). Both are 
sensitive to Ca
2+
 and both are involved in the process of Ca
2+
-induced Ca
2+ 
release 
(CICR). Depletion of internal stores occurs as a result of CICR, whereby Ca
2+
 self-
promotes its own release by activating IP3Rs and also RYRs (Berridge et al., 2000).  
IP3Rs must first be primed by IP3 binding before responding to Ca
2+
 (Berridge et al., 
2000). RYRs can be directly activated by Ca
2+
 but have also been shown to be primed 
by the second messenger cyclic ADP ribose (cADPr) (Berridge et al., 2000; Bootman et 
al., 2001). The second messenger nicotinic acid adenine dinucleotide phosphate 
(NAADP) binds to TPCs (two-pore channels) located on endosome and lysosome 
membranes (Calcraft et al., 2009; Galione et al., 2010). Subsequent release of Ca
2+
 from 
stores can generate local Ca
2+
 signals which can be amplified by CICR though 
activation of IP3Rs and/or RYRs (Zhu et al., 2010).  
 
1.5.2 Ca
2+
 ‘off’ mechanisms 
Ca
2+
 ‘off’ mechanisms located on the PM include the Na+/Ca2+ exchanger and the PM 
Ca
2+
 ATPase (PMCA) which actively remove Ca
2+
 from the cytosol into the 
extracellular environment (Berridge et al., 2000). The sarco/endoplasmic reticulum Ca
2+
 
ATPase (SERCA) located on the ER/SR membrane actively removes Ca
2+
 from the 
cytosol and pumps it back into the ER/SR (Berridge et al., 2000).  Mitochondria are 
also an ‘off’ mechanism as they sequester Ca2+ during Ca2+ signals and then slowly 
release it back once resting levels have been restored. Ca
2+
 binding proteins are also 
considered ‘off’ mechanisms and include Ca2+ buffers and Ca2+ sensors. Buffers such as 
parvalbumin in the cytosol bind Ca
2+
 as it enters the cell and sensors such as calmodulin 
bind Ca
2+
 and in response activate various cellular responses (Berridge et al., 2000).  
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1.5.3 Ca
2+
 signals  
The ability of Ca
2+
 to act as a diverse intracellular messenger is due to the generation of 
highly versatile Ca
2+
 signals that vary in space, time and amplitude (Berridge et al., 
1998, 1999, 2000; Bootman et al., 2001).   
 
Ca
2+
 signals can be highly localised to specific regions of the cell to control highly 
localised events such as vesicle secretion at the PM (Berridge et al., 1998; 1999). An 
increase in [Ca
2+
]i at the mouth of a Ca
2+
 channel allows various cellular responses to 
occur that differ depending on the type of Ca
2+
 channel opened and its location 
(Berridge et al., 1998). These types of Ca
2+
 signal are called elementary events and are 
rapidly removed by the process of simple diffusion (Berridge et al., 1998). Elementary 
events are also the ‘basic building blocks of Ca2+ signalling’ (Berridge et al., 1998), as 
they can initiate the generation of global Ca
2+
 signals through the process of CICR 
(Berridge et al., 1998; 1999). In the process of CICR Ca
2+
 promotes release of itself 
from internal stores by activating IP3Rs and RYRs. This regenerative process can create 
an intracellular Ca
2+
 wave that passes throughout the entire cell. Intracellular Ca
2+
 
waves are seen in the processes of fertilisation and cell proliferation (Berridge et al., 
1998). If cells are connected by gap junctions, the wave can propagate into 
neighbouring cells thereby creating an intercellular Ca
2+
 wave. This allows the 
coordination of many cells to regulate a specific cellular response, such as ciliary beat 
frequency at the lung epithelium (Berridge et al., 1998; 2000; Bootman et al., 2001).    
 
A prolonged increase in the level of [Ca
2+
]i is a signal for apoptosis. Elementary and 
global Ca
2+
 signals therefore occur as brief ‘transients’ or oscillations. Ca2+ signals 
differ in time by variations in the frequency of transients which can occur seconds, 
minutes or hours apart. For example, global Ca
2+
 waves seen after fertilisation occur 
minutes apart, whereas Ca
2+
 transients involved in proliferation occur hours apart 
(Berridge et al., 1998). Differences in the amplitude of Ca
2+
 signals has also been found 
to induce different cellular responses however, it is the spatial and temporal 
characteristic of Ca
2+
 signals that are the key to diversity.   
 
Ca
2+
 plays a vital role in processes that are affected in cancerous cells including 
proliferation, differentiation and apoptosis. It is therefore important that these processes 
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are central aspects of current cancer research (Bergner and Huber, 2008). In 
neuroblastoma the process of differentiation is affected leading to the formation of 
tumours consisting of immature cells. This project therefore concentrates on elucidating 
the role of Ca
2+
 signals, specifically SOCE, in the process of differentiation.  
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1.6 Store-operated Ca
2+
 entry (SOCE) 
SOCE, originally termed capacitative calcium entry (CCE), is the process whereby IP3 
mediated depletion of ER Ca
2+
 stores activates SOCs in the PM to enable extracellular 
Ca
2+
 to enter the cell cytosol and replenish depleted stores (Putney et al., 1986). SOCE 
is a major Ca
2+
 entry pathway in both excitable and non-excitable cells (Berridge et al., 
1998). 
 
In the phosphoinositide signalling pathway, activation of G-protein-coupled receptors 
located at the PM activates phospholipase C (PLC). PLC catalyses the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2), a membrane bound phospholipid, into the 
second messengers IP3 and diacylglycerol (DAG). DAG remains in the PM and 
activates protein kinase C (PKC). IP3 diffuses through the cytosol and binds to and 
activates IP3Rs located on the ER/SR membrane. Opening of these channels allows Ca
2+
 
to move down its concentration gradient from the ER (~500µM) into the cytosol 
(~100nM) and deplete ER stores through IP3Rs and CICR (Bootman et al., 2001). 
Depletion of ER Ca
2+
 stores activates SOCE (Figure 1.4).  
 
STIM1 (stromal interaction molecule 1), Orai1, also known as CRACM1 (Ca
2+
 release-
activated Ca
2+
 modulator 1), and TRPC1 (transient receptor potential channel 1) have 
all been implicated in SOCE. A large body of evidence now supports that STIM1 is the 
ER Ca
2+
 sensor that signals store depletion to Orai1, the pore forming subunit of the 
SOC channel, together forming the elementary unit of SOCE (Luik et al., 2006). Before 
the discovery of these proteins TPRC1 was a prime SOC channel candidate, though a 
role for TRPC1 in SOCE remains controversial (Alicia et al., 2008). However, the 
biophysical properties of SOCE varies between cell types, therefore the composition of 
SOC channels most likely varies between cell types also (Roos et al., 2005; Cheng et 
al., 2008). For example, it is thought that the Ca
2+
 release-activated Ca
2+
 current (ICRAC), 
a highly selective Ca
2+
 current, is mediated through Orai1 channels (Prakriya et al., 
2004; Parekh & Putney, 2005), whereas the store-operated Ca
2+
 current (ISOC), a non-
selective Ca
2+
 current is mediated through TRPC1 channels (Ambudkar et al., 2007b; 
Liu et al., 2007). Furthermore, in some cells complexes between STIM1, Orai1 and 
TRPC1 have been shown to constitute SOCE (Ong et al., 2007; Liao et al., 2008, 2009; 
Cheng et al., 2008).  
Chapter 1 - Introduction
 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Depletion of ER Ca
2+
 stores activates SOCE 
Binding of an agonist (A) to a G-protein-coupled receptor (R) activates phospholipase C 
(PLC) which hydrolyses PIP2 (anchored in the PM) to generate the second messenger 
IP3. IP3 diffuses through the cell cytosol and binds to IP3 receptors (IP3Rs) located in the 
ER membrane. Opening of IP3Rs results in ER store depletion. Depletion of ER Ca
2+
 
stores is signalled, most likely by STIM1, to SOCs located in the PM. SERCA is a Ca
2+
 
ATPase that pumps Ca
2+
 from the cytosol into the ER to replenish depleted stores.  
 
 
 
 
 
 
 
 
 
 
 
 
~ SERCA
ER
IP3R
PM
Cytosol
Extracellular
SOC PLC
R
PIP2
IP3
A
G
STIM1
Ca2+
Ca2+
Ca2+
Chapter 1 - Introduction
 
18 
 
1.6.1 STIM1 
In vertebrates there are two STIM homologues; STIM1 and STIM2 (Liou et al., 2005). 
 
STIM1 is a 77kDa type 1 membrane protein, the majority of which is located in the ER 
membrane (Lewis, 2007); though up to 25% of STIM1 expression can be identified in 
the PM (Zhang et al., 2005). STIM1 is composed of multiple domains; an unpaired EF-
hand and sterile α-motif (SAM) domain reside within the ER lumen at the N-terminal 
region of the protein and a coiled-coil (CC)/ezrin-radixin-moesin (ERM), serine/proline-
rich and lysine-rich domain reside within the cell cytosol at the C-terminal region of the 
protein (Manji et al., 2000; Williams et al., 2001, 2002). 
 
In 2005, STIM1 was first identified as playing a key role in SOCE where knockdown of 
STIM1 in several cell types inhibited thapsigargin (TG) and agonist induced SOCE 
(Roos et al., 2005; Liou et al., 2005). STIM1 was proposed to be a sensor of ER Ca
2+
 
stores and the missing link between Ca
2+
 store depletion and SOCE (Zhang et al., 
2005). 
 
When ER Ca
2+
 stores are replete STIM1 exists as a monomer (Stathopulos et al., 2006, 
2008), located diffusely throughout the ER membrane (Liou et al., 2005; Zhang et al., 
2005; Wu et al., 2006). Following store depletion STIM1 rapidly (<5 seconds) forms 
oligomers in the ER membrane before more slowly (40 seconds) translocating to form 
punctae at pre-existing ER-PM junctions located 10-25nm from the plasma membrane, 
close enough to allow protein-protein interactions between STIM1 and SOCs (Liou et 
al., 2005; Wu et al., 2006). SOCE only occurs in the immediate vicinity directly 
opposite STIM1 puncta (Luik et al., 2006). STIM1 does not permanently reside at ER-
PM junctions (Luik et al., 2006), following replenishment of ER Ca
2+
 stores puncta 
dissociate and STIM1 returns to its uniform distribution throughout the ER membrane 
(Liou et al., 2007).  
 
STIM1 is predicted to sense the level of Ca
2+
 within the ER through its unpaired EF-
hand domain. Consistent with this role is the in vitro Ca
2+ 
binding affinity of the EF-
hand which is 200-600µM (Stathopulos et al., 2006), which overlaps with the 250-
600µM [Ca
2+
] reported within the ER (Demaurex et al., 2003). EF-hand mutant studies, 
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in which critical Ca
2+
 binding residues (Nakayama et al., 1994) were substituted in 
order to lower the Ca
2+
 binding affinity of the EF-hand and therefore mimic store 
depletion, resulted in formation of STIM1 puncta and constitutive activation of SOCE 
even when ER Ca
2+
 stores were full (Liou et al., 2005; Zhang et al., 2005; Spassova et 
al., 2006). This provided strong evidence that the EF-hand of STIM1 is the ER Ca
2+
 
sensor.  
 
Deletion of several cytosolic STIM1 domains prevents SOCE (Baba et al., 2006). The 
SAM domain is essential in STIM1 oligomerisation as SAM deletion mutants are 
unable to form inducible puncta. The cytosolic C-terminus of STIM1 is essential in the 
translocation of STIM1 oligomers to ER-PM junctions (Baba et al., 2006; Huang et al., 
2006; Liou et al., 2007) where deletion of the ERM domain prevented translocation of 
STIM1 to ER-PM junctions (Huang et al., 2006). Similarly, mutant STIM1 lacking the 
polybasic C-terminal (lysine-rich domain) oligomerised following store depletion, but 
failed to translocate to ER-PM junctions (Liou et al., 2007). The lysine-rich domain 
may interact with lipids in the membrane to facilitate SOCE (Huang et al., 2006). 
 
The cytosolic C-terminus of STIM1 activates SOCE in cells expressing Orai1 (Prakriya 
et al., 2006; Muik et al., 2008; Zhang et al., 2008), interaction between STIM1 and 
Orai1 may be mediated through coiled-coil interactions (Luik et al., 2006). 
 
STIM2 is also a type 1 transmembrane protein which shares 66% sequence homology 
with STIM1 (Williams et al., 2001). Like STIM1, STIM2 also has an EF-hand and 
SAM domain located within the ER lumen and a CC, serine/proline-rich and lysine-rich 
domain located in the cell cytosol (Williams et al., 2001; Zheng et al., 2008). STIM2 
however is only expressed in the ER membrane, unlike STIM1 which is also expressed 
in the PM (Zheng et al., 2008). 
 
STIM2, like STIM1, translocates to ER-PM junctions in response to ER store depletion 
and can activate SOCE through interaction with Orai1, STIM2 however responds to 
smaller decreases in ER [Ca
2+
] than STIM1 (Brandman et al., 2007). As knockdown of 
STIM2 reduces basal [Ca
2+
] and overexpression increases basal [Ca
2+
] (Brandman et 
al., 2007) and also inhibits SOCE (Soboloff et al., 2006a) STIM2 is considered a sensor 
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and regulator of basal [Ca
2+
]. Consistent with monitoring changes in basal [Ca
2+
] is the 
binding affinity of the EF-hand domain which is ~500µM (Zheng et al., 2008, 2011). 
 
As STIM1 activates SOCE following store depletion, the role and expression of STIM1 
was investigated in this thesis. 
 
1.6.2 Orai1 
In vertebrates there are three Orai homologues; Orai1, Orai2 and Orai3 (Feske et al., 
2006).  
 
Orai1 is a 33kDa four-transmembrane domain protein located within the PM with both 
N- and C-termini located within the cell cytosol (Prakriya et al., 2006; Gwack et al., 
2007).  
 
In 2006 Orai1 was first identified as an essential component of SOCE (Feske et al., 
2006; Vig et al., 2006a; Zhang et al., 2006). T cells from patients with severe combined 
immunodeficiency (SCID) syndrome failed to activate SOCE following store depletion 
(Feske et al., 2005) which was later attributed to a single point mutation (R91W) in 
Orai1 (Feske et al., 2006). Furthermore transfection with wild-type Orai1 in cells from 
SCID patients restored SOCE.  
 
Overexpression of both Orai1 and STIM1 reconstitutes ICRAC, suggesting that Orai1 is a 
component of SOCs (Mercer et al., 2006; Peinelt et al., 2006; Soboloff et al., 2006b; 
Zhang et al., 2006; Yamashita et al., 2007). STIM1 is obligatory for the function of 
Orai1 as a SOC (Mercer et al., 2006; Peinelt et al., 2006; Zhang et al., 2006) and 
following store depletion STIM1 and Orai1 interact directly with one another as 
determined by co-immunoprecipitation studies (Yeromin et al., 2006; Vig et al., 
2006b). A domain within the C-terminus of Orai1 is thought to be the interaction site 
for STIM1 (Li et al., 2007). Deletion of lysine-rich region did not prevent the activation 
of Orai1 (Li et al., 2007; Zeng et al., 2008) nor did the combined deletion of the 
serine/proline- and lysine-rich regions (Zeng et al., 2008) suggesting that these regions 
are not involved in the direct activation of Orai1.  
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When ER Ca
2+
 stores are replete Orai1 exists as a dimer (Penna et al., 2008), located 
diffusely throughout the PM. Following depletion of ER Ca
2+
 stores, STIM1 interacts 
with Orai1 dimers and induces dimerization to form tetramers that form the pore of the 
SOCs (Mignen et al., 2008b; Penna et al., 2008). Orai1 translocates to ER-PM junction 
directly opposite STIM1 puncta (Luik et al., 2006; Xu et al., 2006). SOCE only occurs 
in the immediate vicinity directly opposite STIM1 puncta (Luik et al., 2006). Ca
2+
 
entering the cell cytosol is taken up into the ER by the SERCA pump to replenish the 
depleted stores. Orai1 does not permanently reside at ER-PM junctions (Luik et al., 
2006) and following replenishment of ER Ca
2+
 stores Orai1 returns to its uniform 
distribution throughout the PM (Liou et al., 2007). 
 
Evidence that Orai1 forms the pore forming subunit of SOCs came from mutant studies 
in which substitution of acidic residues in transmembrane domains 1 and 3 and in the 
extracellular loop region between transmembrane domains 1 and 2 altered Ca
2+
 
permeability and selectivity of ICRAC (Prakriya et al., 2006; Yeromin et al., 2006; Vig et 
al., 2006b). Also the R91W point mutation in SCID patients with dysfunctional ICRAC is 
located in transmembrane domain 1 (Feske et al., 2006). 
 
Orai2 co-expression with STIM1 in HEK293 cells enhanced SOCE though to a lesser 
extent than Orai1 (Mercer et al., 2006).  
 
Orai3 does not generally appear to be involved in SOCE as, unlike Orai1 and Orai2, co-
expression of Orai3 with STIM1 in HEK293 cells did not enhance SOCE (Mercer et al., 
2006; DeHaven et al., 2007) and expression of a mutant Orai3 in HEK293 cells had no 
effect on SOCE (Mignen et al., 2008a).  However Orai3 may be involved in SOCE in 
some instances as Orai3 expression in Orai1 knockdown cells rescued SOCE (Mercer et 
al., 2006). Orai3 has been identified as an essential component of the store-independent, 
arachidonic acid regulated Ca
2+
 (ARC) channels (Mingen et al., 2008a, 2009, 2012). 
Though the expression of mutant Orai3 had no effect on SOCE it significantly reduced 
currents through ARC channels (Mignen et al., 2008a). ARC channels are composed of 
three Orai1 and two Orai3 subunits (Mingen et al., 2009, 2012) and their activation is 
dependent on PM STIM1 (Mignen et al., 2007, 2008a, 2009, 2012). 
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As Orai1 is most strongly associated with SOCE, the role and expression of Orai1 was 
investigated in this thesis. 
1.6.3 TRPC1 
TRPC1 is a 90kDa PM protein that has been implicated in SOCE in many cell types 
(Parekh and Putney, 2005). For example, knockout of TRPC1 in submaxillary acinar 
mouse cells caused an 80% reduction in SOCE (Liu et al., 2007) and in HEK293 cells 
STIM1 and TRPC1 co-immunoprecipitate when co-expressed (Huang et al., 2006). The 
role of TRPC1 as a SOC is controversial, as several studies have shown that TRPC1 is 
not involved in SOCE. Most of the controversy surrounding the role of TRPC1 as a 
SOC is due to its well established role as a ROC. However, recent studies suggest that 
TRPC1 can function as both a ROC and a SOC in a STIM1 dependent manner (Alicia et 
al., 2008).  
 
TRPC1 activation is STIM1 dependent where knockdown of STIM1 inhibits TRPC1 
channel function (Yuan et al., 2007). Store depletion induces translocation of STIM1 
and TRPC1 to ER-PM junctions (Huang et al., 2006). Following store depletion the 
interaction between STIM1 and TRPC1 is increased (Huang et al., 2006; Lopez et al., 
2006; Ong et al., 2007; Pani et al., 2008; Jardin et al., 2008; Alicia et al., 2008; Ng et 
al., 2009).  
 
In contrast with Orai1, deletion of STIM1 lysine-rich or serine/proline-rich domains, or 
both combined, prevents activation of TRPC1 (Zeng et al., 2008). The C-terminal 
lysine-rich tail of STIM1 is essential for gating and activation of TRPC1 channels 
(Huang et al., 2006). Residues 
684
KK
685
 of STIM1s lysine-rich tail were involved in the 
gating of the TRPC1 channel through electrostatic interaction with residues 
639
DD
640
 
residues of TRPC1s C-terminal region (Zeng et al., 2008). 
 
SOCs may be composed of heteromeric complexes that include TRPC1 and Orai1 
(Ambudkar et al., 2007b; Liao et al., 2007, 2008, 2009; Ong et al., 2007; Jardin et al., 
2008a, 2008b; Cheng et al., 2008). Several studies have demonstrated that TRPC1 
forms complexes with both STIM1 and Orai1. Complexes are dynamic where TRPC1 
only acts as a SOC when in the complex and otherwise is not involved in SOCE (Jardin 
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et al., 2008a). The interaction between STIM1 and TRPC1 requires Orai1 in some cell 
types. Prevention of STIM1-Orai1 interactions prevented STIM1-TRPC1 interactions in 
human platelets (Jardin et al., 2008a). Also expression of mutant Orai1 (R91W) reduced 
STIM1-TRPC1 dependent SOCE in HEK293 cells (Liao et al., 2008; Cheng et al., 
2008). Orai1 interaction with STIM1 may confer sensitivity of TRPC1 channels to 
SOCE (Liao et al., 2007, 2008). However, DeHaven et al., 2009, found that TRPC1 
channels function independently of STIM1 and Orai1 in HEK293 cells.  
 
Several studies have proposed that lipid raft domains (LRDs) play an essential role in 
enabling STIM1-TRPC1 interactions. STIM1 can covert TRPC1 from a ROC to a SOC 
by inserting it into LRDs in HEK293 cells (Alicia et al., 2008). Only when TRPC1 is 
inserted into LRDs can it function as a SOC, otherwise it functions as a ROC (Alicia et 
al., 2008). TRPC1 is anchored in the PM at ER-PM junctions by the cholesterol binding 
protein caveolin-1. Following store depletion STIM1 puncta formation causes the 
dissociation of TRPC1 with caveolin-1 enabling STIM1-TRPC1 interactions (Pani et 
al., 2009a, 2009b). STIM1 puncta have been found to be anchored in LRDs (Pani et al., 
2008). LRDs are also important for Orai1-TRPC1 interactions as disturbance of LRDs 
reduced Orai1-TRPC1 interactions and SOCE in human platelets (Jardin et al., 2008b). 
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1.7 Aims 
The aims of this thesis were; 
 
1. To obtain enriched N- and S-type cell populations from the SH-SY5Y 
 neuroblastoma cell line and characterise them morphologically and 
 biochemically before and after 9cRA-induced differentiation (Chapter 3). 
 
2. To characterise SOCE in proliferating and 9cRA-differentiated SH-SY5Y, N- 
 and S-type cells (Chapter 4). 
 
3.  To investigate the roles played by the three key Ca
2+
 signalling proteins; 
 STIM1 (Chapters 5), Orai1 (Chapter 6) and TRPC1  (Chapter 7) in SOCE and 
 differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 - Materials and Methods
 
25 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 - Materials and Methods
 
26 
 
2.1 Materials 
All chemicals were from Sigma-Aldrich (Sigma-Aldrich Company Ltd, Dorset, UK) 
unless otherwise stated.  
 
2.1.1 Cell culture 
SH-SY5Y cells were from Professor Robert A Ross (Fordham University, NY, USA). 
D-MEM with GlutaMAX and Opti-MEM Reduced Serum Medium with GlutaMAX 
were from Invitrogen (Life Technologies Ltd, Paisley, UK). 
 
2.1.2 Transfection  
Silencer Negative Control siRNA and nuclease-free water were from Ambion (Applied 
Biosystems, Warrington, UK). siGENOME SMARTpool siRNA (human STIM1, 
ORA1I and TRPC1) was from Thermo Scientific (Thermo Fisher Scientific, 
Dharmacon Products, Lafayette, CO, USA. Lipofectamine 2000 Transfection Reagent 
and pcDNA3.1/Zeo
(+) 
were from Invitrogen (Life Technologies Ltd, Paisley, UK). 
Cherry-STIM1 and GFP-Orai1 were from Professor Richard S Lewis (Stanford School 
of Medicine, CA, USA). 
 
2.1.3 Immunofluorescence 
FluorSave was from Calbiochem (Merck KGaA, Darmstadt, Germany). Suppliers of 
antibodies used in immunofluorescence experiments are shown in Table 2.1a 
 
2.1.4 Western blotting 
Protease cocktail inhibitor tablets were from Roche (Roche Products Ltd, Hertfordshire, 
UK). Blotting-Grade Blocker nonfat dry milk powder, Protein Assay Dye Reagent 
Concentrate and Precision Plus Dual Color Protein Standards were from Bio-Rad (Bio-
Rad Laboratories Ltd, Hertfordshire, UK). 10% NuPAGE Bis-Tris Gels (1.0mm, 10 
well), NuPAGE MOPS SDS Running Buffer and NuPAGE Antioxidant were from 
Invitrogen (Life Technologies Ltd, Paisley, UK). Suppliers of antibodies used in 
western blotting experiments are shown in Table 2.1b. 
 
2.1.5 Determination of [Ca
2+
]i 
Fura-2/AM, Ionomycin and Thapsigargin were from Calbiochem (Merck KGaA, 
Darmstadt, Germany) 
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a) 
Antibody 
- species raised in 
Supplier 
Catalogue 
number 
Anti-β-Tubulin III 
alexa-fluor 488) - Mouse 
Covance, Princeton, NJ, USA A488-435L 
Anti-Vimentin  
(alexa-fluor 647) - Mouse 
Santa Cruz Biotechnology Inc, 
Santa Cruz, CA, USA 
sc-6260 AF647 
 
b) 
Antibody 
- species raised in 
Supplier 
Catalogue 
number 
Anti-β-Actin - Mouse abcam, Cambridge, UK ab8226 
Anti-Bcl-2 - Mouse 
Santa Cruz Biotechnology Inc, 
Santa Cruz, CA, USA 
sc-7382 
Anti-β-Tubulin III - Mouse Covance, Princeton, NJ, USA MMS-435P 
Anti-Orai1 - Rabbit 
Sigma, Sigma-Aldrich Company  
Ltd, Dorset, UK 
O8264 
Anti-STIM1 - Mouse 
BD Biosciences,  
San Jose,  NJ, USA 
610954 
Anti-TRPC1 - Rabbit 
Alomone Labs Ltd, 
 Jerusalem, Israel 
ACC-010 
Anti-Vimentin - Mouse 
Santa Cruz Biotechnology Inc, 
Santa Cruz, CA, USA 
sc-6260 
Anti-Mouse (HRP) - Rabbit Dako, Glostrup, Denmark PO260 
Anti-Rabbit (HRP) - Swine Dako, Glostrup, Denmark PO217 
 
Table 2.1 Antibodies used with respective suppliers and catalogue numbers 
a) Antibodies used in immunofluorescence experiments (Methods 2.5). b) Primary and 
Secondary antibodies used in western blotting experiments (Methods 2.6). Antibodies 
were validated by siRNA knockdown, recombinant protein expression and, for TRPC1, 
peptide block. 
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2.2 SH-SY5Y cell culture 
SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle’s Medium (D-MEM) with 
GlutaMAX (L-glutamine substitute - 2.5mM) supplemented with foetal calf serum 
(10% v/v), penicillin (100IU.ml
-1
) and streptomycin (100IU.ml
-1
). Cells were kept at 
37°C in a humidified atmosphere consisting of 95% air and 5% CO2. Cells were grown 
in 75cm
2
 flasks and passaged once a week when 90% confluent. If a 1/40 dilution (i.e. 
250µl in 10mls) was used then a 1/30, 1/40 and 1/50 flask would be set up for the 
following week to account for variation in cell growth rate. Cells were not used beyond 
passage 28.  
 
In preparation for the passage of cells D-MEM, phosphate buffered saline (PBS) and 
0.02% (v/v) ethylenediaminetetraacetic acid (EDTA) were pre-warmed to 37°C. Cells 
were washed twice with PBS (10ml) and detached from the flask by incubation with 
EDTA (3ml) for 5 minutes at 37°C. D-MEM (7ml) was added to the flask and the cell 
suspension was pipetted across the surface of the flask five times to fully remove 
adherent cells. The cell suspension (10ml) was centrifuged at 1000rpm for 5 minutes, 
the supernatant was discarded and the cell pellet was re-suspended in D-MEM (10ml). 
The cell suspension was then centrifuged for a second time at 1000rpm for 5 minutes, 
the supernatant was discarded and the cell pellet was re-suspended in D-MEM (10ml). 
The resultant cell suspension was used for seeding of cells into flasks and onto dishes as 
required (2.2.4). 
 
Typically the SH-SY5Y cell line is predominantly composed of N-type cells, though S-
type cells remain present (Introduction 1.3). Due to differences in substrate adherence 
between the two cell phenotypes it was possible to enrich for N- and S-type cell 
populations. The method for enrichment, based on differential adherence, was adapted 
from Piacentini et al., 1996. Every passage performed for the enrichment of either N- or 
S-type cells was done using a flask that was ~80% confluent. Flasks that were 90-100% 
confluent were not appropriate for the enrichment of N- and S-type populations as the 
cells peeled off in sheets preventing enrichment by separation. 
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2.2.1 N-type cell populations 
D-MEM and PBS were pre-warmed to 37°C. Cells were washed once with PBS (10ml) 
and then left to stand for ~60 seconds in PBS (3ml). Flasks were gently tapped to knock 
off the more weakly adhered cells (~10-20% of cells were knocked off). These cells 
were transferred to a new flask containing D-MEM (10ml) and were pipetted up and 
down several times to obtain a uniform cell suspension. The first time this was done the 
cells were called N1 as the SH-SY5Y cell line had been enriched for N-type cells once. 
This process was repeated up to N12.  
 
To remove N-type cells from flasks for use in experiments cells were washed once with 
PBS (10ml) and then left to stand in PBS (3ml) for ~60 seconds. Then ~40% of cells 
were knocked off. These cells were added to D-MEM (7mls). The cell suspension was 
pipetted up and down several times to obtain a uniform cell suspension. Cells were 
counted (Methods 2.2.4) and the required volume plated onto dishes.  
 
2.2.2 S-type cell populations 
D-MEM and PBS were pre-warmed to 37°C. Cells were washed once in PBS (10ml) 
and then left to stand for ~4 minutes in PBS (4ml). Flasks were knocked repeatedly to 
remove N-type cells. The remaining cells still adhered to the flask (~30%) were washed 
with PBS (10ml) a second time. D-MEM (10ml) was added to the flask. The first time 
this was done the cells were called S1 as the SH-SY5Y cell line had been enriched for 
S-type cells once. This process was repeated up to S12.  
 
To remove S-type cells from flasks for use in experiments cells were washed once in 
PBS (10ml) and then left to stand in PBS (4ml) for ~5 minutes. Flasks were knocked 
repeatedly to remove N-type cells. The remaining cells were washed with PBS (10ml) 
and then scraped into PBS (3ml). D-MEM (7mls) was added to the flask and the cell 
suspension was pipetted up and down several times to obtain a uniform cell suspension. 
Cells were counted (Methods 2.2.4) and the required volume plated onto dishes. 
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2.2.3 Differentiation 
Cells were seeded onto dishes at least 24 hours prior to treatment to allow enough time 
to adhere. 9cRA (1mg) was dissolved in AnaLar EtOH to provide a stock concentration 
of 10mM which was aliquoted and stored at -20°C. Differentiation was initiated by the 
addition of 1µM 9cRA to cells at 10-20% confluency. 1µM 9cRA has previously been 
shown to successfully induce differentiation of SH-SY5Y cells (Lovat et al., 1997). 
Differentiation media (D-MEM with 9cRA) was replaced every 2 days and cells were 
used following 7 days of treatment. Previous data from this laboratory have shown that 
differentiation reaches a plateau by 7 days of treatment (Brown et al., 2005). A new 
aliquot of 9cRA was used each week and a new stock batch was made each month. 
Control cells (i.e. proliferating cells) were treated identically with an equal volume of 
vehicle EtOH (0.01% in D-MEM).  
 
 2.2.4 Cell counts 
An improved Neubauer haemocytometer (VWR International Ltd, Leicestershire, UK) 
with a chamber depth of 0.1mm was used for counting cells. Prior to each cell count the 
haemocytometer was cleaned with 70% EtOH and allowed to dry. The glass coverslip 
was then fixed in place and cell suspension was added to the chamber. Cells in the four 
corner squares (each square is 1mm
2
) were counted; cells touching the top and left line 
of each grid were counted and those touching the bottom and right line of each grid 
were not counted. The average number of cells per square was calculated (total number 
of cells / 4) and multiplied by 10
4
 to obtain the number of cells per ml (the volume of 
each square is 0.1µl). The required volume of cells was then seeded onto dishes.  
 
Table 2.2 shows the number of cells seeded onto 35mm dishes for use in fluorimetry 
experiments (35mm dishes contain four wells that hold four 10mm glass coverslips). 
Corresponding 60mm dishes were set up for harvesting of protein with twice the 
number of cells seeded as was seeded for fluorimetry experiments. Corresponding 
35mm dishes were set up for immunofluorescence or DIC images with half as many 
cells seeded as was seeded for fluorimetry experiments. 
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a) 
Cell type EtOH 9cRA 
SH-SY5Y 5 x 10
4
 2 x 10
5
 
N-type 5 x 10
4
 2 x 10
5
 
S-type 10 x 10
4
 4 x 10
5
 
 
b) 
Experiment EtOH 9cRA 
siRNA 6 x 10
5
 (Treatment NA) 
siRNA : 3 day  4 x 10
5
 4 x 10
5
 
7 day : Plasmid DNA  2.5 x 10
4
 1 x 10
5
 
 
 
Table 2.2 Number of cells seeded for fluorimetry experiments 
 
a) Number of cells seeded onto 35mm dishes to obtain ~90% confluency following 7 
days EtOH or 9cRA treatment for SH-SY5Y, N- and S-type cells (assuming treatment 
started ~24 hours after seeding). b) Number of cells seeded onto 35mm dishes to obtain 
~90% confluency following treatment and/or transfection of N-type cells. 3 day 
indicates 3 days EtOH or 9cRA treatment.7 day indicates 7 days EtOH or 9cRA 
treatment. For siRNA transfection assumes transfection started ~48 hours after seeding 
(to provide enough time for cells to obtain a suitable confluency; ~50-60% for siRNA 
transfection alone and ~40% for siRNA transfection followed by 3 days EtOH or 9cRA 
treatment). For 7 days treatment followed by plasmid DNA transfection assumes 
treatment started ~24 hours after seeding. 
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2.3 Transient transfection 
2.3.1 small interfering RNA (siRNA) transfection 
siRNA transfection is used as a tool to down-regulate gene expression. siRNA’s are 
double-stranded RNA (dsRNA) molecules of ~19-22 nucleotides in length that can be 
transfected into cells with Lipofectamine 2000. Lipofectamine is a cationic lipid that 
forms complexes with the negatively charged siRNA’s. The Lipofectamine-siRNA 
complexes are taken into cells by endocytosis. Once inside the cell cytosol siRNA’s 
bind to the RNA induced silencing complex (RISC) which separates the dsRNA and 
destroys the sense strand. The antisense strand remains associated with the RISC 
complex and binds to its corresponding (i.e. target) messenger RNA (mRNA). The 
mRNA is cleaved by the RISC complex and then degraded and therefore cannot be 
translated into protein, effectively silencing the gene. 
 
For siRNA transfection of cells siGENOME SMARTpool siRNA was used which 
consists of 4 nucleotide sequences targeted to the gene of interest (Table 2.3). STIM1, 
ORAI1 and TRPC1 siRNA (10nmol) were resuspended in nuclease-free water (100µl) 
to produce a stock concentration of 100µM which was aliquoted and stored at -20°C.  
 
Cells were grown in antibiotic free D-MEM for 24 hours prior to siRNA transfection 
and were transfected when 40-60% confluent. For 35mm dishes; siRNA (2.5µl) and 
Opti-MEM (250µl) were mixed together and Lipofectamine 2000 (5µl) and Opti-MEM 
(250µl) were mixed together for 15 minutes at RT. The diluted siRNA and the diluted 
Lipofectamine 2000 were mixed together for a further 15 minutes at RT to allow the 
formation of siRNA-Lipofectamine complexes. Complexes were added to cells (final 
siRNA concentration of 125nM) which were placed back in the incubator at 37°C for 
use in experiments following 48 hours. For control cells the equivalent concentration of 
silencer negative control siRNA was added in place of siRNA. 
 
For experiments in which STIM1, Orai1 and TRPC1 were knocked down by siRNA 
transfection followed by treatment with 9cRA (5.2.3, 6.2.3 and 7.2.3) a set of cells 
transfected with STIM1, Orai1 or TRPC1 siRNA followed by EtOH treatment was not 
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included. To ensure that the changes seen were not due to 9cRA treatment alone, 
knockdown of each protein in proliferating cells was determined beforehand.    
 
 
siRNA Target Sequence 
Human STIM1 
CAUCAGAAGUAUACAAUUG 
AGAAAGAGCUAGAAUCUCA 
AGAAGGAGCUAGAAUCUCA 
GGUGGUGUCUAUCGUUAUU 
Human ORAI1 
GCUCACUGGUUAGCCAUAA 
GGCCUGAUCUUUAUCGUCU 
GCACCUGUUUGCGCUCAUG 
CAGCAUUGAGUGUGUACUA 
Human TRPC1 
GAACAUAAAUUGCGUAGAU 
GGACUACGGUUGUCAGAAA 
GAGAAGAACUGCAGUCCUU 
UCAGGUGACUUGAACAUAA 
 
 
Table 2.3 siGENOME SMARTpool siRNA 
 
siGENOME SMARTpool siRNA from Thermo Scientific consists of 4 sequences 
targeted to the mRNA of the protein of interest.  
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2.3.2 Plasmid DNA transfection 
Plasmids are small circular double stranded DNA (dsDNA) molecules that are capable 
of self replication. A gene of interest can be inserted into plasmids which can then 
transfected into cells with Lipofectamine 2000. Once inside cells the gene of interest is 
transcribed and the resultant mRNA is translated into protein and thereby the protein of 
interest is expressed. 
 
A plasmid containing the STIM1 gene and mCherry (Cherry-STIM1) and a plasmid 
containing the Orai1 gene and green fluorescent protein (GFP-Orai1) were used for 
overexpression of STIM1 and Orai1 proteins respectively. For construction of Cherry-
STIM1 and GFP-Orai1 plasmids see Luik et al., 2006. 
 
Cells were grown in antibiotic free D-MEM for 24 hours prior to plasmid DNA 
transfection and were transfected when ~80% confluent. For 35mm dishes; plasmid 
DNA (4µg) and Opti-MEM (250µl) were mixed together and Lipofectamine 2000 
(10µl) and Opti-MEM (250µl) were mixed together for 5 minutes at RT. The diluted 
plasmid DNA and the diluted Lipofectamine 2000 were mixed together for a further 20 
minutes at RT to allow the formation of DNA-Lipofectamine complexes. Complexes 
were added to cells which were placed back in the incubator at 37°C for use in 
experiments following 24 hours. For control cells the equivalent amount of 
pcDNA3.1/Zeo
(+) 
was added in place of plasmid DNA. 
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2.4 Images 
Phase contrast images were taken with a Motic AE21 microscope using a 10x objective.  
 
Differential interference contrast (DIC) images were taken with an Axiovert 200M 
microscope (Carl Zeiss Ltd) coupled to a laser scanning confocal microscope system 
(LSM 510, Carl Zeiss Ltd) using a 40x objective and helium-neon (HeNe) laser 
(633nm).  
 
DIC images were taken to determine the percent differentiation of cells following 
various treatments and transfections (Figure 2.1). To calculate percent differentiation for 
an n of 1, six random images were taken from a single coverslip. The total number of 
cells from all six images was counted (S-type cells were not counted). The total number 
of differentiated cells (≥50µm in length) was also counted from the same six images. 
The total number of differentiated cells was divided by the total number of cells and 
multiplied by a 100 to convert to a percentage. An example of this is shown in Figure 
2.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 - Materials and Methods
 
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 DIC images for percent differentiated cells 
For n=1 six random DIC images were taken of cells on the same coverslip. The total 
number of differentiated N-type cells was divided by the total number of N-type cells 
from all six images and multiplied by 100 to convert to a percentage. In the above 
example the total number of differentiated cells is 31 and the total number of cells is 
194 therefore the percent differentiation calculated for this coverslip is 16% [(31/194) 
x100]. Cells were deemed differentiated if they exhibited neurites of ≥50µm in length 
(determined using Zeiss LSM Image Browser software). Scale bars represent 50µm. 
6/30
4/487/33
5/13 5/34
4/36
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2.5 Immunofluorescence  
PBS, 4% w/v paraformaldehyde (PFA), 0.1% v/v Triton X-100 and 5% w/v bovine 
serum albumin (BSA) were used at 4°C for the following protocol. Cells on 10mm glass 
coverslips were washed with PBS (2 x 5 minutes) and then fixed by incubation with 
PFA for 10 minutes at RT. Fixed cells were washed with PBS (2 x 5 minutes) and then 
permeabilised with Triton X-100 for 10 minutes at RT. Following permeabilisation cells 
were washed with PBS (2 x 5 minutes) and then blocked in BSA for 30 minutes at 4°C. 
Primary antibodies were diluted in BSA (Table 2.4) and then incubated with cells for 2 
hours at 4°C in the dark. Control cells were incubated with BSA only. Cells were again 
washed in PBS (2 x 5 minutes) before incubation with the nucleic acid dye, ethidium 
homodimer-1 (EthD-1), at a 1/500 dilution, for 10 minutes at RT. Cells were washed in 
PBS (2 x 5 minutes) and then in dH20 (1 x 5 minutes) before being mounted onto glass 
slides with FluorSave. Cells were left to dry overnight at RT in the dark and then stored 
at 4°C until use. 
 
Cells were viewed using a laser scanning confocal microscope (LSM 510, Carl Zeiss 
Ltd). The excitation and emission spectra of the fluorophores used in experiments are 
show in Figure 2.2. The emission wavelengths of alexa-fluor 647 and EthD-1 overlap 
and were therefore collected separately. 
 
To collect emission wavelengths separately a multi-track configuration was used as 
when one track is active the other track is switched off thereby preventing cross-talk. 
Track one was set up to detect the vimentin signal (Figure 2.3) and track two was set up 
to detect the β-Tubulin III and EthD-1 signals (Figure 2.4). Images were acquired with 
12 bit data depth, a frame size of 512 x 512 and a scan speed of 9.  
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Antibody Conjugate Dilution used 
Anti-β-Tubulin III Alexa-fluor 488 1/50 
Anti-Vimentin Alexa-fluor 674 1/50 
 
Table 2.4 Antibodies used in immunofluorescence experiments 
Anti-vimentin and anti-β-Tubulin III were both used at a 1/50 dilution. Cells did not 
require incubation with a secondary antibody as fluorescent tags were directly 
conjugated to the primary antibodies.  
 
 
 
 
 
Figure 2.2 Excitation and emission spectra of fluorophores 
Excitation (dashed line) and emission (solid line) spectra of ■ alexa-fluor 488, ■ alexa-
fluor 647 and ■ EthD-1 (from Invitrogen; Fluorescence SpectraViewer). The emission 
of alexa-fluor 647 and EthD-1 overlap and were therefore collected separately. 
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Figure 2.3 Track one set up - Vimentin detection 
This track was set up to collect the emission wavelengths of alexa-fluor 647 (peak 
emission ~670nm). It also takes a bright field image of the cells in channel D (ChD). 
The HeNe laser sends an excitation wavelength of 633nm to the main dichroic mirror 
(HFT 488/543/633) which is reflected 90° to the cells. Light emitted from the cells then 
passes through the main dichroic mirror to a secondary dichroic mirror (NFT 635) 
which only allows light above 635nm to pass through. The light is then directed to a 
long pass (LP) filter of 650nm. Only wavelengths above 650nm can pass through to be 
detected by the photomultiplier tube in channel 1 (Ch1). 
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Figure 2.4 Track two set up - β-Tubulin III and EthD-1 detection 
This track was set up to collect the emission wavelengths of alexa-fluor 488 (peak 
emission ~519) and EthD-1 (peak emission ~615nm). The argon (Ar) laser sends an 
excitation wavelength of 488nm to the main dichroic mirror (HFT 488/543/633) which 
is reflected 90° to the cells. Light emitted from the cells then passes through the main 
dichroic mirror to a secondary dichroic mirror (NFT 635) which reflects light below 
635nm 90° to another secondary dichroic mirror (NFT 545). Light below 545nm (alexa-
fluor 488) is reflected 90° to a band pass (BP) filter of 505-550nm which only allows 
light of 505-550nm to pass through to be detected by the photomultiplier tube in 
channel 2 (Ch2). Light above 545nm (EthD-1) passes through the mirror and is directed 
to a band pass (BP) filter of 560-615nm which only allows light of 560-615nm to pass 
through to be detected by the photomultiplier tube in channel 3 (Ch3). 
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2.6 Western Blotting 
Western blotting is the process whereby proteins are separated based on their molecular 
weight by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(2.6.5), transferred onto a membrane (2.6.7), detected with the use of antibodies and x-
ray film (2.6.8) and analysed using densitometry (2.6.9). 
 
2.6.1 Extraction of proteins from cells 
Cells on 60mm dishes were washed in PBS (4°C) and then lysed by the addition of 
200µl lysis buffer (4°C) for ~1 minute; 1mM EDTA (pH 8), 1mM EGTA (pH 8), 
1.28mM sucrose, 2mM Tris (pH 7.6), 10% (v/v) Triton X-100, dH20 and 1 protease 
inhibitor tablet per 10mls. Cells were scraped off dishes and then broken up by being 
passed through a 20-gauge needle ~10 times. Cells were spun down at 10,000g for 10 
minutes at 4°C to remove cellular debris. The supernatant was aliquoted and stored at -
20°C. 
 
2.6.2 Determination of protein concentration (Bradford assay) 
The Bradford assay is a colorimetric assay used to determine protein concentration. A 
stock BSA solution (1mg/ml in lysis buffer) was used to provide a range of protein 
standards (0µg, 0.05µg, 1µg, 2µg, 5µg, 10µg, 20µg and 40µg). BSA standards and 
protein samples (3µl) were made up to 40µl with dH20. Protein Assay Dye Reagent 
Concentrate (1ml) was then added to the standards and samples which were briefly 
vortexed and left to stand for 15 minutes at RT. The Coomassie Brilliant Blue G-250 
dye within the reagent binds to protein causing a shift in maximum absorption from 
465nm to 595nm with a corresponding change in colour from blue to brown. The 
absorbance measurements from BSA standards at 595nm were plotted to form a 
standard curve to which a line of best fit was added (Figure 2.5). The absorbance 
measured from the 0µg BSA standard was subtracted from each reading. The value of 
the slope (Y), calculated from the line of best fit, was used to calculate the concentration 
of protein samples which were measured in triplicate. The average absorbance from the 
protein samples (divided by 3 as 3µl of protein samples) was divided by the slope (Y) of 
the standard curve. This provided an estimate of protein concentration in µg/µl which 
was used to calculate the volume required to load 20µg and 40µg samples onto gels.  
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Figure 2.5 BSA standard curve 
An example of a standard curve generated from BSA standards of 0.05µg, 1µg, 2µg, 
5µg, 10µg, 20µg and 40µg. The absorption of each standard was measured at 595nm. A 
best fit linear regression line forced through the origin was added using GraphPad Prism 
software. The value for the slope of the line (Y) was used to calculate the concentration 
of protein samples.  
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2.6.3 Chloroform/methanol protein precipitation 
The chloroform/methanol method (Wessel and Flugge, 1984) was used to precipitate 
proteins if concentrations were too low for SDS-PAGE as determined by Bradford 
assay. To the protein samples (20µg or 40µg in 100µl deionised H2O) methanol (4 
volumes) was added and the samples were vortexed. Chloroform (1 volume) was added 
and the samples were vortexed. Deionised H2O (3 volumes) was added and the samples 
were vortexed and then spun down at 13,000 rpm for 2mins. The supernatant above the 
protein layer was removed and discarded. Methanol (3 volumes) was then added and the 
samples were inverted gently to allow mixing. The samples were then again spun at 
13,000rpm for 2 minutes. The supernatant was removed and discarded and the protein 
pellets allowed to air dry for ~5 minutes. 1 x sample buffer (2.6.4) was added to the 
protein pellets which were then heated for 5 minutes at 95°C. Samples were then spun 
down for 10 seconds at 13,000rpm to remove condensation on the underside of the lid. 
Samples could then be loaded directly onto gels or stored at -20°C until required.  
 
2.6.4 Sample buffer 
Sample buffer (1x) was composed of 2% w/v sodium dodecyl sulfate (SDS), 5% v/v 2-
Mercaptoethanol, 10% w/v glycerol and bromophenol blue (pinch) in 60mM Tris (pH 
6.8). SDS is an anionic detergent that denatures proteins by disrupting noncovalent 
bonds. SDS coats proteins with a negative charge relative to molecular weight.  
Mercaptoethanol reduces disulfide bonds. Heating of protein with sample buffer for 5 
minutes at 95°C helps denature the proteins and aids binding of SDS. Glycerol increases 
the viscosity of the protein sample which weighs down samples in wells before the 
current is turned on. Bromophenol blue is a dye used to monitor progression of protein 
separation in SDS-PAGE as it is a small molecule which migrates through the gel 
quickly.  
 
2.6.5 SDS-PAGE 
When an electric field is applied the negatively charged proteins move toward the 
positive electrode located at the bottom of the gel. Proteins are separated based on their 
molecular weight where small proteins move through the porous polyacylamide gel 
quickly and large proteins move through the gel more slowly. 
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20µg protein samples (or 40µg for Orai1) were made up to 20µl with dH20 so that the 
same volume of sample was loaded into each well. 1x sample buffer was added to each 
protein sample. Samples were heated for 5 minutes at 95°C and centrifuged for 10 
seconds at 12,000g to remove condensation on the underside of the lid.  
 
NuPAGE gels (10% Bis-Tris) were clamped into a gel tank (Invitrogen, Life 
Technologies Ltd, Paisley, UK). The inner chamber was filled with NuPAGE MOPS 
SDS buffer (200ml) with antioxidant (500µl). The addition of antioxidant to the inner 
chamber maintains proteins in a reduced state during electrophoresis. The outer 
chamber was filled with NuPAGE MOPS SDS buffer (600ml). The comb was removed 
and each well was washed with buffer from the inner chamber using a Hamilton 
syringe. Protein samples and the molecular weight marker (10µl) were loaded into the 
wells using a Hamilton syringe (25µl). Electrophoresis was carried out at a constant 
voltage of 200V for ~1 hour or until dye front reached the bottom of the gel.  
 
2.6.6 Transfer 
Following SDS-PAGE proteins were transferred from gels onto nitrocellulose 
membranes at 50V (constant) for 2 hours using a wet transfer system. A transfer 
cassette was set up to transfer the proteins from the gel onto a nitrocellulose membrane. 
Foam sponges, blotting paper and nitrocellulose membranes were cut to fit transfer 
cassettes and then pre-equilibrated in transfer buffer (25mM Tris, 192mM glycine, 20% 
v/v methanol). The gel was removed from its casing. The transfer cassette was then 
constructed as follows; 1x sponge, 2x sheets of blotting paper, gel, nitrocellulose 
membrane, 2x sheets of blotting paper and 1x sponge (Figure 2.6). Air bubbles were 
removed following the placement of the nitrocellulose membrane on the gel by carefully 
rolling a glass pipette over the surface. Transfer cassettes were placed in the transfer 
tank (BioRad, Bio-Rad Laboratories Ltd, Hertfordshire, UK) in an orientation so that 
the gel was closest to the negative electrode and the nitrocellulose membrane was 
closest to the positive electrode so that when an electric field was applied the negatively 
charged proteins moved towards the positive electrode and bound to the nitrocellulose 
membrane. A cooling unit was placed in the transfer tank to prevent overheating during 
transfer (Bio-Ice Cooling Unit). Transfer tanks were then placed on a magnetic stirplate 
to ensure the buffer was continuously stirred throughout transfer.  
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Figure 2.6 Transfer Cassette 
Proteins were transferred from gels onto nitrocellulose membranes (represented by blue 
arrow) using a wet transfer system. The transfer cassette was set up in a ‘sandwich’ 
formation; sponge, blotting paper, gel, nitrocellulose membrane, blotting paper, sponge. 
Transfer cassettes were placed in the transfer tank in an orientation so that the gel was 
closest to the negative electrode (-) and the nitrocellulose membrane was closest to the 
positive electrode (+). Application of an electric field causes the negatively charged 
proteins to move toward the positive electrode and bind to the nitrocellulose membrane. 
Transfers were performed at a constant voltage of 50V for 2 hours. 
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2.6.7 Blocking 
Following the transfer of proteins onto nitrocellulose membranes the cassette was 
disassembled and the gel was discarded. Membranes were briefly washed in PBS and 
then incubated with block (PBS, 5% w/v non-fat dried milk, 0.02% v/v Triton X-100) 
for 1 hour at RT with gentle agitation to block unoccupied sites on membranes to 
prevent non-specific binding of antibodies. 
 
2.6.8 Immunodetection 
Membranes were placed in 50ml falcon tubes (with the side that was in contact with the 
gel facing inwards) with 3mls of incubation buffer (PBS, 2.5% w/v non-fat dried milk) 
containing primary antibody (see Table 2.5a). Membranes were incubated overnight at 
4°C on rollers. Following incubation with primary antibody membranes were washed (3 
x 5 minutes) in wash buffer (PBS, 2.5% w/v non-fat dried milk, 0.2% v/v Triton X-100) 
to remove any unbound primary antibody.  
 
Membranes were then incubated with horseradish peroxidise (HRP) conjugated 
secondary antibody in 5mls of incubation buffer (see Table 2.5b) for 1-2 hours at RT on 
rollers. Following secondary antibody incubation membranes were washed (3 x 10 
minutes) in wash buffer to remove any unbound secondary antibody.  
 
Immunoreactive bands on membranes were developed by processing in a solution 
containing, 1.25mM luminol in 0.1M Tris (pH 8.5), 0.09mM p-coumaric acid and 
0.09% v/v hydrogen peroxide for 1 minute. Membranes were wrapped in saran wrap, 
placed in a film cassette and exposed to x-ray film (Hyperfilm
TM
, GE Healthcare, Life 
Sciences, Amersham, Bucks, UK) for various times (2 seconds - 10 minutes) depending 
on the primary antibody used. Regions of film exposed to light (i.e. from HRP) darken. 
Exposed film was placed in Kodak Developer until immunoreactive bands were visible, 
briefly washed in water and then placed in Kodak fix for 5 minutes. 
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a) 
Primary antibody Dilution used 
Anti-β-Actin 1/10000 
Anti-Bcl-2 1/200 
Anti-β-Tubulin III 1/20000 
Anti-Orai1 1/100 
Anti-STIM1 1/200 
Anti-TRPC1 1/200 
Anti-Vimentin 1/200 
 
b) 
Secondary antibody Conjugate Dilution used 
Anti-Mouse HRP 1/5000 
Anti-Rabbit HRP 1/5000 
 
Table 2.5 Antibodies used for western blotting  
a) Primary antibodies used for western blotting. All primary antibodies were incubated 
with blots overnight at 4°C. b) Secondary antibodies used for western blotting. The 
appropriate corresponding secondary antibody was used following primary antibody 
incubation. Secondary antibodies were incubated with blots for 1-2 hours at RT. All 
antibody dilutions were made up in incubation buffer. 
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2.6.9 Densitometry analysis 
X-ray films were scanned onto a computer where they could be analysed using ImageJ 
software (Rasband W, 1997-2007). The integrated pixel density (sum of pixel values in 
selected area) of each band was measured (Figure 2.7). The selection area remained 
constant for each set of bands analysed. A background value was also subtracted from 
each band. Values were then expressed as a ratio of β-actin in order to determine the 
expression levels of proteins. 
 
 
 
 
 
 
 
Figure 2.7 Densitometry analysis of western blots 
Blots were analysed using ImageJ software (Rasband W, 1997-2007). The same area 
was measured for each band using the same box (dashed red).   
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2.7 Determination of [Ca
2+
] i  
For measurements of [Ca
2+
]i cells were seeded onto 10mm diameter glass coverslips 
and used when ~90% confluent. Ca
2+
 measurements were made on individual 
coverslips. 
 
Cells were washed two times with Krebs buffer (10mM glucose, 118mM NaCl, 4.7mM 
KCl, 1.2mM KH2PO4, 1.2mM MgSO4, 4.2mM NaHCO3, 10mM HEPES, 2mM CaCl2, 
800μM sulfinpyrazone, pH 7.4) and then loaded with the Ca2+-sensitive fluorescent 
indicator dye, fura-2/AM (3μM) for 45 minutes at RT in the dark. 
 
Fura-2/AM is membrane permeable and insensitive to Ca
2+
 due to acetoxymethyl (AM) 
esters disguising carboxylate groups. During loading fura-2/AM diffuses across the PM 
and once inside the cell cytosol is activated by cleavage of AM esters to fura-2. Fura-2 
is sensitive to Ca
2+
 (due to exposure of carboxylate groups) and cannot diffuse across 
the PM as it becomes polar. However, fura-2 can be pumped out of cells or taken up 
into organelles, such as mitochondria, by organic anion transporters. This results in poor 
loading and/or inaccurate fluorescent readings. Sulfinpyrazone (an organic anion 
transport inhibitor) is therefore added to Krebs buffer to prevent this from occurring.  
 
Following loading cells were washed twice in Krebs buffer and incubated for a further 
25 minutes at RT in the dark to allow fura-2/AM to fully de-esterify.  
 
Each coverslip was washed twice in Ca
2+
-free Krebs buffer and then mounted in a 
coverslip holder (PerkinElmer, Beaconsfield, UK). Coverslip holders were inserted into 
a Hellma fluorescence UV Quartz 10mm cuvette (Scientific Laboratory Supplies Ltd, 
Nottingham, UK) containing Ca
2+
-free Krebs buffer and a magnetic stirrer. The cuvette 
was then placed into a fluorimeter (PerkinElmer, LS-50B) for measurement of [Ca
2+
]i in 
cells. Before beginning each experiment an excitation wavelength scan (250-450nm) 
was performed to identify poor confluency and/or dye loading (Figure 2.8). Less than 
5% of coverslips were rejected on this basis.  
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Figure 2.8 Examples of excitation wavelength scans 
Blue trace: A scan showing good fura-2 loading and high cell confluency as determined 
by the high peak of fluorescence intensity (~300) units and the low shoulders either side 
of the peak. Red trace: A scan showing poor fura-2 loading and low cell confluency as 
determined by the low peak of fluorescence intensity (~100 units) and the high shoulder 
to the left of the peak. Coverslips for which such scans were obtained were rejected for 
use in Ca
2+
 add-back experiments.  
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Ca
2+
 add-back experiments were performed in order to measure both store depletion and 
resultant Ca
2+
 entry (i.e. SOCE). Fura-2 fluorescence was monitored continuously using 
excitation and emission wavelengths of 340nm and 510nm respectively. A typical Ca
2+
 
add-back trace is shown Figure 2.9a. 
 
Following the establishment of a steady baseline TG (200nM) was added to the cuvette. 
TG is a selective inhibitor of the SERCA pump which causes Ca
2+
 to leak from the ER 
into the cell cytosol. The resultant increase in [Ca
2+
]i is observed as an increase in fura-2 
fluorescence. Although depletion of ER Ca
2+
 stores activates the SOCE pathway only 
store depletion is measured as cells are in Ca
2+
-free buffer.  
 
Following store depletion (TG response), Ca
2+
 (CaCl2, 2mM) was added to the cuvette. 
An increase in [Ca
2+
]i concentration occurs as extracellular Ca
2+
 enters the cells to 
replenish depleted stores. The increase in [Ca
2+
]i, observed as an increase in fura-2 
fluorescence, reveals the activity of the SOCE pathway.  
 
The Ca
2+
 ionophore ionomycin (50µM) was added to the cuvette. Ionomycin increases 
cell membrane permeability to Ca
2+
 resulting in a massive influx of Ca
2+
 into the cell. 
This saturates the fura-2 dye causing a large sharp rise in [Ca
2+
]i and therefore 
fluorescence. This provides a maximum fluorescence (Fmax) value.  
 
Mn
2+
 (MnCl2, 1mM) was added to the cuvette. Fura-2 has a greater affinity for Mn
2+
 
than Ca
2+
 and therefore quenches the dye. This results in a sharp drop in fluorescence, 
providing an indirect measurement of the minimum fluorescence (Fmin), known as auto-
fluorescence (AF).  
 
The Fmax and AF values were used to calibrate Ca
2+
 add-back traces to translate changes 
in fluorescence to changes in [Ca
2+
]i. Perkin Elmer Winlab software uses the formula of 
Grynkiewicz et al, 1985 which assumes a dissociation constant (Kd) of 224nM and an 
instrument constant (IC) of 3. To calculate Fmin and [Ca
2+
]i the following equations were 
used: 
Fmin = 1 / IC (Fmax - AF) 
 
[Ca
2+
]i = Kd (F - Fmin) / (Fmax - F) 
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Each trace was individually calibrated to account for variation in confluency and/or dye 
loading in cells. A typical calibrated trace is shown Figure 2.10a. 
 
To quantify store depletion and resultant Ca
2+
 entry the areas from TG responses and 
Ca
2+
 responses were calculated from calibrated traces using Perkin Elmer Winlab 
software. An example of the regions selected to calculate the area of TG and Ca
2+
 
responses is indicated by the dashed lines in Figure 2.10a. For each set of experiments 
performed data are presented in histograms showing the mean areas obtained. 
 
TG is dissolved in DMSO and therefore control Ca
2+
 add-back traces were performed 
by adding the equivalent volume of vehicle control DMSO (0.02%) in place of TG. A 
typical control Ca
2+
 add-back trace is shown in Figure 2.9b. Control Ca
2+
 add-back 
traces were calibrated; a typical control calibrated trace is shown Figure 2.10b. For each 
dish (4 coverslips in total) 1 coverslip was used as a control (DMSO: Figure 2.9b) and 
the other 3 coverslips were used to determine the TG response (Figure 2.9a). The mean 
areas obtained from calibrated control DMSO traces were subtracted from the mean 
areas obtained from calibrated TG traces. All histograms presented throughout this 
thesis are basal-subtracted (i.e. DMSO response) and are therefore response to stimulus 
only. 
 
To calculate the percentage decrease in [Ca
2+
]i following treatments and/or transfections 
the mean Ca
2+
 response was divided by the control Ca
2+
 response and multiplied by 100 
to obtain the treated/transfected mean as a percentage of the control mean. This value 
was then subtracted from 100 to provide the percentage decrease. 
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Figure 2.9 Ca
2+
 add-back experiments 
a) Typical trace from a Ca
2+
 add-back experiment. An increase in fluorescence is 
observed following the addition of TG (200nM), due to store depletion, and Ca
2+
 
(2mM), due to Ca
2+
 entering the cell cytosol. The addition of ionomycin (I) (50µM) and 
Mn
2+
 (1mM) provided the maximum and minimum fluorescence respectively and 
therefore enabled calibration of the trace. b) Typical trace from a control Ca
2+
 add-back 
experiment. Vehicle control DMSO (0.02%) was added in place of TG. The addition of 
Ca
2+
 (2mM) reveals Ca
2+
 entry not specific to SOCE. Ionomycin (I) (50µM) and Mn
2+
 
(1mM) were added to enable calibration of traces. 
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Figure 2.10 Calibrated Ca
2+
 add-back traces 
a) Typical calibrated trace from a Ca
2+
 add-back experiment. An increase in [Ca
2+
]i is 
observed following the addition of TG (200nM), due to store depletion, and Ca
2+
 
(2mM), due to Ca
2+
 entering the cell cytosol. x indicates the area measured to calculate 
the TG response. y indicates the area measured to calculate the Ca
2+
 response b) Typical 
calibrated trace from a control Ca
2+
 add-back experiment. A small increase in [Ca
2+
]i is 
observed following the addition of DMSO (0.02%) and Ca
2+
 (2mM). x indicates the 
area measured to calculate the DMSO response. y indicates the area measured to 
calculate the Ca
2+
 response. Values obtained from DMSO control traces were subtracted 
from TG traces. 
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2.8 Statistics 
Data are generally presented as mean ± SEM of n determinations (Cumming et al., 
2007). Statistical comparisons of mean values were performed using GraphPad Prism 
software. For unpaired groups a two-tailed Student’s t-test was used. For groups of three 
or more, one-way analysis of variance (ANOVA) was used. Statistical significance was 
accepted at P<0.05. The level of significance was also indicated on graphs (P<0.05*, 
P<0.01**, P<0.001***). 
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Chapter 3 
Results I - 9cRA-induced differentiation of SH-SY5Y 
cells and enrichment for N- and S-type cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 - Results I
 
57 
 
3.1 Introduction 
SH-SY5Y neuroblastoma cells differentiate into neuronal-like cells following RA 
treatment (Brown et al., 2005). The first aim of this chapter was to define 9cRA-
induced differentiation of SH-SY5Y cells both morphologically and biochemically.  
 
The SH-SY5Y cell line is composed of two identifiable cell phenotypes; ‘neuroblastic’ 
N-type cells and ‘substrate-adherent’ S-type cells. N-type cells are the predominant cell 
type of the SH-SY5Y cell line, which itself is classed as an N-type cell line 
(Introduction 1.3). N-type cells are the neuroblast population that commonly form the 
bulk of most neuroblastoma tumours. These cells are of the sympathoadrenal neural 
crest cell lineage and are those that differentiate into neuronal-like cells following 9cRA 
treatment. S-type cells are a population derived from a non-neuronal neural crest cell 
lineage. These cells are precursors to glial type cells of the SNS. Although the minority 
cell type in the SH-SY5Y cell line S-type cells can compose 5-15% of the cell 
population. The second aim of this chapter was to enrich for N- and S-type cell 
populations from the SH-SY5Y cell line and define these cell populations both 
morphologically and biochemically prior to and following 9cRA-induced 
differentiation. 
 
N- and S-type cell populations were enriched from the SH-SY5Y cell line which was 
possible due to differences in substrate adherence between the cells, where N-type cells 
are weakly adherent and S-type cells are strongly adherent (Methods 2.2). N- and S-type 
cells were defined biochemically in order to further characterise the two cell types. The 
neuronal protein β-Tubulin III (a component of microtubules) and the non-neuronal 
protein vimentin (an intermediate filament protein) were used to provide 
immunofluorescent profiles for both proliferating and differentiated SH-SY5Y, N- and 
S-type cells. The level of expression of the proto-oncogene Bcl-2 was also investigated 
in SH-SY5Y, N- and S-type cells.  
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3.2 Results 
3.2.1 SH-SY5Y cells differentiate into a neuronal like phenotype following 9cRA 
treatment 
SH-SY5Y neuroblastoma cells were treated with 1µM 9cRA for 7 days in order to 
induce differentiation. Cells treated with 9cRA will henceforth be referred to as 
differentiated cells. Differentiated cells were characterised by rounded cell bodies and 
longer, straighter, less branched neurite extensions (Figure 3.1b). Differentiation was 
quantified morphologically by measuring neurite length, where cells were deemed 
differentiated if they had one or more neurite extensions of ≥50µm in length (Pahlman 
et al., 1981, 1984; Nicolini et al., 1998; Brown et al., 2005). Control cells were treated 
with an equal volume of EtOH as vehicle (0.01% of culture media volume). Cells 
treated with EtOH will henceforth be referred to as proliferating cells. Proliferating cells 
were characterised by elongated or rounded cell bodies and many short, branched 
neurite like processes (Figure 3.1a). The morphological appearance of proliferating cells 
was the same as before treatment with EtOH.   
 
Differentiated cell populations (Figure 3.1b) were far less confluent compared to 
proliferating cell populations (Figure 3.1a), demonstrating that 9cRA treatment inhibits 
proliferation. The effect of inhibition of proliferation can be seen when seeding cells for 
experiments; for differentiated cells to have an equal confluency to proliferating cells 
after 7 days treatment, 4 times as many cells need to be seeded (Methods 2.2.4). This 
can also be seen by comparing the cell counts for 7 day treated proliferating (4097 cells) 
and differentiated cells (1035 cells) where cells were seeded at the same density prior to 
treatment (Figure 3.2). The growth rate of proliferating cells remained the same as 
before treatment with EtOH.  
 
Morphologically, as determined by neurite length, there was a significant increase in the 
percentage of differentiated cells following only 1 day of 9cRA treatment; 2.95±0.36% 
vs. 6.71±1.60%, P=0.0404 (Figure 3.2). By 7 days 9cRA treatment 34.79±3.71% of 
cells were classed as differentiated (compared to 7 day EtOH 2.03±0.19%, P<0.0001). 
This indicates a heterogeneous response to 9cRA treatment where some cells respond 
more quickly compared with others. The extent of differentiation seen in proliferating 
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cells did not significantly change throughout the 7 days of EtOH treatment and never 
exceeded 3%. The percentage of differentiated cells did not increase beyond ~35% even 
following 8 or more days of 9cRA treatment and therefore never reached 100%. It is 
noteworthy however that the extent of morphological differentiation may actually be 
higher than that seen (~35%) as only neurites that were fully visible could be counted. 
Nevertheless cells are clearly heterogeneous in their response to 9cRA as cells of a 
proliferating morphology are always present in 9cRA differentiated cell populations.  
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Figure 3.1 9cRA treatment of SH-SY5Y cells induces morphological 
differentiation  
Cells were treated with either vehicle EtOH or 1µM 9cRA for 7 days. DIC images of 
cells were taken following treatment. a) Proliferating cells (vehicle EtOH treated) 
display many short branched processes (arrow). b) Differentiated cells (1µM 9cRA 
treated) exhibit neurite extensions (arrow). Cells were deemed differentiated if they 
exhibited neurites of ≥50µm in length. The same numbers of cells were seeded onto 
coverslips prior to treatment. Images are representative of >50 images. Scale bars 
represent 50µm. 
 
 
 
 
 
 
 
 
 
 
 
b)  Differentiated cells (9cRA)a)  Proliferating cells (EtOH)
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Figure 3.2 9cRA treatment of SH-SY5Y cells induces morphological 
differentiation over 7 days as determined by neurite length  
Cells were treated with either vehicle EtOH (proliferating) or 1µM 9cRA 
(differentiated) for 1-7 days. DIC images were taken of cells following treatment. Cells 
with one or more neurite extensions of ≥50µm in length were classed as differentiated. 
Differentiated cells were counted and expressed as a percentage of the total cell 
population. Following 7 days 9cRA treatment (i.e. the point at which the cells were used 
in this study) ~35% of cells were classed as differentiated, compared with only ~2% in 
7 day proliferating cells. Day 1; proliferating cells, n=7 (101/3373 cells), differentiated 
cells n=7 (176/3417 cells), P=0.0404
*
. Day 2; proliferating cells, n=6 (61/2494 cells), 
differentiated cells n=7 (213/3233 cells), P=0.0107
*
. Day 3; proliferating cells, n=6 
(84/2928 cells), differentiated cells, n=6 (243/2636 cells), P<0.0001
***
. Day 4; 
proliferating cells, n=6 (86/2996 cells), differentiated cells n=4 (151/1469 cells), 
P=0.0017
**
. Day 5; proliferating cells, n=6 (62/3193 cells), differentiated cells n=6 
(253/1721 cells), P<0.0001
***
. Day 6; proliferating cells, n=6 (87/4091 cells), 
differentiated cells n=6 (248/1163 cells), P<0.0001
***
. Day 7; proliferating cells, n=6 
(83/4097 cells), differentiated cells n=6 (319/1035 cells), P<0.0001
***
.  
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3.2.2 Bcl-2 is a biochemical marker of differentiation 
Previous studies in this laboratory have shown that the anti-apoptotic proto-oncogene 
Bcl-2 is expressed in both proliferating and differentiated SH-SY5Y cells (Riddoch et 
al., 2007). Immunolocalisation studies revealed that Bcl-2 expression was up-regulated 
in differentiated cells compared to proliferating cells, as determined by an increase in 
fluorescence (Riddoch et al., 2007). The same anti-Bcl-2 antibody was used in this 
study to observe changes in protein expression following 1-7 days of EtOH 
(proliferating) and 9cRA (differentiated) treatment.  
 
Bcl-2 is expressed in both proliferating (Figure 3.3a) and differentiated (Figure 3.3b) 
SH-SY5Y cells as identified by the presence of a band at 26kDa, the molecular weight 
for Bcl-2 (Hanada et al., 1993). Proliferating cells (EtOH) showed no change in the 
level of Bcl-2 expression throughout the 7 days treatment whereas differentiated cells 
(9cRA) showed increased Bcl-2 expression. Blots were re-probed with an anti-β-actin 
antibody which was used as a loading control. The increase in Bcl-2 expression in 
differentiated cells was confirmed by quantitative analysis where Bcl-2 was expressed 
as a ratio of β-actin (Figure 3.3c). Bcl-2 expression was significantly up-regulated in 
differentiated cells compared to proliferating cells following 5 days of 9cRA treatment, 
P=0.0217. Up-regulated Bcl-2 expression in differentiated cells following 7 days 9cRA 
treatment was used as a biochemical marker for differentiation.  
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Figure 3.3 Expression of Bcl-2 increases in SH-SY5Y cells following 9cRA 
treatment 
Western blots were performed on protein extracted from 1-7 day EtOH (proliferating) 
and 9cRA (differentiated) treated SH-SY5Y cells (Methods 2.6). Blots were probed 
with anti-Bcl-2 antibody which detected a band of 26kDa. Blots were re-probed with 
anti-β-actin antibody, used as a loading control, which detected a band of 42kDa.  
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a) Western blot showing Bcl-2 protein expression in proliferating cells treated with 
vehicle EtOH for 1-7 days. b) Western blot showing Bcl-2 protein expression in 
differentiated cells treated with 1µM 9cRA for 1-7 days. c) Quantitative measurements 
of bands were performed using densitometry (ImageJ software, Methods 2.6.9). Bcl-2 
was expressed as a ratio of β-actin for days 1-7 of EtOH and 9cRA treatment. Bcl-2 
expression increases with 9cRA treatment over 7 day and becomes significantly up-
regulated by 5 days treatment. Day 1, P=0.8102. Day 2, P=0.1136. Day 3, P=0.3175, 
Day 4, P=0.3045. Day 5, P=0.0217
*
. Day 6, P=0.0198
*
. Day 7, P=0.0036
**
, n=4 
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3.2.3 Enrichment for N- and S-type cells 
The SH-SY5Y cell line is composed of N-type and S-type cells. The two cell types 
show differences in their substrate adherence where N-type cells are weakly substrate 
adherent and S-type cells are strongly substrate adherent. It was therefore possible to 
enrich for an N-type population and an S-type population from the SH-SY5Y cell line 
(Figure 3.4). Each time the cells types were enriched for they were numbered 
accordingly (Methods 2.2). N8 and S8 enrichments were used for the experiments 
performed in this chapter. 
 
The SH-SY5Y cell line is classed as an N-type cell line, although due to the 
heterogeneous nature of these cells, S-type cells are still present at a level of ~10% 
(Figure 3.4a) and are usually identified as patches amongst the N-type cells. The 
morphology of N-type cells is the same as that described for the SH-SY5Y cells. The 
cells have rounded or elongated cell bodies with many short, branched neurite-like 
processes (Figure 3.4b). N-type cells grow rapidly and can grow on top of one another. 
Attached neurospheres can be identified in SH-SY5Y and N-type cell populations 
(Figure 3.5). These are balls of cells thought to be derived from neural stem cells (Bez 
et al., 2003). S-type cells are larger and flatter than N-type cells. They show contact 
inhibition of growth (Figure 3.4c) and grow at a slower rate than the N-type cells.  
 
Following 1µM 9cRA treatment for 7 days N-type cells differentiate into a neuronal like 
phenotype with long, straight neurite extensions (Figure 3.6c), as was seen with the SH-
SY5Y cell population (Figure 3.1b). S-type cells also change morphology following 
9cRA treatment and become larger and flatter in appearance (Figure 3.6d). 
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Figure 3.4 Enrichment for N- and S-type cell populations 
Phase contrast images were taken of cells using a Motic AE21 microscope. a) The SH-
SY5Y cell line, although predominantly composed of N-type cells (block arrow) is 
heterogeneous in nature in that it is also composed of S-type cells (dashed arrow). Due 
to differences in substrate adherence between the two cell types it is possible to enrich 
for N- and S-type cell populations (Methods 2.2). b) N-type cell population (N8). Cells 
are small with elongated cell bodies, short processes (block arrow) and are often seen 
growing as aggregates. c) S-type cell population (S8). Cells are flatter and slightly 
larger (dashed arrow) than N-type cells and grow as a contact inhibited layer. Scale bars 
represent 50µm. 
 
 
c)  S-type cellsb)  N-type cells
a)  SH-SY5Y
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Figure 3.5 N-type cells can form neurospheres 
Phase contrast images were taken of cells using a Motic AE21 microscope. Attached 
neurospheres (black arrows) are occasionally identified in SH-SY5Y and N-type cell 
populations. Scale bars represent 50µm. 
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Figure 3.6 9cRA treatment of enriched N- and S-type cell populations 
Phase contrast images were taken of cells using a Motic AE21 microscope a) N-type 
cell population. b) S-type cell population. c) N-type cell population differentiated with 
1µM 9cRA for 7 days. Cells develop neurite extensions of ≥50µm in length (block 
arrow). d) S-type cell population differentiated with 1µM 9cRA for 7 days. Cells are 
more epithelial-like becoming larger and flatter (dashed arrow). Scale bars represent 
50µm. 
 
 
 
 
 
a) N-type cells - Proliferating (EtOH) b) S-type cells - Proliferating (EtOH)
c) N-type cells - Differentiated (9cRA) d) S-type cells - Differentiated (9cRA)
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3.2.4 N-type cells are positive to a neuronal marker whereas S-type cells are 
positive to a non-neuronal marker 
Immunofluorescent studies were performed on SH-SY5Y, N- and S-type cells in order 
to define the cells biochemically. As previously described (Introduction 1.3) the SH-
SY5Y cell line is predominantly composed of N-type cells. β-Tubulin III is a 
component of microtubules in neuronal cells (Draberova et al., 1998; Katsetos et al., 
2003) and was therefore used to determine the neuronal like nature of the N-type cells. 
Vimentin is an intermediate filament protein that is expressed in non-neuronal cells 
derived from the neural crest such as Schwann cells and glial cells (Ciccarone et al., 
1989) and was therefore used to determine the non-neuronal nature of S-type cells.  
 
Proliferating and differentiated SH-SY5Y, N- and S-type cells were stained with an 
anti-β-Tubulin III antibody (green), an anti-vimentin antibody (red) and the dye EthD-1 
(blue), which stains the cell nuclei. The SH-SY5Y cell line is predominantly composed 
of N-type cells which stain positive for β-Tubulin III (Figure 3.7). However patches of 
S-type cells, which stain positive for vimentin, are often identified within SH-SY5Y cell 
populations. This is consistent with the observation that S-type cells are present within 
the SH-SY5Y population at around 5-15% (nb not all fields of view contain patches of 
S-type cells).  
 
Both proliferating and differentiated N-type cells stain positive for β-Tubulin III (Figure 
3.8). Cells that stain positive for vimentin can be identified in N-enriched cell 
populations; these are S-type cells that remain present in all N-enriched populations 
albeit at a very low number. Again the difference in cell morphology following 9cRA 
treatment can be seen. Proliferating cells have elongated cell bodies with short, 
branched neurite like processes. Differentiated cells have rounded cell bodies and long, 
unbranched neurites of over 50µm in length. Neurite like extensions stain positive for β-
Tubulin III (Figure 3.9 arrow i).Vimentin was identifited in some neurite extensions 
(Figure 3.9 arrow ii), although a non-neuronal protein, vimentin has been shown to be 
involved in the initiation of neurite outgrowth and is temporarily present before being 
replaced with neuronal proteins (Shea et al., 1993). 
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Both proliferating and differentiated S-type cells stain positive for vimentin (Figure 
3.10). S-type cells also stain positive for β-Tubulin III throughout their cell cytoplasm, 
to the extremity of the cells, slightly beyond vimentin staining. The staining however is 
weak in comparison to vimentin staining and appears also to be weaker again in 
differentiated cells compared to proliferating cells. Following 9cRA treatment 
differentiated cells are much larger and flatter in comparison to the proliferating 
controls.  
 
The distinct immunofluorescent profiles of N- and S-type cells are consistent with the 
morphological differences previously observed between the two cell types (Figures 3.4 
and 3.6). 
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Figure 3.7 Immunofluorescent profile of the SH-SY5Y cell line 
Cells were stained with β-Tubulin III antibody (green), vimentin antibody (red) and the 
nuclear stain EthD-1 (blue). N-type cells stain positive for β-Tubulin III and S-type cells 
stain positive for vimentin. Images were captured using laser scanning confocal 
microscopy a) Proliferating (7 day EtOH treated) SH-SY5Y cells are predominantly 
comprised of N-type cells which stain positively for β-Tubulin III throughout the cell 
cytoplasm and down the short neurite like processes. Patches of S-type cells are often 
identified (dashed arrow). b) Differentiated (7 day 9cRA treated) SH-SY5Y cells are 
predominantly comprised of N-type cells which develop neurite extensions of ≥50µm in 
length that stain positive for β-Tubulin III (block arrow). As with the proliferating cells, 
patches of S-type cells can often be identified (dashed arrow). Images are representative 
of over 20 images. Scale bars represent 50µm. 
 
 
 
 
 
 
 
 
 
b)  Differentiated cells (9cRA)a)  Proliferating cells (EtOH)
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Figure 3.8 Immunofluorescent profile of N-type cells 
Cells were stained with β-Tubulin III antibody (green), vimentin antibody (red) and the 
nuclear stain EthD-1 (blue). N-type cells stain positive for β-Tubulin III and S-type cells 
stain positive for vimentin. Images were captured using laser scanning confocal 
microscopy a) Proliferating (7 day EtOH treated) N-type cells stain positively for β-
Tubulin III throughout the cell cytoplasm and down the short neurite like processes. S-
type cells are still present in enriched populations (dashed arrow). b) Differentiated (7 
day 9cRA treated) N-type cells develop neurite extensions of ≥50µm in length that stain 
positive for β-Tubulin III (block arrow). S-type cells again remain present in enriched 
populations (dashed arrow). Images are representative of over 60 images. Scale bars 
represent 50µm. 
 
 
 
 
 
 
 
 
 
 
b)  Differentiated cells (9cRA)a)  Proliferating cells (EtOH)
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Figure 3.9 Vimentin is present in neurites in some N-type cells 
Cells were stained with β-Tubulin III antibody (green), vimentin antibody (red) and the 
nuclear stain EthD-1 (blue). As indicated by arrow i) neuronal like extensions stain 
positively for β-Tubulin III. The non-neuronal protein vimentin can however also be 
identified in developing neurite extensions as indicated by arrow ii). Vimentin is 
thought to be replaced by β-Tubulin III as neurite extensions develop; arrow iii). Arrow 
iv) indicates an area positive for vimentin staining which may be the initiation point of a 
future neurite outgrowth. Scale bar represents 50µm. 
 
 
 
 
 
 
 
 
 
 
 
 
i)
ii)
iii)
iv)
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Figure 3.10 Immunofluorescent profile of S-type cells 
Cells were stained with β-Tubulin III antibody (green), vimentin antibody (red) and the 
nuclear stain EthD-1 (blue). N-type cells stain positive for β-Tubulin III and S-type cells 
stain positive for vimentin. Images were captured using laser scanning confocal 
microscopy a) Proliferating (7 day EtOH treated) S-type cells stain positively for 
vimentin throughout the cell cytoplasm. They also however stain weakly for β-Tubulin 
III throughout the cell cytoplasm. b) Differentiated (7 day 9cRA treated) S-type cells 
become larger and flatter and they too stain positive for both vimentin and β-Tubulin III 
(dashed arrow). Images are representative of over 50 images. Scale bars represent 
50µm. 
 
 
 
 
 
 
 
 
 
 
b)  Differentiated cells (9cRA)a)  Proliferating cells (EtOH)
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Western blots were performed on proliferating and differentiated SH-SY5Y, N-type and 
S-type cell protein extracts to quantify the immunofluorescent profile seen for each cell 
type.  
 
β-Tubulin III is expressed in proliferating and differentiated SH-SY5Y, N- and S-type 
cells as determined by the presence of a band at 50kDa in response to anti-β-Tubulin III 
antibody (Figure 3.11a). The level of β-Tubulin III expression does not appear to be 
different between SH-SY5Y and N-type cells but appears to be reduced in S-type cells. 
Quantification of western blots (Figure 3.11b) revealed that β-Tubulin III expression 
was not altered in SH-SY5Y (P=0.1672) or N-type (P=0.1175) cells following 9cRA 
induced differentiation. Also β-Tubulin III expression was not significantly different 
between proliferating SH-SY5Y and N-type cells (P=0.3504) and also differentiated 
SH-SY5Y and N-type cells (P=0.2179); which may be expected due to the SH-SY5Y 
cell line being predominantly composed of N-type cells. Although β-Tubulin III was 
present in S-type cells, expression was significantly lower in proliferating S-type cells 
compared to proliferating SH-SY5Y (P=0.0009) and N-type cells (P=0.0017). 
Following 9cRA treatment of S-type cells the level of β-Tubulin III expression became 
significantly down-regulated compared to proliferating S-type cells, P<0.0001.  
 
Vimentin expression was not detected in SH-SY5Y or N-type cells (Figure 3.12a). 
Although vimentin positive cells were seen in both SH-SY5Y (Figure 3.7) and N-type 
(Figure 3.8) cell populations the number of cells and/or the level of expression is 
presumably too low to be detected by the vimentin antibody used in this study. S-type 
cells stain positive for vimentin as determined by the presence of a band at 57kDa, the 
molecular weight of vimentin (Hanada et al., 1993), in response to anti-vimentin 
antibody. Quantification of western blots (Figure 3.12b) revealed that vimentin 
expression was not significantly different following 9cRA treatment, P=0.8792. From 
the morphological profile of S-type cells (Figure 3.6) it can be seen that the cells 
increase in size following 9cRA-induced differentiation however the level of vimentin 
protein remains unchanged.   
 
The protein Bcl-2 is expressed in proliferating and differentiated SH-SY5Y, N-type cell 
and S-type cells as determined by the presence of a band at 26kDa, in response to anti-
Bcl-2 antibody (Figure 3.13a). Quantification of western blots (Figure 3.13b) revealed 
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that following 7 days 9cRA treatment Bcl-2 protein expression becomes significantly 
up-regulated in SH-SY5Y cells (P=0.0198) and N-type cells (P=0.0271). Bcl-2 protein 
expression remains unchanged following 9cRA-induced differentiation of S-type cells 
(P=0.2325) and therefore is solely used as a biochemical marker for SH-SY5Y and N-
type cell differentiation and not S-type cell differentiation.  
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Figure 3.11 β-Tubulin III is expressed in SH-SY5Y, N-type and S-type cells  
Western blots were performed on protein extracted from SH-SY5Y, N-type and S-type 
cells following 7 days EtOH (proliferating = P) or 9cRA (differentiated = D) treatment.  
a) Blots were probed with anti-β-Tubulin III antibody which detected a band at 50kDa. 
Blots were then re-probed with anti-β-actin antibody, used as a loading control, which 
detected a band of 42kDa. b) Quantitative measurements of bands were performed 
using densitometry (ImageJ software, Methods 2.6.4).  β-Tubulin III was then expressed 
as a ratio of β-actin. β-Tubulin III expression does not change following 9cRA 
treatment in SH-SY5Y (P=0.1672) or N-type cells (P=0.1175) compared to their 
respective proliferating controls. However β-Tubulin III expression becomes 
significantly reduced in S-type cells following 9cRA treatment compared to 
proliferating controls, P<0.0001
***
. β-Tubulin III expression is also significantly lower 
in proliferating S-type cell populations compared to SH-SY5Y (P=0.0009
***
) and N-
type (P=0.0017
**
) proliferating cell populations. For SH-SY5Y cells n=8, for N-type 
cells n=9 and for S-type cells n=9. 
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Figure 3.12 Vimentin is only expressed in S-type cells  
 
Western blots performed on protein extracted from SH-SY5Y, N-type and S-type cells 
following 7 days EtOH (proliferating = P) or 9cRA (differentiated = D) treatment.  
a) Blots were probed with anti-vimentin antibody which detected a band at 57kDa. 
Blots were then re-probed with anti-β-actin antibody, used as a loading control, which 
detected a band of 42kDa. b)  Quantitative measurements of bands were performed 
using densitometry (ImageJ software, Methods 2.6.4). Vimentin was then expressed as a 
ratio of β-actin. Vimentin expression is not detected in SH-SY5Y or N-type cell 
populations. Vimentin is expressed in S-type cells, the level of which does not change 
following 9cRA treatment; P=0.8792. For SH-SY5Y cells n=8, for N-type cells n=8 and 
for S-type cells n=8. 
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Figure 3.13 Bcl-2 expression in SH-SY5Y, N-type and S-type cells  
Western blots performed on protein extracted from SH-SY5Y, N-type and S-type cells 
following 7 days EtOH (proliferating = P) or 9cRA (differentiated = D) treatment. a) 
Blots were probed with anti-Bcl-2 antibody which detected a band of 26kDa. Western 
blots were then re-probed with anti-β-actin antibody, used as a loading control, which 
detected a band of 42kDa. b) Quantitative measurements of bands were performed 
using densitometry (ImageJ software, Methods 2.6.4). Bcl-2 was then expressed as a 
ratio of β-actin. Bcl-2 expression significantly increases with 9cRA treatment in SH-
SY5Y cells; P=0.0198
*
 and N-type cells; P=0.0271
*
. Bcl-2 protein expression is not 
significantly different between proliferating and differentiated S-type cell population; 
P=0.2325. For SH-SY5Y cells n=6, for N-type cells n=7 and for S-type cells n=7. 
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3.3  Discussion 
SH-SY5Y cells were induced to differentiate by treatment with 9cRA for 7 days (Figure 
3.1). Following 1 day treatment there was a significant increase in the number of 
differentiated cells compared to proliferating controls (Figure 3.2). This result has also 
been observed by others (Cheung et al., 2009). Changes in gene expression can occur 
within a few hours of RA treatment (LaRosa et al., 1988), consistent with the effects of 
RA being observed following only 1 day treatment. By 7 days 9cRA treatment ~35% of 
cells were classed as differentiated (Figure 3.2). The proportion of differentiated cells 
did not exceed ~35%, even following 8 or more days 9cRA treatment, although this is 
possibly an underestimation of the actual number of differentiated cells as only cells 
with fully visible neurite extensions were classed as differentiated. However it is clear 
that not all cells respond to 9cRA treatment as some cells still continue to proliferate. 
The response to RA is therefore heterogeneous for two reasons, firstly because some 
cells respond more quickly than others and secondly because some cells do not respond 
at all. The heterogeneous response of SH-SY5Y cells to 9cRA has previously been 
observed (Brown et al., 2005).  
 
The reasons underlying heterogeneity are unknown but one possibility is a cell-
phenotype dependent sensitivity to RA. The SH-SY5Y cell line is comprised of two 
distinct cell phenotypes derived from the embryonic neural crest. The neuroblastic N-
type cells, precursors to sympathetic neurons and cells of the adrenal medulla and the 
non-neuronal S-type cells, precursors to glial, Schwann and melanocytic cells 
(Introduction 1.2). Following 9cRA treatment N-type cells differentiate into neuronal-
like cells and S-type cells differentiate into epithelial-like cells (Figure 3.5). S-type cells 
were not included in the cell counts performed to determine percent differentiation 
(Methods 2.4) and therefore the results obtained show that heterogeneity is a feature of 
the N-type cells. However, a third cell phenotype has also been identified in 
neuroblastoma cell lines. I-type cells have been hypothesised to be a cancer stem cell as 
they have the ability of self renewal and they express both N- and S-type markers, 
making them potential progenitors for both the N- and S-type cells (Ciccarone et al., 
1989; Ross et al., 1995, 2007). They are morphologically difficult to distinguish from 
N-type cells (Messi et al., 2008; Acosta et al., 2009) and therefore could be present in 
the SH-SY5Y cell line. Studies have suggested that I-type cells, the most malignant of 
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the 3 cell phenotypes (Ross et al., 2003, 2007), may mediate RA resistance in 
neuroblastoma tumours and cell lines. Therefore, one possible explanation for the 
heterogeneous response observed following 9cRA treatment is that I-type cells are 
present in the SH-SY5Y cell line and it is these cells that fail to differentiate. RA 
resistant I-type cells have been identified within the SK-N-SH neuroblastoma cell line, 
the parental cell line of SH-SY5Y cells (Messi et al., 2008). However, the N-type 
neuroblastoma cell line IMR-32 is also resistant to RA (Lasorella et al., 1995) and 
therefore regardless of cell phenotype other mechanisms must also be involved in RA 
resistance and sensitivity. RA exerts most of its effects by altering gene transcription 
through activation of RARs and RXRs (Niles, 2000) and therefore variability in 
activation and/or expression of RARs and RXRs may also provide an explanation for 
the heterogenic response observed.  
 
As well as inducing differentiation of cells, 9cRA is used in the treatment of 
neuroblastoma due to its anti-proliferative effects. This effect was observed in this study 
and has also been observed by many others in the SH-SY5Y cell line (Reynolds et al., 
1991; Lovat et al., 1994; Redfern et al., 1995; Lasorella et al., 1995; Brown et al., 
2005).  RA may mediate its anti-proliferative effects through repression of the growth 
stimulating transcription factor AP1 (Leder et al., 1990; Chambon, 1996; Altucci & 
Gronemeyer, 2011).     
 
N- and S-type cell populations were enriched from the SH-SY5Y cell line (Figure 3.4), 
possible due to differences in substrate adherence properties where N-type cells are 
weakly adherent and S-type cells are strongly adherent (Ciccarone et al., 1989; Ross et 
al., 1995; Gaitonde et al., 2001). Although N- and S-type cells have clearly distinct 
morphologies, cell types were also defined biochemically. β-Tubulin III is a component 
of microtubules in neuronal cell types (Draberova et al., 1998; Katsetos et al., 2003; 
Shin et al., 2010) and was identified in both proliferating and differentiated N-type cells 
(Figures 3.7, 3.8 and 3.11). Expression of β-Tubulin III did not change following 9cRA 
treatment. It was expected that β-Tubulin III expression may increase as cells became 
more neuronal-like, as has been observed with neurofilament-68 (Messi et al., 2008). 
However, the expression of other neuronal markers, such as neurofilament-200 also 
remain unchanged following RA treatment of SH-SY5Y cells (Encinas et al., 2000; 
Cheung et al., 2009).  
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β-Tubulin III staining, albeit weak, was also surprisingly identified in both proliferating 
and differentiated S-type cells. Yet S-type cells have also been found to stain positively 
for the neuronal marker NF-68 (Messi et al., 2008; Acosta et al., 2009). Possibly the S-
type cells stain positive for neuronal proteins as they have only recently committed to 
an S-type cell fate through the process of transdifferentiation. Interestingly, β-Tubulin 
III expression became significantly down-regulated following 9cRA-induced 
differentiation (Figure 3.11). S-type cells clearly change morphology following 9cRA 
treatment, becoming more epithelial-like (Figures 3.6 & 3.10). Following RA treatment 
S-type cells have been found to differentiate into Schwann cells (Tsokos et al., 1987) 
and melanocytic cells (Slack et al., 2002). The down-regulation in β-Tubulin III 
expression may therefore be due to S-type cells moving further away from a neuronal 
phenotype. 
 
S-type cells stained positive for vimentin, the expression of which did not change 
following 9cRA-induced differentiation (Figure 3.13). Vimentin is an intermediate 
filament protein found in non-neuronal cells, it was not detected in N-type cells using 
western blotting (Figure 3.12). However some neurite extensions of some N-type cells 
stained positively for vimentin in immunofluorescence studies (Figure 3.9). Vimentin 
has been shown to be a transient requirement in the initiation of neurite outgrowth 
(neuritogenesis). In NB2a/d1 neuroblastoma cells (Shea et al., 1993) and in 
hippocampal neurons (Boyne et al., 1996), knockdown of vimentin significantly 
inhibited neurite initiation. Expression of vimentin rapidly declines as cells become 
post-mitotic and is replaced by neurofilament proteins (Shea et al., 1993; Boyne et al., 
1996; Yabe et al., 2003; Dubey et al., 2004). 
 
An increase in Bcl-2 protein expression was observed in SH-SY5Y (Figures 3.3 and 
3.13) and N-type cells (Figure 3.13) following 7 days 9cRA treatment. This result has 
also been observed in this laboratory (Riddoch et al., 2007) and by others (Lasorella et 
al., 1995). There was no change in Bcl-2 expression in S-type cells following 7 days 
9cRA treatment which also stained weakly for Bcl-2 (Figure 3.13). In SH-SY5Y cells 
Bcl-2 expression became significantly up-regulated compared to proliferating controls 
after 5 days 9cRA treatment. Lasorella et al., 1995 observed a significant increase in 
Bcl-2 expression in SH-SY5Y cells following 6 days RA treatment. An increase in Bcl-
2 expression has also been observed in neuroblastoma cells differentiated with phorbol 
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ester (Hanada et al., 1993), which suggests that the increase in Bcl-2 is an effect of 
differentiation itself. Consistent with this notion, Bcl-2 is widely expressed in the 
developing and adult nervous system (Merry et al., 1994) and neurons removed from 
Bcl-2 deficient mouse embryos grow at a slower rate compared to controls (Hilton et 
al., 1997). Bcl-2 is known to play a key role in controlling neuronal cell survival, via its 
regulation of both caspase-dependent and caspase-independent cell death pathways 
(Akhtar et al., 2004; Merry and Korsmeyer, 1997). This may explain in part the 
temporal relationship between the increase in Bcl-2 expression (day 5) and 
morphological differentiation (day 1). Bcl-2 was used as a biochemical marker of 
differentiation for N-type cells only as expression was not altered in 9cRA differentiated 
S-type cells (Figure 3.13). 
 
With the use of morphological and biochemical markers for N- and S- type cells, it was 
possible to investigate both Ca
2+
 signalling and differentiation responses that were 
specific to cell phenotype. 
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Chapter 4 
Results II - SOCE in SH-SY5Y, N- and S-type cells 
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4.1 Introduction 
Previous studies from this laboratory have shown that SOCE becomes down-regulated 
in SH-SY5Y cells following 9cRA-induced differentiation (Brown et al., 2005). SOCE 
is the process whereby external Ca
2+
 enters cells via SOCs located on the PM in 
response to depletion of ER Ca
2+
 stores (Introduction 1.6). 
 
The SH-SY5Y cell line is heterogeneous (Chapter 3) and although predominantly 
composed of N-type cells, S-type cells are present typically at a level of ~5-15%. 
 
The aims of this chapter were to characterise SOCE in SH-SY5Y, N- and S-type cells 
following 9cRA-induced differentiation in order to determine the extent that N- and S-
type cells contribute to SOCE down-regulation. This was achieved by measuring SOCE 
in SH-SY5Y, N- and S-type cell populations following 9cRA-induced differentiation. 
N- and S-type cells were enriched from the SH-SY5Y cell line (Methods 2.2). 
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4.2 Results 
4.2.1 SOCE in SH-SY5Y cells  
SH-SY5Y cells were treated with 1µM 9cRA (differentiated) or the equivalent volume 
of vehicle EtOH (proliferating) for 7 days. To measure SOCE cells were loaded with the 
Ca
2+
 sensitive fluorescent indicator dye fura-2/AM, which enabled continuous 
measurement of cytosolic Ca
2+
. Loaded cells, maintained in Ca
2+
-free buffer, were then 
stimulated with TG in order to deplete ER Ca
2+
 stores. TG binds to and inhibits the 
SERCA pump located on the ER membrane causing a leak of Ca
2+
 from the ER into the 
cytosol. Depletion of ER Ca
2+
 stores activates SOCE whereby external Ca
2+
 enters the 
cytosol in order to replenish depleted stores. The addition of Ca
2+
 to the Ca
2+
-free 
buffer, in what is termed an ‘add-back’ experiment, enabled the measurement of Ca2+ 
influx and therefore the activity of the SOCE pathway.  
 
Calibrated fluorescence traces (i.e. showing ∆[Ca2+]i) from proliferating and 
differentiated SH-SY5Y cell populations suggested that store depletion in response to 
TG addition (200nM) was similar between proliferating and differentiated cells (Figure 
4.1). Subsequent Ca
2+
 entry following the addition of Ca
2+
 (2mM) suggested however 
that SOCE was reduced in differentiated cells compared to proliferating cells.  
 
In order to quantify Ca
2+
 entry into the cell cytosol the area from under TG and Ca
2+
 
responses was calculated from calibrated fluorescence traces (Methods 2.7) and 
presented in graphs as mean ± SEM of n determinations. Store depletion (TG response) 
was not significantly different between proliferating (10.72±1.6µMs) and differentiated 
(10.05±2.42µMs) SH-SY5Y cells, P=0.8253 (Figure 4.2). SOCE (Ca
2+
 response) 
following store depletion was however significantly down-regulated in 9cRA 
differentiated cells (10.23±2.5µMs) compared to proliferating cells (19.63±3.1µMs) by 
~48%, P=0.0308. 9cRA-induced differentiation of SH-SY5Y cells therefore causes 
down-regulation of SOCE, as previously observed by Brown et al., 2005. 
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Figure 4.1 Ca
2+
 add-back traces from SH-SY5Y cells  
Typical calibrated fluorescence traces showing ∆[Ca2+]i in proliferating and 
differentiated SH-SY5Y cells. The addition of TG (200nM) causes an increase in [Ca
2+
]i 
as Ca
2+
 is depleted from ER stores. The addition of Ca
2+
 (2mM) to the Ca
2+
-free buffer 
causes an increase in [Ca
2+
]i as Ca
2+
 enters the cytosol via the SOCE pathway. Store 
depletion appears to be similar between proliferating and differentiated cells. SOCE 
appears to be reduced in differentiated cells compared to proliferating cells. 
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Figure 4.2 SOCE in SH-SY5Y cells 
SH-SY5Y cells were treated with either EtOH (proliferating) or 9cRA (differentiated) 
for 7 days. a) Blots were performed on protein extracts from the cells fluorimetry 
experiments were performed on. In SH-SY5Y cells vimentin is not detected, β-Tubulin 
III is present, β-actin is used as a loading control and Bcl-2, a biochemical marker of 
differentiation, increases following 9cRA treatment. b) Graph shows Ca
2+
 entry into the 
cytosol following ER store depletion in response to stimulation with TG (200nM) and 
subsequent Ca
2+
 entry via the SOCE pathway following the addition of Ca
2+
 (2mM) in 
proliferating and differentiated cells. Store depletion was not significantly different 
between proliferating and differentiated cells, P=0.8253. SOCE was however 
significantly down-regulated by ~48% in differentiated cells compared to proliferating 
cells, P=0.0308
*
. For proliferating cells n=8, for differentiated cells n=9.  
 
0
5
10
15
20
25
TG
Ca2+
*
C
a
2
+
 e
n
tr
y
 i
n
to
 c
y
to
so
l
(a
re
a
 -

M
s)
Proliferating Differentiated
a)
b)
P D
42kDaβ-actin
26kDaBcl-2
50kDaβ-Tubulin III
57kDaVimentin
Chapter 4 - Results II
 
89 
 
4.2.2 SOCE in N-type cells 
The SH-SY5Y cell line is predominantly composed of N-type cells (Introduction 1.3), it 
was therefore expected that the down-regulation of SOCE observed in SH-SY5Y cells 
following 9cRA-induced differentiation (Figure 4.2) would also be observed in N-type 
cells. N-type cells are of a neuronal cell lineage, precursors to neuronal cells of the SNS. 
Following enrichment cells were treated with EtOH or 9cRA (1µM) for 7 days to 
provide proliferating and differentiated cell populations respectively.  
 
Calibrated fluorescence traces from proliferating and differentiated N-type populations 
(N8) suggested that store depletion in response to TG addition (200nM) was similar 
between proliferating and differentiated cells (Figure 4.3). Subsequent Ca
2+
 entry 
following the addition of Ca
2+
 (2mM) suggested however that SOCE was reduced in 
differentiated cells compared to proliferating cells. As with the SH-SY5Y cells (Figure 
4.1) there was a visible reduction in SOCE in N-type cells following 9cRA-induced 
differentiation.  
 
The area from under TG and Ca
2+
 responses was calculated in order to quantify Ca
2+
 
entry into the cell cytosol. Store depletion (TG response) was not significantly different 
between proliferating (9.45±0.78µMs) and differentiated (7.5±0.76µMs) cells, 
P=0.0883 (Figure 4.4). SOCE (Ca
2+
 response) following store depletion was however 
significantly down-regulated in 9cRA differentiated cells (7.64±1.83µMs) compared to 
proliferating cells (14.85±1.74µMs) by ~49%, P=0.0018. Therefore, as with the SH-
SY5Y cells (Figure 4.2), 9cRA-induced differentiation of N-type cells is accompanied 
by down-regulation of SOCE. 
 
4.2.2.1     Enrichment of N-type cells 
Reference to ‘N-type cells’ throughout this thesis refers to N-type cells enriched for 
from the SH-SY5Y cell line 8 times, i.e. S8 (Methods 2.2.1). N-type (N8) cells were 
enriched from a typical SH-SY5Y population consisting of an N- to S-type cell ratio of 
~90:10%. SH-SY5Y cells and N-type (N8) cells had very similar SOCE profiles 
(Figures 4.2 and 4.4 respectively). Further experiments revealed that N4 cells (also 
enriched from a typical SH-SY5Y population) also had a similar SOCE profile to SH-
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SY5Y cells where SOCE was down-regulated by ~62% (Figure 4.5a). N12 cells also 
showed a similar profile with a ~43% down-regulation in SOCE (Figure 4.5b).  
 
However, the importance of enrichment was seen when a batch of SH-SY5Y cells with 
an unusually high percentage of S-type cells was used. The batch contained ~50% S-
type cells and an enrichment of N4 was not sufficient to obtain a typical SOCE profile 
of SH-SY5Y cells (Figure 4.6a). SOCE was not affected by 9cRA treatment, showing a 
similar profile to S-type cell populations (4.2.3). An enrichment of N8 however, showed 
~52% down-regulated SOCE in response to 9cRA (Figure 4.6b), comparable to a 
typical SOCE profile of SH-SY5Y cells. An enrichment of N8 was therefore determined 
an acceptable level of enrichment to attribute responses to N-type cells. 
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Figure 4.3 Ca
2+
 add-back traces from N-type cells  
Typical calibrated fluorescence traces showing ∆[Ca2+]i in proliferating and 
differentiated N-type cells (N8). The addition of TG (200nM) causes an increase in 
[Ca
2+
]i as Ca
2+
 is depleted from ER stores. The addition of Ca
2+
 (2mM) to the Ca
2+
-free 
buffer reveals Ca
2+
 entry into the cytosol via the SOCE pathway. Store depletion 
appears to be similar between proliferating and differentiated cells. SOCE appears to be 
reduced in differentiated cells compared to proliferating cells. 
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Figure 4.4 SOCE in N-type cells 
N-type cells (N8) were enriched from the SH-SY5Y cell line. Cells were then treated 
with either EtOH (proliferating) or 9cRA (differentiated) for 7 days. a) Blots were 
performed on protein extracts from the cells that fluorimetry experiments were 
performed on. In N-type cells vimentin is not detected, β-Tubulin III is present, β-actin 
is used as a loading control and Bcl-2, a biochemical marker of differentiation, increases 
following 9cRA treatment. b) Graph shows Ca
2+
 entry into the cytosol following ER 
store depletion in response to stimulation with TG (200nM) and subsequent Ca
2+
 entry 
via the SOCE pathway following the addition of Ca
2+
 (2mM) in proliferating and 
differentiated cells. Store depletion was not significantly different between proliferating 
and differentiated cells, P=0.0883. SOCE was however significantly down-regulated by 
~49% in differentiated cells compared to proliferating cells, P=0.0018
**
. For 
proliferating cells n=24, for differentiated cells n=18.  
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Figure 4.5 SOCE in N4 and N12 cells 
N-type cells (N4 and N12) were enriched from a typical SH-SY5Y cell population. 
Cells were then treated with either EtOH (proliferating) or 9cRA (differentiated) for 7 
days. a) N4 cells. Store depletion in response to stimulation with TG (200nM) was not 
significantly different between proliferating and differentiated cells, P=0.5919. SOCE 
was however significantly down-regulated by ~62% in differentiated cells compared to 
proliferating cells, P=0.0082
**
. For proliferating cells n=15 for differentiated cells n=17. 
b) N12 cells. Store depletion in response to stimulation with TG (200nM) was not 
significantly different between proliferating and differentiated cells, P=0.3762. SOCE 
was however significantly down-regulated by ~43% in differentiated cells compared to 
proliferating cells, P=0.0049
**
. For proliferating cells n=13 for differentiated cells n=16. 
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Figure 4.6 SOCE in N4 and N8 cells from (high S-type cell %) 
N-type cells (N4 and N8) enriched from a batch of SH-SY5Y cells with an unusually 
high percentage of S-type cells (~50%). Cells were then treated with either EtOH 
(proliferating) or 9cRA (differentiated) for 7 days. a) N-type cells were enriched from 
the SH-SY5Y cell line four times (N4). Store depletion (TG, 200nM) was not 
significantly different between proliferating and differentiated cells, P=0.2530. Ca
2+
 
entry (Ca
2+
, 2mM) was also not significantly different between proliferating and 
differentiated cells, P=0.7108. n=8. b) N8 cells. Store depletion in response to 
stimulation with TG (200nM) was not significantly different between proliferating and 
differentiated cells, P=0.7015. Subsequent Ca
2+
 entry via the SOCE pathway following 
the addition of Ca
2+
 (2mM) was also not significantly different between proliferating 
and differentiated cells, P=0.0350
*
. n=4. 
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4.2.3 SOCE in S-type cells 
S-type cells are of a non-neuronal cell lineage, precursors to glial type cells of the SNS. 
Following enrichment cells were treated with EtOH or 9cRA (1µM) for 7 days to 
provide proliferating and differentiated cell populations respectively.  
 
Calibrated fluorescence traces from proliferating and differentiated S-type cell 
populations suggested that store depletion in response to TG addition (200nM) was 
similar between proliferating and differentiated cells (Figure 4.7). Subsequent Ca
2+
 
entry following the addition of Ca
2+
 (2mM) also suggested that SOCE was similar 
between proliferating and differentiated cells. 
 
Store depletion (TG response) was not significantly different between proliferating 
(6.63±0.77µMs) and differentiated (6.50±1.10µMs) cells, P=0.9245 (Figure 4.8). SOCE 
(Ca
2+
 response) following store depletion was also not significantly different between 
proliferating (10.15±1.48µMs) and differentiated (11.74±3.14µMs) cells, P=0.6574. 
Therefore, 9cRA-induced differentiation of S-type cells has no effect on SOCE. 
 
4.2.3.1     Enrichment of S-type cells 
Reference to ‘S-type cells’ throughout this thesis refers to S-type cells enriched for from 
the SH-SY5Y cell line 8 times, i.e. S8 (Methods 2.2.2). An enrichment of S8 was 
chosen in order to correspond with the selection of N8 cells as discussed in section 
4.2.2.1. However an enrichment of S4 (Figure 4.9a) produced a similar result to S8 cells 
(Figure 4.8) whereby both store depletion were not significantly different between 
proliferating and differentiated cells. An S-type population can therefore be successfully 
obtained after only 4 enrichments. S12 cells also showed a similar profile to S8 cells 
(Figure 4.9b).   
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Figure 4.7 Ca
2+
 add-back traces from S-type cells  
Typical calibrated fluorescence traces showing ∆[Ca2+]i in proliferating and 
differentiated S-type cells. The addition of TG (200nM) causes an increase in [Ca
2+
]i as 
Ca
2+
 is depleted from the ER stores. The addition of Ca
2+
 (2mM) to the Ca
2+
-free buffer 
reveals Ca
2+
 entry into the cytosol via the SOCE pathway. As can be seen from the 
traces both store depletion (TG response) and resultant SOCE (Ca
2+
 response) appear to 
be similar between proliferating and differentiated cells. 
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Figure 4.8 SOCE in S-type cells 
S-type cells (S8) were enriched from the SH-SY5Y cell. Cells were then treated with 
either EtOH (Proliferating) or 9cRA (Differentiated) for 7 days. a) Blots were 
performed on protein extracts from the cells that fluorimetry experiments were 
performed on. In S-type cells vimentin is present, β-Tubulin III is down-regulated in 
9cRA differentiated cells, β-actin is used as a loading control and Bcl-2 was not 
detected. b) Graph shows Ca
2+
 entry into the cytosol following ER store depletion in 
response to stimulation with TG (200nM) and subsequent Ca
2+
 entry via the SOCE 
pathway following the addition of Ca
2+
 (2mM) in proliferating and differentiated cells. 
Store depletion was not significantly different between proliferating and differentiated 
cells, P=0.9245. SOCE was not significantly different between proliferating and 
differentiated cells, P=0.6574. For proliferating cells n=15, for differentiated cells n=16.  
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Figure 4.9 SOCE in S4 and S12 cells 
S-type cells (S4 and S12) were enriched from SH-SY5Y cells. Cells were then treated 
with either EtOH (Proliferating) or 9cRA (Differentiated) for 7 days. Stores were 
depleted by the addition of TG (200nM) and subsequent Ca
2+
 entry occurred following 
the addition of Ca
2+
 (2mM) a) S4 cells. Store depletion was not significantly different 
between proliferating and differentiated cells, P=0.1207. SOCE was not significantly 
different between proliferating and differentiated cells, P=0.6607. For proliferating cells 
n=14 for differentiated cells n=10. b) S12 cells. Store depletion was not significantly 
different between proliferating and differentiated cells, P=0.2868. SOCE was not 
significantly different between proliferating and differentiated cells, P=0.8898. For 
proliferating cells n=23 for differentiated cells n=23. 
0
5
10
15
20
25
TG
Ca
2+
C
a
2
+
 e
n
tr
y
 i
n
to
 c
y
to
so
l
(a
r
e
a
 -

M
s)
Proliferating Differentiated
0
5
10
15
20
25
TG
Ca2+
C
a
2
+
 e
n
tr
y
 i
n
to
 c
y
to
so
l
(a
re
a
 -

M
s)
b)
Proliferating Differentiated
a)
Chapter 4 - Results II
 
99 
 
4.3 Discussion 
A previous study from this laboratory (Brown et al., 2005) reported that 9cRA-induced 
differentiation of SH-SY5Y cells was accompanied by a down-regulation in SOCE. The 
aim of the work presented in this chapter was to determine whether this down-
regulation was a feature of N-type cells, S-type cells or both cell types. N- and S-type 
cells were enriched from the SH-SY5Y cell line (Results 3.2). 
 
The results show that 9cRA-induced down-regulation of SOCE is a feature of N-type 
cells (Figure 4.4). Although an enrichment of N4 (Figure 4.5a) was usually sufficient to 
observe the SOCE down-regulation profile that matched that of a standard SH-SY5Y 
cell population (Figures 4.2), this was not always the case. Some batches of mixed 
population cells contained higher proportions of S-type cells; in these batches 
enrichment of N-type cells to N8 was required to observe the SOCE down-regulation 
profile (Figure 4.6b). It was therefore determined that when preparing enriched N-type 
cells an enrichment to N8 would be used throughout the remainder of this thesis. 
 
Enrichment for S-type populations provided the opportunity to compare SOCE between 
N- and S-type cells to determine the level of contribution of each cell type to the down-
regulation in SOCE measured in SH-SY5Y cells. SOCE in S-type cells (S8) was 
unaffected following 9cRA-induced differentiation (Figure 4.8). As with the N-type 
cells, S-type cells were also enriched to S4 and S12, to determine the level of 
enrichment required to obtain an S-type population. SOCE was unchanged in both S4 
and S12 cells (Figure 4.9) indicating that it is possible to obtain an S-type population 
following only 4 enrichments. An enrichment of S8 however was used for the 
remainder of this thesis to correspond with the level of enrichment selected for N-type 
cells. 
 
Due to the ability of cell types to transdifferentiate (Introduction 1.2), both N- and S-
type cells remain present in enriched populations. Yet the results show that there is a 
clear difference in the SOCE profile between N- and S-enriched cell populations. The 
enrichment for N- and S-type cells successfully enabled the differences between N- and 
S-type cells to be identified: down-regulation of SOCE observed in SH-SY5Y cells 
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following 9cRA-induced differentiation is a feature of N-type cells and not of S-type 
cells. 
 
9cRA treatment of N-type cells induces differentiation of these neuronal precursor cells 
into more neuronal-like cells. 9cRA treatment of S-type cells induces differentiation of 
these non-neuronal multi-potent precursor cells (Schwann, glial cells and melanocytes) 
into more epithelial-like cells (Chapter 3). It is not surprising that SOCE remains 
unchanged in S-type cells as SOCE is an essential and universal form of Ca
2+
 signalling 
in non-excitable cells (Berridge et al., 2000; Parekh and Putney, 2005). The present 
results reveal therefore that SOCE down-regulation is a feature of neuronal cells only 
and suggest that as the cells reach a neuronal fate their Ca
2+
 signalling profile changes.  
 
Ca
2+
 signals are known to play a key role in neuronal development. A down-regulation 
in SOCE has been observed during neural retina development (Sakaki et al., 1997) and 
also in differentiating NG 108-15X glioma cells (Ichikawa et al., 1998). Similarly, a 
non-voltage dependent Ca
2+
 entry pathway with characteristics of SOCE was lost during 
differentiation of embryonic rat cortical neurons (Maric et al., 2000). The key point 
connecting the present findings with all of these studies is the suggestion that SOCE 
occurs more intensely in proliferating cells compared with differentiated cells.  
 
Unpublished data from this laboratory by Dr Victoria Hann showed that N-type cells 
grow as normal in low Ca
2+ 
 media (0.001mM), however they are unable to differentiate 
following 9cRA treatment (7 day, 1µM), as determined by lack of neurite growth and 
lack of down-regulated SOCE. This suggests that Ca
2+
 entry into the cells is a 
requirement for differentiation to occur. However, it appears that entry is only required 
for the first 3 days of the 7 day differentiation process as at this point switching the cells 
from normal Ca
2+
 media (1.8mM) to low Ca
2+
 media (0.001mM) did not prevent the 
differentiation process (as deemed by neurite outgrowth and down-regulation of SOCE). 
These results raise the possibility that down-regulation of SOCE could be required for 
maintenance of the differentiated state. This possibility is examined further in 
subsequent chapters in this thesis. 
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The mechanism(s) underlying the down-regulation of SOCE in N-type cells is not clear. 
One possibility that can be excluded is a decrease in the size of the thapsigargin-
sensitive Ca
2+
 store, since this store remains fully intact after 9cRA-treatment (Figures 
4.3 and 4.4b). One limitation of the SOCE measurements is they are measured using 
cell populations. It remains unclear therefore whether differentiated cells have a fully 
down-regulated SOCE pathway (with the measured SOCE being a property of the 
contaminating proliferating cells) or whether a SOCE pathway may still be present and 
functioning in differentiated cells, albeit at a decreased level. Such a pathway may have 
alterations in its spatial and/or temporal characteristics such that the signal may only be 
detected using high resolution imaging techniques (Bootman et al., 2001). However, 
given that the SOCE pathway in N-type cells is substantially down-regulated, a more 
likely possibility is that expression of one or more proteins involved in the pathway 
become down-regulated. There is a report of an increase in TG-stimulated Ca
2+
 influx 
accompanied by up-regulation of TRPC after differentiation of human stem cells to 
platelets (den Dekker et al., 2001). The observation of a down-regulation of SOCE in 
the present study may reflect the down-regulation (or absence) of a particular SOCE 
protein in 9cRA-differentiated cells, which is present in proliferating cells. This 
possibility was examined in subsequent chapters in which the level of expression of the 
proteins STIM1 (Chapter 5), Orai1 (Chapter 6) and TRPC1 (Chapter 7) were 
investigated. 
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Chapter 5 
Results III - STIM1 
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5.1 Introduction 
The proteins STIM1, Orai1 and TRPC1 have been demonstrated to be involved in 
SOCE (Introduction 1.6). This chapter focuses on the involvement of STIM1 in SOCE 
and also in differentiation of N-type cells. 9cRA-induced differentiation resulted in a 
significant down-regulation of SOCE in N-type cells whereas SOCE remained 
unaffected in S-type cells (Chapters 4).  
 
As STIM1 is proposed to sense ER Ca
2+
 levels and signal store depletion to SOCs, the 
relationship between STIM1 expression, SOCE and also differentiation was 
investigated in N-type cells. In order to do this STIM1 protein expression was both 
knocked down using siRNA transfection and overexpressed using plasmid DNA 
transfection in N-type cells (Methods 2.3). Manipulation of STIM1 expression was 
quantified by western blot (Methods 2.6). The effects on SOCE were measured using 
Ca
2+
 imaging experiments (Methods 2.8) and the effects on differentiation were 
determined morphologically by analysis of DIC images (Methods 2.4) and 
biochemically by measurement of Bcl-2 expression. 
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5.2 Results 
5.2.1 STIM1 in SH-SY5Y, N- and S-type cells before and after 9cRA-induced 
differentiation 
SOCE becomes down-regulated in SH-SY5Y and N-type cells following 9cRA-induced 
differentiation, it however remains unchanged in S-type cells (Chapter 4). In order to 
determine any changes in STIM1 protein expression associated with the observed 
changes in SOCE, western blots were performed on protein extracted from SH-SY5Y, 
N- and S-type cells before and after 9cRA-induced differentiation (Methods 2.6).  
 
STIM1 is expressed in proliferating (7 day EtOH treated) and differentiated (7 day 
9cRA treated) SH-SY5Y, N- and S-type cells as determined by a band detected at 
84kDa by an anti-STIM1 antibody (Figure 5.1a). Blots were re-probed with β-actin, 
used as a loading control, and STIM1 was expressed as a ratio of β-actin in order to 
quantify changes in band intensity (Figure 5.1b).  
 
STIM1 protein expression decreased in SH-SY5Y cells by ~53% and in N-type cells by 
~49% following 9cRA-induced differentiation. The extent of down-regulation of SOCE 
for SH-SY5Y cells was ~48% (Figure 4.2) and for N-type cells was ~49% (Figure 4.4). 
The changes observed in SOCE are consistent with those seen in STIM1 expression and 
suggest that STIM1 is involved in the process of SOCE in SH-SY5Y and N-type cells. 
The level of STIM1 protein expression in S-type cells remained unchanged following 
9cRA-induced differentiation (Figure 5.1). This is consistent with the level of SOCE in 
S-type cell populations following 9cRA-induced differentiation which also remained 
unchanged following treatment (Figure 4.8).  
 
When looking at STIM1 expression, gels were run for 1 hour 15 minutes. This showed a 
double band in SH-SY5Y and N-type proliferating cells. The upper (Figure 5.1c) and 
lower (Figure 5.1d) STIM1 band were analysed individually. The upper band showed 
no significant difference in STIM1 expression following 9cRA treatment (P>0.05) 
whereas the lower band showed significant down-regulation of STIM1expression 
(P<0.05). This would suggest STIM1 exists in two different states. STIM1 knockdown 
(Figure 5.2 and 5.5) and overexpression (Figure 5.8) gels were run for 1 hour which did 
not show separation of bands. 
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Figure 5.1 STIM1 expression decreases in SH-SY5Y and N-type cells 
following 9cRA-induced differentiation  
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Cells were treated with EtOH (proliferating - P) or 9cRA (differentiated - D) for 7 days 
following which cells were harvested for protein. a) Western blots were performed on 
protein extracts from SH-SY5Y, N- and S-type cells. Blots were probed with anti-
STIM1 antibody which detected a band at 84kDa. Blots were re-probed with anti-β-
actin antibody which detected a band at 42kDa. The band detected by the β-actin 
antibody was used as a loading control. b) Quantitative measurements of bands were 
performed using densitometry (ImageJ software, Methods 2.6.9). STIM1 was expressed 
as a ratio of β-actin expression. STIM1 protein expression becomes significantly 
reduced in 9cRA-differentiated SH-SY5Y cells, P=0.0142 and also N-type cells, 
P=0.0364 compared to proliferating controls. STIM1 protein expression remained 
unchanged in S-type cells following 9cRA treatment, P=0.9053. c) Quantitative analysis 
of upper STIM1 band.STIM1 expression was not significantly different following 9cRA 
treatment in SH-SY5Y (P=0.3749) cells and N-type (P=0.4439) cells. d) Quantitative 
analysis of lower STIM1 band. STIM1 expression was significantly down-regulated 
following 9cRA treatment in SH-SY5Y (P=0.0053
**
) cells and N-type (P=0.0075
**
) 
cells.  n=4. 
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5.2.2 Knockdown of STIM1 in N-type cells down-regulates SOCE but does not 
induce differentiation 
9cRA-induced differentiation of both SH-SY5Y and N-type cells resulted in the down-
regulation of SOCE (Figures 4.2 and 4.4) and also STIM1 protein expression (Figure 
5.1). No changes in either SOCE (Figure 4.8) or STIM1 protein expression (Figure 5.1) 
were observed in S-type cell populations following 9cRA-induced differentiation and 
therefore these cells were not studied further. SH-SY5Y cells and N-type cells so far 
have shown the same results as one another. This confirms that the SH-SY5Y cell line 
is predominantly composed of N-type cells. N-type cells were therefore used for the 
remainder of studies in this chapter. 
 
To investigate whether down-regulation of STIM1 could be responsible for down-
regulation of SOCE, STIM1 protein expression was knocked down in untreated (i.e. 
proliferating) N-type cells (Figure 5.2). STIM1 protein expression was knocked down 
by transfecting the cells with STIM1 siRNA for 48 hours (Methods, 2.3.1). Control cells 
were treated with a scrambled sequence not targeted to a specific gene (control siRNA). 
STIM1 siRNA transfection of N-type cells successfully resulted in the knockdown of 
STIM1 protein expression as observed by the reduced STIM1 band intensity (84kDa 
band) in response to anti-STIM1 antibody in comparison to control siRNA transfected 
cells (Figure5.2a). β-actin protein expression was used as a loading control to enable 
quantification of STIM1 knockdown (Figure 5.2b). STIM1 was expressed as a ratio of 
β-actin protein expression. STIM1 protein expression was significantly down-regulated 
by ~50% in STIM1 siRNA transfected cells compared to control siRNA transfected 
cells, P=0.0386 
 
Bcl-2 protein expression was used as a measure of biochemical differentiation (Figure 
5.2a) and was quantified by the expression of Bcl-2 as a ratio of β-actin expression 
(Figure 5.2c). Bcl-2 protein expression was not significantly different between control 
siRNA and STIM1 siRNA transfected cells, P=0.9910.  
 
Following transfection of cells and the subsequent knockdown of STIM1 protein, Ca
2+
 
add-back experiments were performed to measure SOCE and DIC images were taken to 
determine the extent of morphological differentiation. 
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Ca
2+
 add-back experiments revealed that store depletion (TG response) was not 
significantly different between control siRNA (14.75±1.83µMs) and STIM1 siRNA 
(12.96±1.95µMs) transfected cells, P=0.5117 (Figure 5.3). SOCE (Ca
2+
 response) 
following store depletion was however significantly down-regulated in STIM1 siRNA 
transfected cells (12.13±1.78µMs) compared to control siRNA transfected cells 
(30.80±4.13µMs), P=0.0005. This suggests STIM1 plays an important role in SOCE in 
proliferating N-type cells as STIM1 knockdown down-regulates SOCE by ~60%.  
 
DIC images were taken of the cells to correspond with the protein samples and the Ca
2+
 
add-back experiments to see whether there was any affect on differentiation as 
determined by neurite length (≥50µm) (Figure 5.4). DIC images of control siRNA cells 
revealed cellular differentiation to be 3.21±0.35% compared to STIM1 siRNA cells 
which were 4.67±0.87%, P=0.1721. Knockdown of STIM1 for 48 hours in N-type cells 
does not significantly affect the extent of morphological differentiation. 
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Figure 5.2 Knockdown of STIM1 in N-type cells 
N-type cells were transfected with either control siRNA or STIM1 siRNA for 48 hours. 
a) Western blots were performed on protein extracted from control siRNA (C) and 
STIM1 siRNA (S) transfected cells. A band at 84kDa was detected with anti-STIM1 
antibody. Blots were re-probed with anti-β-actin antibody (42kDa), used as a loading 
control. Blots were then re-probed with anti-Bcl-2 antibody (26kDa), used as a 
biochemical marker of differentiation. b) Quantitative measurements of bands were 
performed using densitometry (ImageJ software, Methods 2.6.9). STIM1 was 
significantly down-regulated following STIM1 siRNA transfection compared to control 
siRNA transfected cells; P=0.0386
*
. c) Quantitative measurements of Bcl-2 protein 
expression show that Bcl-2 expression was not significantly different between control 
siRNA and STIM1 siRNA transfected cells; P=0.9910. n=6. 
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Figure 5.3 Knockdown of STIM1 in N-type cells down-regulates SOCE 
N-type cells were transfected with either control siRNA or STIM1 siRNA for 48 hours. 
Ca
2+
 add-back experiments were performed on cells following treatment. Store 
depletion in response to the addition of TG (200nM) was not significantly different 
between control siRNA and STIM1 siRNA transfected cell (P=0.51117). However, 
SOCE in response to the addition of Ca
2+
 (2mM) was significantly down-regulated in 
STIM1 siRNA transfected cells compared to control siRNA transfected cells 
(P=0.0005
***
). For control siRNA transfected cells n=16 and for STIM1 siRNA 
transfected cells n=14. 
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Figure 5.4 Knockdown of STIM1 in N-type cells does not induce 
morphological differentiation 
Cells were transfected with either control siRNA or STIM1 siRNA for 48 hours. DIC 
image of N-type cells transfected with a) control siRNA and b) STIM1 siRNA. Scale 
bars equal 50µm. c) Quantification of DIC images; differentiated cells (neurite 
extensions ≥50µm) were counted and expressed as a percentage of the total cell 
population. For control siRNA ~3% of cells were classed as differentiated (66/2190 
cells). For STIM1 siRNA almost 5% of cells were classed as differentiated (110/2355 
cells), There was no significant difference in the extent of morphological differentiation 
between control siRNA and STIM1 siRNA transfected cells, P=0.1721. n=4. 
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5.2.3 Knockdown of STIM1 followed by 9cRA treatment down-regulates SOCE 
but does not affect differentiation 
Knockdown of STIM1 did not itself induce differentiation (Figure 5.4). In the next 
series of experiments it was investigated as to whether knockdown of STIM1 affected 
the ability of 9cRA to induce differentiation of N-type cells.  
 
STIM1 was knocked down in N-type cells by transfection with STIM1 siRNA for 48 
hours (Methods 2.3). Following knockdown cells were then treated with either EtOH or 
9cRA for a further 3 days. In total this amounts to 5 days treatment; 48 hours of 
transfection followed by 3 days of EtOH or 9cRA treatment. Data from our laboratory 
have shown that effects of 9cRA on SOCE (i.e. down-regulation) are apparent 
following 3 days of treatment; 3 days treatment is therefore a suitable time scale to 
determine whether knockdown of STIM1 has any affect on SOCE or differentiation of 
9cRA treated cells.  
 
Three sets of cells were used; two sets were transfected with control siRNA for 48 
hours, one was then treated with EtOH and the other with 9cRA for 3 days. The final set 
was transfected with STIM1 siRNA for 48 hours followed by 9cRA treatment for 3 
days. Henceforth cells transfected with control siRNA followed by EtOH treatment will 
be referred to as control EtOH cells, those transfected with control siRNA followed by 
9cRA treatment will be referred to as control 9cRA cells and those transfected with 
STIM1 siRNA followed by 9cRA treatment will be referred to as STIM1 knockdown 
cells.  
 
Western blot analysis showed the expression of STIM1, as identified by the presence of 
a band at 84kDa in response to anti-STIM1 antibody, in control EtOH, control 9cRA 
and STIM1 knockdown cells (Figure 5.5). There is a visible reduction in band intensity 
in control 9cRA cells and STIM1 knockdown cells compared to control EtOH cells. 
This was quantified by expressing STIM1 as a ratio of β-actin expression, which 
revealed a significant decrease in STIM1 protein expression by ~46% in control 9cRA 
cells and ~58% in STIM1 knockdown cells, P=0.0332 and P=0.0193 respectively.  
 
Bcl-2 expression (Figure 5.5a) was quantified by expression of Bcl-2 as a ratio of β-
actin expression (Figure 5.5c). Bcl-2 protein expression was not significantly up-
Chapter 5 - Results III
 
113 
 
regulated in control 9cRA cells and STIM1 knockdown cells compared to control EtOH 
cells, P>0.05. Bcl-2 expression was not significantly up-regulated in SH-SY5Y cells 
until day 5 9cRA treatment.  
 
Following transfection of cells and the subsequent knockdown of STIM1 protein, Ca
2+
 
add-back experiments were performed to measure SOCE and DIC images were taken to 
determine the extent of morphological differentiation. 
 
Ca
2+
 add-back experiments revealed that there was no significant difference in store 
depletion between control EtOH (12.56±1.89µMs), control 9cRA (11.75±0.76µMs) and 
STIM1 knockdown cells (12.43±1.12µMs), P>0.05. SOCE was down-regulated in 
control 9cRA cells (13.25±1.77µMs) compared to control EtOH cells (21.52±1.11µMs), 
P<0.05 (Figure 5.6). This result shows a similar relationship to 7 day EtOH and 9cRA 
treated cells (Figure 4.4), confirming that following 3 days 9cRA treatment SOCE 
becomes significantly down-regulated. SOCE measured in STIM1 knockdown cells 
(9.88±1.64µMs) was also significantly down-regulated compared to control EtOH cells 
(P<0.01).  
 
DIC images were taken of the cells to correspond with the protein samples and the Ca
2+
 
add-back experiments performed in order to see whether there was any affect on 
morphological differentiation (Figure 5.7). Images of control EtOH cells revealed 
cellular differentiation to be 1.25±0.12% compared to control 9cRA cells which were 
classed as 6.91±0.35% differentiated; P<0.001. This confirmed that the transfection 
procedure did not affect the ability of the cells to differentiate as the extent of 
differentiation was comparable to 3 day 9cRA treated cells (Figure 3.2). STIM1 
knockdown cells were determined to be 7.33±0.68% differentiated (P<0.001 against 
control EtOH). This demonstrates that knockdown of STIM1 in N-type cells does not 
affect the ability of the cell to differentiate in response to 9cRA as values seen are 
comparable to control 9cRA cells, P>0.05. 
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Figure 5.5  Knockdown of STIM1 in N-type cells followed by 9cRA treatment 
N-type cells were transfected with either control siRNA or STIM1 siRNA for 48 hours 
and then treated with either EtOH or 9cRA for a further 3 days. a) Western blots were 
performed on protein extracted from control EtOH (CE), control 9cRA (C9) and STIM1 
knockdown (S9) cells. A band at 84kDa was detected with anti-STIM1 antibody. Blots 
were re-probed with anti-β-actin antibody (42kDa), used as a loading control and with 
anti-Bcl-2 antibody (26kDa), used as a biochemical marker of differentiation. b) 
Quantitative measurements of bands were performed using densitometry (ImageJ 
software, Methods 2.6.9). STIM1 was significantly knocked down in control 9cRA cells 
and STIM1 knockdown cells compared to control EtOH cells, P<0.05
*
 c) Quantitative 
measurements of Bcl-2 protein expression revealed that Bcl-2 expression was not 
significantly up-regulated in either 9cRA control or STIM1 knockdown cells compared 
to EtOH treated cells, P>0.05. n=3. 
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Figure 5.6 Knockdown of STIM1 in N-type cells followed by 9cRA treatment 
down-regulates SOCE 
N-type cells were transfected with either control siRNA or STIM1 siRNA for 48 hours, 
followed by EtOH or 9cRA treatment for 3 days. Ca
2+
 add-back experiments were 
performed on cells following treatment. Store depletion in response to TG (200nM) was 
not significantly different between control EtOH, control 9cRA and STIM1 knockdown 
cells (P>0.05). SOCE in response to the addition of Ca
2+
 (2mM) was significantly 
down-regulated in control 9cRA cells compared to control EtOH cells, P<0.05
*
. SOCE 
in STIM1 knockdown cells was also significantly down-regulated compared to control 
EtOH cells, P<0.01
**
 and not significantly different to control 9cRA cells, P>0.05. For 
control EtOH cells n=3, control 9cRA cells n=5 and for STIM1 knockdown cells n=6. 
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Figure 5.7 Knockdown of STIM1 in N-type cells followed by 9cRA treatment 
does not affect morphological differentiation 
Cells were transfected with either control siRNA or STIM1 siRNA for 48 hours and 
then treated with EtOH or 9cRA for 3 days. DIC image of N-type cells transfected with 
a) control siRNA followed by EtOH treatment, b) control siRNA followed by 9cRA 
treatment and c) STIM1 siRNA followed by 9cRA treatment. Scale bars represent 
50µm. d) Quantification of DIC images; differentiated cells (neurite extensions ≥50µm) 
were counted and expressed as a percentage of the total cell population. For control 
EtOH ~1% of cells were classed as differentiated (88/7399 cells), n=8. For control 
9cRA ~7% of cells were classed as differentiated (330/4674 cells), n=10. For STIM1 
knockdown ~7% of cells were classed as differentiated (349/4980 cells), n=12. There 
was a significant increase in the number of differentiated cells in control 9cRA and 
STIM1 knockdown cells compared to control EtOH treated cells, P<0.001***. 
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5.2.4 Overexpression of STIM1 in 9cRA-differentiated cells restores SOCE and 
decreases the extent of morphological differentiation 
SOCE is down-regulated in 7 day 9cRA-differentiated N-type cells (Figure 4.4) as is the 
protein STIM1 (Figure 5.1). Furthermore, knockdown of the STIM1 protein in 
untreated (i.e. proliferating) N-type cells resulted in the down-regulation of SOCE 
(Figure 5.3). As knockdown of STIM1 resulted in the down-regulation of SOCE the 
next step was to investigate whether overexpression of STIM1 in 9cRA-differentiated 
cells (i.e. cells in which STIM1 and SOCE is down-regulated) would restore SOCE to 
levels seen in proliferating cells.  
 
Three sets of cells were used, one set was treated with EtOH for 7 days and the other 
two sets were treated with 9cRA for 7 days. Following this the EtOH and one of the 
9cRA treated sets were transfected with control vector (pcDNA 3.1) for 24 hours and 
the other 9cRA treated set was transfected with Cherry-STIM1 for 24 hours (Methods 
2.3.2). Cells treated with EtOH for 7 days and then transfected with the control vector 
for 24 hours will be referred to as EtOH control cells. Cells treated with 9cRA for 7 
days and then transfected with the control vector for 24 hours will be referred to as 
9cRA control cells. Cells treated with 9cRA for 7 days and then transfected with 
Cherry-STIM1 will be referred to as STIM1 overexpressed cells.  
 
Following treatment and transfection cells were harvested for protein, Ca
2+
 add-back 
experiments were performed and corresponding DIC images were taken. 
 
STIM1 was present in EtOH control, 9cRA control and STIM1 overexpressed cells as 
identified by the presence of a band at 84kDa in response to anti-STIM1 antibody 
(Figure 5.8a). As expected, STIM1 expression was significantly down-regulated in 
9cRA control cells compared to EtOH control cells, P<0.05. The band detected at 
~104kDa indicates overexpression of STIM1 (the band is higher than the molecular 
weight of STIM1 due to the presence of the cherry tag). STIM1 expression was 
significantly increased in STIM1 overexpressed cells compared to EtOH and 9cRA 
control cells, P<0.001.  
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The protein Bcl-2 is up-regulated in 9cRA controls and in STIM1 overexpressed cells in 
comparison to EtOH control cells, as determined by a band detected at 26kDa in 
response to anti-Bcl-2 antibody. This indicates that biochemical differentiation of the 
cells had occurred in response to 9cRA treatment and this had not been affected by 
STIM1 protein overexpression (Figure 5.8a and c).  
 
Ca
2+
 add-back experiments revealed store depletion in response to TG (200nM) was not 
significantly different between EtOH control (12.96±1.38µMs), 9cRA control 
(9.90±2.14µMs) and STIM1 overexpressed cells (9.89±0.95µMs), P>0.05. As expected 
however, SOCE in response to the addition of Ca
2+
 (2mM) was significantly down-
regulated in 9cRA control cells (15.06±1.10µMs) compared to EtOH control cells 
(23.06±1.11µMs), P<0.01. This result is consistent with previous data where 7 day 
9cRA treatment of N-type cells down-regulated SOCE (Figures 4.4). SOCE in response 
to the addition of Ca
2+
 in STIM1 overexpressed cells (20.35±1.33µMs) was not 
significantly different to EtOH control cells, P>0.05. Overexpression of STIM1 in 
9cRA-differentiated cells has the ability to restore SOCE in cells which previously had 
down-regulated SOCE. This further supports a role for STIM1 in SOCE in N-type cells.  
 
Corresponding DIC images revealed that, as expected, 9cRA control cells were 
significantly more differentiated compared to EtOH control cells; 36.14±3.88% 
compared to 2.33±0.46%, P<0.001 (Figure 5.10). This result is similar to previous data 
where 7 days 9cRA treatment saw a significant increase in the extent of morphological 
differentiation compared to EtOH treated cells (Figure 3.2). The extent of cellular 
differentiation in STIM1 overexpressed cells was 21.27±4.35%, although significantly 
higher than EtOH controls, P<0.05 this was also significantly lower compared to 9cRA 
controls, P<0.05. Overexpression of STIM1 therefore reduces the level of 
differentiation normally seen following 9cRA treatment suggesting that STIM1 drives 
the cells toward a proliferating state.  
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Figure 5.8 Overexpression of STIM1 in N-type cells 
Cells were treated with EtOH or 9cRA for 7 days followed by transfection with either 
control vector or cherry-STIM1 for 24 hours. O/E: Overexpression a) STIM1 is 
expressed in EtOH control cells (EC), 9cRA control cells (9C) and STIM1 
overexpressed cells (9S) as identified by the presence of a band at 84kDa in response to 
anti-STIM1 antibody and for STIM1 overexpressed cells at ~104kDa due to the 
presence of the cherry tag. Blots were re-probed with anti-β-actin antibody (42kDa), 
used as a loading control and with anti-Bcl-2 antibody (26kDa), used as a biochemical 
marker of differentiation.  b) Quantitative measurements of bands were performed using 
densitometry (ImageJ software, Methods 2.6.9) where STIM1 was expressed as a ratio 
of β-actin. STIM1 protein expression was significantly down-regulated in 9cRA control 
cells compared to EtOH control cells, P<0.05
*
 and was significantly up-regulated in 
STIM1 overexpressed cells compared to EtOH and 9cRA control cells (P<0.001
***
). c) 
Quantification of Bcl-2 protein expression revealed Bcl-2 was significantly increased in 
9cRA control and STIM1 overexpressed cells compared to EtOH control cells, P<0.05
*
. 
n=4.  
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Figure 5.9 Overexpression of STIM1 in 9cRA-differentiated N-type cells 
restores SOCE 
Cells were treated with EtOH or 9cRA for 7 days followed by transfection with either 
control vector or Cherry-STIM1. O/E: Overexpression. Store depletion in response to 
the addition of TG (200nM) was not significantly different between EtOH control, 
9cRA control and STIM1 overexpressed cells (P>0.05). SOCE in response to the 
addition of Ca
2+
 (2mM)  was significantly down-regulated in 9cRA control cells 
compared to EtOH control cells, P<0.01**. SOCE in STIM1 overexpressed cells was 
significantly up-regulated compared to 9cRA control cells, P<0.05
*
 and not 
significantly different to EtOH control cells, P>0.05. n=11. 
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Figure 5.10 Overexpression of STIM1 in 9cRA-differentiated cells decreases 
morphological differentiation 
Cells were treated with EtOH or 9cRA for 7 days and then transfected with either 
control vector or Cherry-STIM1 for 24 hours. O/E: Overexpression. DIC image of N-
type cells treated with a) EtOH followed by transfection with control vector, b) 9cRA 
followed by transfection with control vector and c) 9cRA followed by transfection with 
Cherry-STIM1. Scale bars represent 50µm. d) Quantification of DIC images; 
differentiated cells (neurite extensions ≥50µm) were expressed as a percentage of the 
total cell population. The percent differentiation in EtOH control cells was ~2% 
(51/2036 cells), n=6, in 9cRA control cells was ~36% (504/1752 cells), n=12 and in 
STIM1 overexpressed cells ~21% (171/786 cells), n=6. The extent of differentiation 
was significantly higher in 9cRA control cells, P<0.001
***
 and STIM1 overexpressed 
cells, P<0.05
*
 compared to EtOH control cells. However, differentiation was 
significantly reduced in STIM1 overexpressed cells compared to 9cRA control cells, 
P<0.05
*
.  
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5.3 Discussion 
A down-regulation in SOCE was observed in 9cRA-differentiated SH-SY5Y and N-
type cells (Chapter 4). The down-regulation in SOCE was accompanied by a down-
regulation in STIM1 protein expression (Figure 5.1), consistent with a role for STIM1 
in SOCE (Roos et al., 2005; Liou et al., 2005; Zhang et al., 2005).  
 
To investigate the role of STIM1 in proliferating N-type cells, STIM1 was knocked 
down (Figure 5.2) and the effects on SOCE and differentiation were determined. 
Knockdown of STIM1 in proliferating N-type cells resulted in down-regulated SOCE 
(Figure 5.3), again consistent with a role for STIM1 in SOCE. Knockdown of STIM1 
did not induce biochemical (Figure 5.2) or morphological (Figure 5.4) differentiation in 
proliferating N-type cells, suggesting that the down-regulation in STIM1 alone is not 
sufficient to induce the differentiation of cells that is observed following 9cRA 
treatment.  
 
To investigate whether the down-regulation of STIM1 seen in 9cRA-differentiated N-
type cells plays a role in the 9cRA-induced switch from proliferation to differentiation, 
STIM1 was knocked down in proliferating cells. These cells were then induced to 
differentiate by the addition of 9cRA (Figure 5.5). Knockdown of STIM1 in 
proliferating N-type cells down-regulated SOCE to a similar level observed in control 
9cRA cells (Figure 5.6). SOCE is therefore not further down-regulated by 9cRA 
treatment following STIM1 knockdown suggesting that 9cRA treatment down-regulates 
STIM1 to a level that has already been achieved by knockdown. Knockdown of STIM1 
in proliferating N-type cells did not prevent 9cRA-induced differentiation where the 
extent of differentiation was comparable to control 9cRA cells (Figure 5.7). That 
premature down-regulation of STIM1 did not prevent 9cRA-induced differentiation 
suggests that normal levels of STIM1 are not required for 9cRA to induce 
differentiation.  
 
Next it was investigated as to whether down-regulation of STIM1 was required to 
maintain down-regulated SOCE and the differentiated state of N-type cells. STIM1 was 
overexpressed in 9cRA-differentiated N-type cells (Figure 5.8). Overexpression of 
STIM1 restored SOCE to levels comparable to that of proliferating cells (Figure 5.9). 
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This result shows that, although not normally observed in differentiated N-type cells, 
these cells are capable of supporting a SOCE response involving STIM1. Interestingly, 
overexpression of STIM1 in 9cRA-differentiated N-type cells reduced the number of 
differentiated cells compared to 9cRA controls (Figure 5.10), as determined 
morphologically. SOCE and STIM1 appear to be associated with a proliferative state in 
N-type cells and raises the possibility that STIM1 down-regulation is part of the 
molecular mechanism by which cells remain in the differentiated state. 
 
The observation that in proliferating N-type cells knockdown of STIM1 down-regulates 
SOCE has also been observed in many other cell types, including endothelial progenitor 
cells (Kuang et al., 2010; Shi et al., 2010), proliferating endothelial cells (Abdullaev et 
al., 2008), vascular smooth muscle cells (Aubart et al., 2009; Portier et al., 2009), 
myoblasts (Darbellay et al., 2009; 2010) and adipocytes (Graham et al., 2009).  
 
Also consistent with these findings in N-type SH-SY5Y cells, knockdown of STIM1 in 
HEK293 cells inhibited SOCE and did not itself induce differentiation (El Boustany et 
al., 2010). In other cell types however knockdown of STIM1 expression alone appears 
sufficient to influence differentiation. For example, knockdown of STIM1 decreased 
differentiation in myoblasts (Darbellay et al., 2009, 2010), but increased differentiation 
in adipocytes (Graham et al., 2009). 
 
STIM1 down-regulation in N-type SH-SY5Y cells is not alone sufficient to induce 
differentiation, however overexpression studies indicated that normal down-regulation 
could be required to maintain the differentiated state. A similar result was found in 
adipoctyes, where overexpression of STIM1 increased SOCE and also hindered the 
ability of the cells to differentiate (Graham et al., 2009). The reduction in differentiation 
observed in STIM1 overexpressing N-type cells suggests that STIM1 favours 
proliferation of cells. In other cell types STIM1 has been found to be involved in 
proliferation. For example, STIM1 becomes upregulated in proliferating vascular 
smooth muscle cells (Aubart et al., 2009; Portier et al., 2009) and is also transiently up-
regulated during the initial phase of myogenesis of C2C12 cells (Kiviluoto et al., 2011). 
Further evidence consistent with results obtained in this study, STIM1 expression 
decreases over the course of osteoclast differentiation (Zhou et al., 2011) and RA 
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treatment of rat mesangial cells down-regulated SOCE and STIM1 protein expression 
which was associated with decreased proliferation (Zhang et al., 2007). 
 
It is noteworthy that 9cRA-induced STIM1 down-regulation was confined to N-type 
SH-SY5Y cells. N-type cells are progenitors to neurons of the SNS (Introduction 1.2). 
Excitable cells (such as neuronal cells) possess alternative families of PM Ca
2+
 
channels, notably VOCs, which may provide alternative Ca
2+
 entry pathways through 
which ER Ca
2+
 stores can be replenished (Berridge, 1998). A previous study from the 
laboratory (Brown et al., 2005) has shown that an up-regulation in VOCE may occur in 
9cRA-differentiated SH-SH5Y cells. In S-type cells SOCE was unaltered following 
9cRA-induced differentiation (Chapter 4). Consistent with no change in SOCE, there 
was no change in STIM1 expression following 9cRA treatment (Figure 5.1). S-type 
cells are precursors to non-neuronal cell types, which are non-electrically excitable. It is 
well established that SOCE is essential for the generation of Ca
2+
 signals in the majority 
of non-excitable cells (Parekh and Putney, 2005). It is therefore not surprising that S-
type cells retain SOCE in both proliferating and differentiated states.  
 
In summary, these finding provide a possible molecular mechanism underlying the 
down-regulation of SOCE observed in N-type SH-SY5Y cells (Chapter 4). The effects 
on SOCE observed following both knockdown and overexpression of STIM1 in N-type 
SH-SY5Y cells, are consistent with a role for STIM1 in SOCE and contribute to the 
large body of evidence indicating that STIM1 is the ER Ca
2+
 sensor that mediates SOCE 
(Introduction 1.6.1). Knockdown studies of STIM1 in proliferating N-type cells did not 
support a role for STIM1 in the induction of differentiation that is observed following 
9cRA treatment. However, overexpression of STIM1 in differentiated N-type cells 
suggests that STIM1 may play a role in maintaining cells in a proliferative state and 
therefore that the 9cRA-induced down-regulation of STIM1 may be required to 
maintain cells in a differentiated state. 
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6.1 Introduction 
The proteins STIM1, Orai1 and TRPC1 have been demonstrated to be involved in 
SOCE (Introduction, 1.6). This chapter focuses on the involvement of Orai1 in SOCE 
and also in differentiation of N-type cells. 9cRA-induced differentiation resulted in a 
significant down-regulation in SOCE (Chapter 4) and in the expression of STIM1 
(Chapter 5) in N-type cells. SOCE and the expression of STIM1 remained unaffected in 
S-type cells (Chapters 4 and 5 respectively).  
 
As Orai1 is proposed to form the SOC that STIM1 activates in response to store 
depletion, the relationship between Orai1 expression, SOCE and also differentiation 
was investigated in N-type cells. In order to do this Orai1 protein expression was both 
knocked down (using siRNA transfection) and overexpressed (using plasmid DNA 
transfection) in N-type cells (Methods 2.3). Manipulation of Orai1 expression was 
quantified by western blot (Methods 2.6). The effects on SOCE were measured using 
Ca
2+
 imaging experiments (Methods 2.8) and the effects on differentiation were 
determined morphologically by analysis of DIC images (Methods 2.4) and also 
biochemically by measurement of Bcl-2 expression. 
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6.2 Results 
6.2.1 Orai1 in SH-SY5Y, N- and S-type cells before and after 9cRA-induced 
differentiation 
SOCE becomes down-regulated in SH-SY5Y and N-type cells following 9cRA-induced 
differentiation, it however remains unchanged in S-type cells (Chapter 4). In order to 
determine any changes in Orai1 protein expression associated with the observed 
changes in SOCE, western blots were performed on protein extracted from SH-SY5Y, 
N- and S-type cells before and after 9cRA-induced differentiation.  
 
Orai1 is expressed in proliferating (7 day EtOH treated) and differentiated (7 day 9cRA 
treated) SH-SY5Y, N-type and S-type cells as determined by a band detected at 47kDa 
by an anti-Orai1 antibody (Figure 6.1a). Blots were re-probed with β-actin, used as a 
loading control, and Orai1 was then expressed as a ratio of β-actin in order to quantify 
changes in band intensity (Figure 6.1b).  
 
Orai1 protein expression was significantly decreased in SH-SY5Y cells by ~60% 
(P=0.0415) and in N-type cells by ~64% (P=0.0379) following 9cRA-induced 
differentiation. The extent of down-regulation of SOCE for SH-SY5Y cells was ~48% 
(Figure 4.2) and for N-type cells was ~49% (Figure 4.4). The changes observed in 
SOCE are similar to those seen in Orai1 protein expression and are consistent with the 
involvement of Orai1 in the process of SOCE in SH-SY5Y and N-type cells. The level 
of Orai1 protein expression in S-type cell populations remained unchanged following 
9cRA-induced differentiation (P=0.6605, Figure 6.1b). This is consistent with the level 
of SOCE in S-type cells following 9cRA-induced differentiation, which also remained 
unchanged after treatment (Figure 4.6).  
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Figure 6.1 Orai1 expression decreases in SH-SY5Y and N-type cells 
following 9cRA-induced differentiation  
SH-SY5Y, N-type and S-type cells were treated with EtOH (proliferating - P) or 9cRA 
(differentiated - D) for 7 days. Following treatment cells were harvested for protein. a) 
Western blot performed on protein extracts. Blots were probed with anti-Orai1 antibody 
which detected a band at 47kDa. Blots were re-probed with anti-β-actin antibody which 
detected a band at 42kDa. b) Quantitative analysis of Orai1 expression as determined by 
densitometry using ImageJ software (Methods 2.6.9); Orai1 was expressed as a ratio of 
β-actin expression (loading control). Orai1 protein expression was significantly reduced 
in 9cRA-differentiated SH-SY5Y cells, P=0.0415
*
 and also N-type cells, P=0.0379
*
 
compared to proliferating controls. Orai1 protein expression was unchanged in S-type 
cells following 9cRA treatment, P=0.6605. n=4. 
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6.2.2 Knockdown of Orai1 in N-type cells down-regulates SOCE and induces 
morphological differentiation 
9cRA-induced differentiation of both SH-SY5Y and N-type cells results in the down-
regulation of SOCE (Figures 4.2 and 4.4 respectively) and also Orai1 protein expression 
(Figure 6.1). In S-type cells no changes were seen in either SOCE (Figure 4.8) or Orai1 
protein expression (Figure 6.1) following 9cRA-induced differentiation and therefore 
these cells were not studied further. SH-SY5Y cells and N-type cells had similar levels 
of Orai1 expression, which confirmed that the SH-SY5Y cell line used in this study 
were predominantly composed of N-type cells. N-type cells were therefore used for the 
remainder of experiments in this chapter.  
 
To investigate whether down-regulation of Orai1 could be responsible for down-
regulation of SOCE, Orai1 protein expression was knocked down in untreated (i.e. 
proliferating) N-type cells (Figure 6.2). Orai1 protein expression was knocked down by 
transfecting the cells with Orai1 siRNA for 48 hours (Methods, 2.3.1). Control cells 
were transfected with a scrambled sequence not targeted to a specific gene (control 
siRNA). Transfection of N-type cells with Orai1 siRNA successfully resulted in the 
knockdown of Orai1 protein expression as observed by the reduced band intensity at 
47kDa as detected by anti-Orai1 antibody in comparison to control siRNA transfected 
cells (Figure 6.2a). β-actin protein expression was used as a loading control to enable 
quantification of Orai1 knockdown, where Orai1 was expressed as a ratio of β-actin 
protein expression (Figure 6.2b). Orai1 protein expression was significantly knocked 
down by ~62% in Orai1 siRNA transfected cells compared to control siRNA transfected 
cells, P=0.0131. 
 
Bcl-2 protein expression was used as a measure of biochemical differentiation (Figure 
6.2a) and was quantified by the expression of Bcl-2 as a ratio of β-actin expression 
(Figure 6.2c). Bcl-2 protein expression was not significantly different between control 
siRNA and Orai1 siRNA transfected cells, P=0.3268.  
 
Following transfection of cells and the subsequent knockdown of Orai1 protein, Ca
2+
 
add-back experiments were performed to measure SOCE and DIC images were taken to 
determine the extent of morphological differentiation.  
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Ca
2+
 add-back experiments revealed that store depletion (TG response) was not 
significantly different between control siRNA (6.85±0.83µMs) and Orai1 siRNA 
(5.86±0.71µMs) transfected cells, P=0.3714 (Figure 6.3). SOCE (Ca
2+
 response) 
following store depletion was however significantly down-regulated in Orai1 siRNA 
transfected cells (6.30±1.48µMs) compared to control siRNA transfected cells 
(13.67±1.49µMs), P=0.0015. Knockdown of the Orai1 protein down-regulated SOCE 
by ~54% revealing the role that Orai1 plays in SOCE in proliferating N-type cells.  
 
DIC images were taken of the cells to correspond with the protein samples and the Ca
2+
 
add-back experiments to see whether there was any affect on differentiation as 
determined by neurite length (≥50µm) (Figure 6.4). DIC images of control siRNA 
transfected cells revealed cellular differentiation to be 3.21±0.35% compared to Orai1 
siRNA transfected cells which were 8.13±1.36%, P=0.0127. Knockdown of Orai1 in N-
type cells has therefore significantly induced morphological differentiation. This would 
suggest that the Orai1 protein plays a key role in the switch from proliferation to 
differentiation in N-type cells as knockdown of Orai1 is sufficient to induce 
morphological differentiation. Knockdown of Orai1 had no effect on proliferation as 
determined by the mean number of cells counted from each coverslip; control siRNA; 
527.25±45.95, n=4 vs. Orai1 siRNA; 486.50±20.75, n=4, P=0.4498. The increase in 
differentiated cells as determined by morphological differentiation was not consistent 
with biochemical differentiation as measured by Bcl-2 protein expression which 
remained similar to control siRNA cells (Figure 6.2c). 
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Figure 6.2 Knockdown of Orai1 in N-type cells 
N-type cells were transfected with either control siRNA or Orai1 siRNA for 48 hours. 
a) Western blot performed on protein extracted from control siRNA (C) and Orai1 
siRNA (O) transfected cells. A band at 47kDa was detected with anti-Orai1 antibody. 
Blots were re-probed with anti-β-actin antibody (42kDa), used as a loading control and 
with anti-Bcl-2 antibody (26kDa), used as a biochemical marker of differentiation. b) 
Quantitative measurements were performed on western blots by densitometry (using 
ImageJ software, Methods 2.6.9). Orai1 was significantly down-regulated following 
Orai1 siRNA transfection compared to control siRNA transfected cells; P=0.0131. c) 
Quantitative measurements of Bcl-2 protein expression show that Bcl-2 expression was 
not significantly different between control siRNA and Orai1 siRNA transfected cells; 
P=0.3268. n=4. 
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Figure 6.3 Knockdown of Orai1 in N-type cells down-regulates SOCE 
N-type cells were transfected with either control siRNA or Orai1 siRNA for 48 hours 
following which Ca
2+
 add-back experiments were performed. Store depletion in 
response to the addition of TG (200nM) was not significantly different between control 
siRNA and Orai1 siRNA transfected cells, P=0.3714. SOCE in response to the addition 
of Ca
2+
 (2mM) was significantly down-regulated in Orai1 siRNA transfected cells 
compared to control siRNA transfected cells (P=0.0015
**
). For control siRNA 
transfected cells n=15 and for Orai1 siRNA transfected cells n=15. 
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Figure 6.4 Knockdown of Orai1 in N-type cells induces morphological 
differentiation 
Cells were transfected with either control siRNA or Orai1 siRNA for 48 hours. DIC 
image of N-type cells transfected with a) control siRNA and b) Orai1 siRNA. Scale 
bars equal 50µm. c) Quantification of DIC images; differentiated cells (neurite 
extensions ≥50µm) were counted and expressed as a percentage of the total cell 
population. For control siRNA ~3% of cells were classed as differentiated (66/2109 
cells). For Orai1 siRNA ~8% of cells were classed as differentiated (159/1946 cells). 
There was a significant increase in the extent of morphological differentiation in Orai1 
siRNA transfected cells compared to control siRNA transfected cells, P=0.0127
*
. n=4. 
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6.2.3 Knockdown of Orai1 in N-type cells followed by 9cRA treatment down-
regulates SOCE and enhances morphological differentiation 
The knockdown of Orai1 alone in N-type cells down-regulated SOCE (Figure 6.3) and 
also significantly induced morphological differentiation (Figure 6.4). In the next series 
of experiments it was investigated whether knockdown of Orai1 affected the ability of 
9cRA to further induce differentiation of N-type cells.  
 
Orai1 was knocked down in N-type cells by transfection with Orai1 siRNA for 48 
hours. Following knockdown cells were then treated with either EtOH or 9cRA for a 
further 3 days. In total this amounts to 5 days treatment; 48 hours of transfection 
followed by 3 days of EtOH or 9cRA treatment. Three sets of cells were used; two sets 
were transfected with control siRNA for 48 hours, one was then treated with EtOH and 
the other with 9cRA for 3 days. The final set was transfected with Orai1 siRNA for 48 
hours followed by 9cRA treatment for 3 days. Henceforth cells transfected with control 
siRNA followed by EtOH treatment will be referred to as control EtOH cells, those 
transfected with control siRNA followed by 9cRA treatment will be referred to as 
control 9cRA cells and those transfected with Orai1 siRNA followed by 9cRA 
treatment will be referred to as Orai1 knockdown cells.  
 
Western blot analysis showed the expression of Orai1, as identified by the presence of a 
band at 47kDa in response to anti-Orai1 antibody, in control EtOH, control 9cRA and 
Orai1 knockdown cells (Figure 6.5). Expression of Orai1 as a ratio of β-actin expression 
revealed a knockdown in Orai1 protein expression by ~41% in control 9cRA cells and 
~35% in Orai1 knockdown cells. 
 
Bcl-2 protein expression was used as a biochemical measure of differentiation (Figure 
6.5a and c). Bcl-2 protein expression was increased in control 9cRA cells and Orai1 
knockdown cells compared to EtOH control cells. 
  
Following transfection of cells and the subsequent knockdown of Orai1 protein, Ca
2+
 
add-back experiments were performed to measure SOCE and DIC images were taken to 
determine the extent of morphological differentiation. 
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Ca
2+
 add-back experiments revealed that there was no significant difference in store 
depletion between control EtOH (12.56±1.89µMs), control 9cRA (11.75±0.76µMs) and 
Orai1 knockdown cells (12.65±0.77µMs), P>0.05. SOCE was down-regulated in 
control 9cRA cells (13.25±1.77µMs) compared to control EtOH cells (21.52±1.11µMs), 
P<0.05 (Figure 6.6). This result shows a similar relationship to 7 day EtOH and 9cRA 
treated cells (Figure 4.4), confirming that following 3 days 9cRA treatment SOCE 
becomes significantly down-regulated. SOCE measured in Orai1 knockdown cells 
(15.65±1.03µMs) was also significantly down-regulated compared to control EtOH 
cells (P<0.05) but not to control 9cRA cells (P>0.05). 
 
DIC images were taken of the cells to correspond with the protein samples and the Ca
2+
 
add-back experiments performed in order to see whether there was any affect on 
morphological differentiation (Figure 6.7). Images of control EtOH cells revealed 
morphological differentiation to be 1.21±0.12% compared to control 9cRA cells which 
were classed as 6.95±0.52% differentiated; P<0.001. This confirmed that the 
transfection procedure did not affect the ability of the cells to differentiate as the extent 
of differentiation was comparable to 3 day 9cRA treated cells (Figure 3.2). Orai1 
knockdown cells were determined to be 14.44±0.94%, significantly more differentiated 
than both control EtOH and control 9cRA cells, P<0.001. These results demonstrate that 
knockdown of Orai1 in N-type enhances morphological differentiation induced by 
9cRA treatment without enhancing biochemical differentiation as judged by Bcl-2 
expression. This is consistent with the effects on untreated cells where Orai1 
knockdown induced morphological differentiation (Figure 6.4) independently of Bcl-2 
expression (Figure 6.2).    
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Figure 6.5 Knockdown of Orai1 in N-type cells followed by 9cRA treatment 
N-type cells were transfected with either control siRNA or Orai1 siRNA for 48 hours 
and then treated with either EtOH or 9cRA for a further 3 days. a) Western blots were 
performed on protein extracted from control EtOH (CE), control 9cRA (C9) and Orai1 
knockdown (O9) cells. A band at 47kDa was detected with anti-Orai1 antibody. Blots 
were re-probed with anti-β-actin antibody (42kDa), used as a loading control and with 
anti-Bcl-2 antibody (26kDa), used as a biochemical marker of differentiation. b) 
Quantitative measurements were performed on western blots by densitometry (using 
ImageJ software, Methods 2.6.9). Orai1 was decreased in control 9cRA cells and Orai1 
knockdown cells compared to control EtOH cells. c) Quantitative measurements of Bcl-
2 protein expression show that Bcl-2 expression was increased in both 9cRA treated 
cells and Orai1 knockdown cells compared to control EtOH cells, n=1. 
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Figure 6.6 Knockdown of Orai1 in N-type cells followed by 9cRA treatment 
down-regulates SOCE 
N-type cells were transfected with either control siRNA or Orai1 siRNA for 48 hours, 
followed by EtOH or 9cRA treatment for 3 days. Ca
2+
 add-back experiments were 
performed on cells following treatment. Store depletion in response to the addition of 
TG (200nM) was not significantly different between control EtOH, control 9cRA and 
Orai1 knockdown cells, P>0.05. SOCE in response to the addition of Ca
2+
 (2mM) was 
significantly down-regulated in control 9cRA cells compared to control EtOH cells 
(P<0.05
*
). SOCE in Orai1 knockdown cells was also significantly down-regulated 
compared to control EtOH cells, P<0.05
*
 but not to control 9cRA cells, P>0.05. For 
control EtOH cells n=3, control 9cRA cells n=5 and for Orai1 knockdown cells n=8. 
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Figure 6.7 Knockdown of Orai1 in N-type cells followed by 9cRA treatment 
enhances morphological differentiation 
Cells were transfected with either control siRNA or Orai1 siRNA for 48 hours and then 
treated with EtOH or 9cRA for 3 days. DIC image of N-type cells transfected with a) 
control siRNA followed by EtOH treatment, b) control siRNA followed by 9cRA 
treatment and c) Orai1 siRNA followed by 9cRA treatment. Scale bars represent 50µm. 
d) Quantification of DIC images; differentiated cells (neurite extensions ≥50µm) were 
counted and expressed as a percentage of the total cell population. For control EtOH 
~1% of cells were classed as differentiated (88/7399 cells) n=8. For control 9cRA ~7% 
of cells were classed as differentiated (330/4674 cells) n=10. For Orai1 knockdown 
~14% of cells were classed as differentiated (586/4152 cells) n=12. The extent of 
differentiation was significantly higher in 9cRA control cells and Orai1 knockdown 
cells compared to control EtOH cells, P<0.001
***
 and was significantly higher in Orai1 
knockdown cells compared to control 9cRA cells, P<0.001
***
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6.2.4 Overexpression of Orai1 in 9cRA-differentiated cells restores SOCE and 
decreases the extent of morphological differentiation 
SOCE is down-regulated in 7 day 9cRA-differentiated N-type cells (Figure 4.4) as is the 
protein Orai1 (Figure 6.1). Furthermore, knockdown of Orai1 in untreated (i.e. 
proliferating) N-type cells resulted in the down-regulation of SOCE (Figure 6.3). As 
knockdown of Orai1 resulted in the down-regulation of SOCE the next step was to 
investigate whether overexpression of Orai1 in 9cRA-differentiated cells (i.e. cells in 
which Orai1 and SOCE is down-regulated) would restore SOCE to levels seen in 
proliferating cells.  
 
Three sets of cells were used, one set was treated with EtOH for 7 days and the other 
two sets were treated with 9cRA for 7 days. Following this the EtOH and one of the 
9cRA treated sets were transfected with control vector (pcDNA 3.1) for 24 hours and 
the other 9cRA treated set was transfected with GFP-Orai1 for 24 hours (Methods 
2.3.2). Cells treated with EtOH for 7 days and then transfected with the control vector 
pcDNA 3.1 for 24 hours will henceforth be referred to as EtOH control cells. Cells 
treated with 9cRA for 7 days and then transfected with the control vector pcDNA 3.1 
for 24 hours will be referred to as 9cRA control cells. Cells treated with 9cRA for 7 
days and then transfected with the GFP-Orai1 will be referred to as Orai1 overexpressed 
cells.  
 
Following treatment and transfection cells were harvested for protein, Ca
2+
 add-back 
experiments were performed and corresponding DIC images were taken. 
 
Orai1 was present in EtOH control, 9cRA control and Orai1 overexpressed cells as 
identified by the presence of a band at 47kDa in response to anti-Orai1 antibody (Figure 
6.8a). As expected, Orai1 expression was significantly decreased in 9cRA control cells 
compared to EtOH control cells, P<0.05. The band detected at ~65kDa indicates 
overexpression of Orai1 (the band is higher than the molecular weight of Orai1 due to 
the presence of the GFP tag). Orai1 expression was significantly increased in Orai1 
overexpressed cells compared to EtOH control and 9cRA control cells, P<0.001.  
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The protein Bcl-2, used as a biochemical marker of differentiation, was significantly 
increased in 9cRA controls and Orai1 overexpressed cells compared to EtOH control 
cells, P<0.05 (Figure 6.8a and c). 
 
Ca
2+
 add-back experiments revealed store depletion in response to TG (200nM) was not 
significantly different between EtOH control (10.16±1.12µMs), 9cRA control 
(9.79±1.54µMs) and Orai1 overexpressed (9.44±0.99µMs) cells, P>0.05. As expected, 
SOCE in response to the addition of Ca
2+
 (2mM) was significantly down-regulated in 
9cRA control cells (14.50±1.97µMs) compared to EtOH control cells (24.60±3.48µMs), 
P<0.001. This result is consistent with previous data where 7 day 9cRA treatment 
down-regulated SOCE in N-type cells (Figure 4.4).  SOCE in response to the addition 
of Ca
2+
 in Orai1 overexpressed cells (22.66±2.27µMs) was however significantly up-
regulated compared to 9cRA control cells, P<0.001 and not significantly different to 
EtOH control cells, P>0.05. Overexpression Orai1 in 9cRA-differentiated cells has the 
ability to restore SOCE in cells which previously had down-regulated SOCE. This 
further supports the important role Orai1 plays in SOCE in these cells.  
 
Corresponding DIC images revealed that, as expected, 9cRA control cells were 
significantly more differentiated compared to EtOH control cells; 36.14±3.88% 
compared to 2.33±0.46%, P<0.001 (Figure 6.10). This result is similar to previous data 
where 7 days 9cRA treatment saw a significant increase in the extent of morphological 
differentiation compared to EtOH treated cells (Figure 3.2). The extent of cellular 
differentiation in Orai1 overexpressed cells was 22.53±2.98%, although significantly 
higher than EtOH control cells, P<0.05 the extent of differentiation was significantly 
lower compared to 9cRA controls, P<0.05. Therefore in Orai1 overexpressed cells a 
greater number of cells were proliferating suggesting Orai1 expression drives cells 
toward a proliferating state. 
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Figure 6.8 Overexpression of Orai1 in N-type cells 
Cells were treated with EtOH or 9cRA for 7 days followed by transfection with either 
control vector or GFP-Orai1. O/E: Overexpression. a) Orai1 is expressed in EtOH 
control cells (EC), 9cRA control cells (9C) and Orai1 overexpressed cells (9O) as 
identified by the presence of a band at 47kDa in response to anti-Orai1 antibody and for 
Orai1 overexpressed cells at ~65kDa due to the presence of the GFP tag. b) 
Quantification of Orai1 protein expression was performed using densitometry (ImageJ 
software, Methods 2.6.9) where Orai1 was expressed as a ratio of β-actin (42kDa), used 
as a loading control. Orai1 protein expression was significantly decreased in 9cRA 
control cells compared to EtOH control cells, P<0.05
*
 and was significantly increased in 
Orai1 overexpressed cells compared 9cRA control cells and EtOH control cells 
(P<0.05
*
), n=4 c) Quantification of Bcl-2 protein expression reveals Bcl-2, a marker of 
biochemical differentiation, was significantly increased in 9cRA control (P=0.0108) and 
Orai1 overexpressed cells (P=0.0193) compared to EtOH control cells, n=3.  
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Figure 6.9 Overexpression of Orai1 in 9cRA-differentiated N-type cells 
restores SOCE 
Cells were treated with EtOH or 9cRA for 7 days followed by transfection with either 
control vector or GFP-Orai1. O/E: Overexpression. Store depletion in response to the 
addition of TG (200nM) was not significantly different between EtOH control, 9cRA 
control and Orai1 overexpressed cells, P>0.05. SOCE in response to the addition of 
Ca
2+
 (2mM) was significantly down-regulated in 9cRA control cells compared to EtOH 
control cells, P<0.001
***
. SOCE in Orai1 overexpressed cells was significantly up-
regulated compared to 9cRA control cells, P<0.001
***
 and not significantly different to 
EtOH control cells, P>0.05. For EtOH control cells n=14, for 9cRA control cells n=12, 
for Orai1 overexpressed cells n=11. 
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Figure 6.10 Overexpression of Orai1 in 9cRA-differentiated cells decreases 
morphological differentiation 
Cells were treated with EtOH or 9cRA for 7 days and then transfected with either 
control vector or Cherry-STIM1 for 24 hours. O/E: Overexpression. DIC image of N-
type cells treated with a) EtOH followed by transfection with control vector, b) 9cRA 
followed by transfection with control vector and c) 9cRA followed by transfection with 
GFP-Orai1. Scale bars represent 50µm. d) Quantification of DIC images; differentiated 
cells (neurite extensions ≥50µm) were expressed as a percentage of the total cell 
population. The percent differentiation in EtOH control cells was ~2% (51/2036 cells), 
n=6, in 9cRA control cells was ~36% (504/1752 cells), n=12 and in Orai1 
overexpressed cells ~23% (141/588 cells), n=6. The extent of differentiation was 
significantly higher in 9cRA control cells, P<0.001
***
 and Orai1 overexpressed cells, 
P<0.01
**
 compared to EtOH control cells. However, differentiation was significantly 
reduced in Orai1 overexpressed cells compared to 9cRA control cells, P<0.05
*
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6.3 Discussion 
A down-regulation in SOCE was observed in SH-SY5Y and N-type cells following 
9cRA-induced differentiation (Chapter 4). The down-regulation in SOCE was 
accompanied by a down-regulation in STIM1 protein expression (Chapter 5), consistent 
with a role for STIM1 in SOCE. Results presented in this chapter show that Orai1 
protein expression also becomes down-regulated following 9cRA-induced 
differentiation of SH-SY5Y and N-type cells (Figure 6.1), consistent with a role for 
Orai1 in SOCE.  
 
To investigate the role of Orai1 in proliferating N-type cells, Orai1 was knocked down 
(Figure 6.2) and the effects on SOCE and differentiation were determined. Knockdown 
of Orai1 in proliferating N-type cells resulted in down-regulated SOCE (Figure 6.3), 
again consistent with a role for Orai1 in SOCE. However, whereas knockdown of 
STIM1 in proliferating cells did not itself induce differentiation (Chapter 5), 
knockdown of Orai1 in proliferating N-type cells induced a significant increase in the 
number of differentiated N-type cells (Figure 6.4). This result suggests that unlike 
STIM1, the down-regulation in Orai1 may be directly involved in the induction of 
differentiation that is observed following 9cRA treatment. One possibility is that Orai1 
may be a negative regulator of differentiation. 
 
To investigate this possibility further we examined whether the down-regulation of 
Orai1 plays a role in the 9cRA-induced switch from proliferation to differentiation. 
Orai1 was knocked down in proliferating N-type cells, these cells were then induced to 
differentiate by the addition of 9cRA (Figure 6.5). Knockdown of Orai1 in proliferating 
cells down-regulated SOCE to a similar level observed in control 9cRA cells (Figure 
6.6). SOCE is therefore not further down-regulated by 9cRA treatment following Orai1 
knockdown, suggesting that 9cRA treatment down-regulates Orai1 to a level that has 
already achieved by knockdown. However, whereas knockdown of STIM1 in a similar 
experiment had no effect on the extent 9cRA-induced differentiation (Chapter 5), N-
type cells with Orai1 knockdown were significantly more differentiated that control 
9cRA cells (Figure 6.7). Thus, not only does down-regulation of Orai1 expression itself 
induce differentiation, down-regulation also enhances the extent of differentiation 
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induced by 9cRA treatment. This result is also consistent with the notion that Orai1 may 
be a negative regulator of differentiation. 
 
To further investigate whether Orai1 may be a negative regulator of differentiation we 
examined whether overexpression of Orai1 in 9cRA-differentiated cells could restore 
SOCE and drive cells towards proliferation. Orai1 was overexpressed in 9cRA-
differentiated N-type cells (Figure 6.8). Overexpression of Orai1 restored SOCE to 
levels comparable to that of proliferating cells (Figure 6.9). This result is again 
consistent with a role for Orai1 in SOCE. Overexpression of Orai1 in 9cRA-
differentiated N-type cells reduced the number of differentiated cells compared to 9cRA 
controls, as determined morphologically (Figure 6.10). This result shows that an 
increased expression of Orai1 drives N-type cells toward proliferation, further 
supporting the notion that Orai1 is a negative regulator of differentiation in these cells. 
 
Knockdown of Orai1 has been shown to down-regulate SOCE in many cell types 
(Introduction 1.6.2). The role of Orai1 in SOCE was first identified in patients with 
SCID with impaired ICRAC which was traced to a single point mutation in Orai1. 
Interestingly, both T and B cells from SCID patients displayed dysfunctional 
proliferation (Feske et al., 2006), thus also highlighting a potential role for Orai1 in 
proliferation. Subsequent studies have confirmed this role as knockdown of Orai1 has 
been reported to inhibit proliferation in endothelial cells (Abdullaev et al., 2008), 
vascular smooth muscle cells (Portier et al., 2009), arterial smooth muscle cells 
(Baryshnikov et al., 2009) and HEK293 cells (El Boustany et al., 2010). Furthermore, 
an increase in Orai1 has been observed following vascular smooth muscle cell injury 
associated with an increased requirement for cellular proliferation (Zhang et al., 2011) 
and also during proliferation of airways smooth muscle cells (Zou et al., 2011).    
 
These data suggest that SOCE channels with Orai1 at their core are required for 
proliferation and that silencing of the protein results in a decrease in proliferation rate. 
In N-type cells, knockdown of Orai1 is required to drive the cells down a differentiation 
pathway. The mechanisms by which Orai1 is able to influence the balance between 
proliferation and differentiation are unknown. An interaction between a cell cycle 
component and a Ca
2+
 channel protein has been described previously: the complex 
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cdc2/cyclin B1 regulates IP3R activity (Malathi et al., 2005). Orai1 may interfere with a 
cell cycle component to induce N-type SH-SY5Y cell proliferation. 
 
It is noteworthy that Orai1 protein expression was unaltered (i.e. not down-regulated) 
following 9cRA-induced differentiation of S-type cells. STIM1 expression was also 
unaltered upon 9cRA-treatment of S-type cells (Chapter 5). These findings would 
explain the observation that SOCE was not down-regulated in 9cRA-differentiated S-
type cells (Chapter 4). Interestingly, the level of expression of Orai1 in S-type cells 
(Figure 6.1) was considerably lower than the level of expression STIM1 (Figure 5.1). 
This raises the possibility that Orai1 may not be the only putative SOCE channel protein 
in S-type cells. 
 
In summary, Orai1 forms an element of SOCE in proliferating N-type cells, along with 
STIM1 (Chapter 5). In addition, evidence suggests that the decrease in Orai1 expression 
observed following 9cRA differentiation is a key enabling step in the differentiation 
process. Orai1 therefore plays a direct role in the switch from proliferation to 
differentiation. This is in contrast to STIM1, which has no direct role in the switch from 
proliferation to differentiation but which may play a role in maintaining the 
differentiated state. Prostate cancer cells with down-regulated Orai1 were more resistant 
to apoptosis (Flourakis et al., 2010). The current standard treatment protocol for high-
risk neuroblastoma in the UK includes the use of retinoic acid, after chemotherapy and 
bone-marrow transplantation (Matthay et al., 1999). However RA-differentiated 
neuroblastoma cells are more resistant to the apoptosis-inducing effects of 
chemotherapeutic drugs (Lasorella et al., 1995), this is a limitation in the use of 
conventional retinoids for neuroblastoma therapy. Whether this resistance could be due 
down-regulation of Orai1 needs to be determined. 
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7.1 Introduction 
The proteins STIM1, Orai1 and TRPC1 have been demonstrated to be involved in 
SOCE (Introduction, 1.6). This chapter focuses on the involvement of TRPC1 in SOCE 
and also in differentiation of N-type cells. 9cRA-induced differentiation of N-type cells 
down-regulated SOCE (Chapter 4) and the levels of STIM1 (Chapter 5) and Orai1 
(Chapter 6) expression. In S-type cells SOCE and the level of STIM1 and Orai1 
expression remained unaffected (Chapters 4, 5 and 6 respectively).  
 
As TRPC1 has been implicated in SOCE, possibly as a SOC itself or as part of a 
complex with STIM1 and Orai1, the relationship between TRPC1 expression, SOCE 
and also differentiation was investigated in N-type cells. In order to do this TRPC1 
protein expression was knocked down (using siRNA transfection) in N-type cells 
(Methods 2.3.1). The effects on SOCE were measured using Ca
2+
 imaging experiments 
(Methods 2.7) and the effects on differentiation were determined morphologically by 
analysis of DIC images (Methods 2.4). 
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7.2 Results 
7.2.1 TRPC1 in SH-SY5Y, N- and S-type cells before and after 9cRA-induced 
differentiation 
SOCE is down-regulated in SH-SY5Y and N-type cells following 9cRA-induced 
differentiation, however it remains unchanged in S-type cells (Chapter 4). In order to 
determine any changes in TRPC1 protein expression associated with the observed 
changes in SOCE, western blots were performed on protein extracted from SH-SY5Y, 
N-type and S-type cells before and after 9cRA-induced differentiation (Methods 2.6).  
 
TRPC1 is expressed in proliferating (7 day EtOH treated) and differentiated (7 day 
9cRA treated) SH-SY5Y and N-type cells, as determined by a band detected at 90kDa 
by an anti-TRPC1 antibody (Figure 7.1a). Blots were re-probed with β-actin, used as a 
loading control; TRPC1 was then expressed as a ratio of β-actin in order to quantify 
changes in band intensity (Figure 7.1b). TRPC1 protein expression increased in SH-
SY5Y cells by ~48% and in N-type cells by ~53% following 9cRA-induced 
differentiation. SOCE in SH-SY5Y and N-type cells was down-regulated following 
9cRA induced differentiation (Chapter 4). This would suggest that TRPC1 is not a SOC 
in SH-SY5Y or N-type cells. TRPC1 was not detected in S-type cells suggesting that 
TRPC1 does not play a role in Ca
2+
 signalling in these cells. Unfortunately due to 
problems with the TRPC1 antibody used this experiment was only performed once. 
TRPC1 protein expression has however previously been shown in our laboratory to 
increase in SH-SY5Y cells following 9cRA-induced differentiation (Figure 7.2). 
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Figure 7.1 TRPC1 expression increases in SH-SY5Y and N-type cells 
following 9cRA-induced differentiation  
Cells were treated with EtOH (proliferating - P) or 9cRA (differentiated - D) for 7 days. 
Following treatment cells were harvested for protein. a) Western blots were performed 
on protein extracts from SH-SY5Y, N-type and S-type cell populations. Blots were 
probed with anti-TRPC1 antibody which detected a band at 90kDa. Blots were re-
probed with anti-β-actin antibody which detected a band at 42kDa. The band detected 
by the β-actin antibody was used as a loading control. b) Quantitative analysis of 
TRPC1 expression as determined by densitometry using ImageJ software (Methods 
2.6.9); TRPC1 was expressed as a ratio of β-actin expression. TRPC1 protein 
expression appears to up-regulated in 9cRA-differentiated SH-SY5Y and N-type cells 
compared to proliferating controls. TRPC1 is not expressed in S-type cells. n=1. 
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Figure 7.2 TRPC1 expression increases in SH-SY5Y following 9cRA-induced 
differentiation  
SH-SY5Y cells were treated with EtOH (proliferating - P) or 9cRA (differentiated - D) 
for 7 days. Following treatment cells were harvested for protein and western blots were 
performed on protein extracts. Blots were probed with anti-TRPC1 antibody which 
detected a band at 90kDa. Blots were re-probed with anti-β-actin antibody used as a 
loading control (42kDa). TRPC1 expression was up-regulated in 9cRA-differentiated 
SH-SY5Y cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The blot presented in this figure (7.2) was performed by Dr Victoria Hann.  
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7.2.2 Knockdown of TRPC1 in proliferating N-type cells does not affect SOCE or 
induce differentiation 
9cRA-induced differentiation of both SH-SY5Y and N-type cells results in the down-
regulation of SOCE (Figures 4.2 and 4.4) and the up-regulation of TRPC1 protein 
expression (Figure 7.1). TRPC1 expression was not detected in S-type cells (Figure 7.1) 
and therefore these cells were not studied further. SH-SY5Y cells and N-type cells so 
far have shown the same results as one another. As in Chapters 5 and 6, N-type cells 
were used for the remainder of studies in this chapter.  
 
Following transfection of cells and the subsequent knockdown of TRPC1 protein, Ca
2+
 
add-back experiments were performed to measure SOCE. DIC images were taken to 
determine the extent of morphological differentiation.  
 
Ca
2+
 add-back experiments revealed that store depletion (TG response) was not 
significantly different between control siRNA (12.53±1.22 µMs) and TRPC1 siRNA 
(13.58±1.23µMs) transfected cells, P=0.5767 (Figure 7.3). SOCE (Ca
2+
 response) 
following store depletion was also not significantly different between control siRNA 
(20.94±1.61µMs) and TRPC1 siRNA (21.45±2.34µMs) transfected cells, P=0.8536. 
That knockdown of TRPC1 protein did not affect SOCE suggests that TRPC1 is not 
involved in the SOCE pathway in proliferating N-type cells.  
 
DIC images of the cells were taken to correspond with the Ca
2+
 add-back experiments to 
see whether there was any affect on differentiation as determined by neurite length 
(≥50µm) (Figure 7.4). DIC images of control siRNA cells revealed morphological 
differentiation to be 3.21±0.35% compared to TRPC1 siRNA cells which were 
3.42±0.38%, P=0.7013. Knockdown of TRPC1 for 48 hours in N-type cells does not 
significantly affect the extent of morphological differentiation. Knockdown of TRPC1 
had no effect on proliferation as determined by the mean number of cells counted from 
each coverslip; control siRNA; 527.25±45.95, n=4 vs. TRPC1 siRNA; 491.75±31.74, 
n=4, P=0.5485. 
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Figure 7.3 Knockdown of TRPC1 in N-type cells does not affect SOCE 
N-type cells were transfected with either control siRNA or TRPC1 siRNA for 48 hours. 
Ca
2+
 add-back experiments were performed on cells following transfection. Store 
depletion in response to the addition of TG (200nM) was not significantly different 
between control siRNA and TRPC1 siRNA transfected cells (P=0.5767). SOCE in 
response to the addition of Ca
2+
 (2mM) was also not significantly different between 
control siRNA and TRPC1 siRNA transfected cells (P=0.8536). For control siRNA 
transfected cells n=15 and for TRPC1 siRNA transfected cells n=9. 
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Figure 7.4 Knockdown of TRPC1 in N-type cells does not induce 
morphological differentiation 
Cells were transfected with either control siRNA or TRPC1 siRNA for 48 hours. DIC 
image of N-type cells transfected with a) control siRNA and b) TRPC1 siRNA. Scale 
bars equal 50µm. c) Quantification of DIC images; differentiated cells (neurite 
extensions ≥50µm) were counted and expressed as a percentage of the total cell 
population. For control siRNA ~3% of cells were classed as differentiated (66/2190 
cells), n=4. For TRPC1 siRNA almost ~3% of cells were classed as differentiated 
(66/1967 cells), n=4. There was no significant difference in the extent of morphological 
differentiation between control siRNA and TRPC1 siRNA transfected cells, P=0.7013. 
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7.2.3 Knockdown of TRPC1 prevents SOCE down-regulation and reduces the 
extent of morphological differentiation induced by 9cRA treatment 
Knockdown of TRPC1 did not inhibit SOCE in proliferating cells (Figure 7.3) or induce 
differentiation (Figure 7.4). In the next series of experiments it was investigated as to 
whether knockdown of TRPC1 affected the ability of 9cRA to down-regulate SOCE or 
induce differentiation of N-type cells.  
 
TRPC1 was knocked down in N-type cells by transfection with TRPC1 siRNA for 48 
hours (Methods 2.3.1). Following knockdown cells were then treated with either EtOH 
or 9cRA for a further 3 days. In total this amounts to 5 days treatment; 48 hours of 
transfection followed by 3 days of EtOH or 9cRA treatment. Data from our laboratory 
have shown that effects of 9cRA on SOCE (i.e. down-regulation) are apparent 
following 3 days of treatment; 3 days treatment is therefore a suitable time scale to 
determine whether knockdown of TRPC1 has any affect on differentiation of 9cRA 
treated cells.  
 
Three sets of cells were used; two sets were transfected with control siRNA for 48 
hours, one was then treated with EtOH and the other with 9cRA for 3 days. The final set 
was transfected with TRPC1 siRNA for 48 hours followed by 9cRA treatment for 3 
days. Henceforth cells transfected with control siRNA followed by EtOH treatment will 
be referred to as control EtOH cells, those transfected with control siRNA followed by 
9cRA treatment will be referred to as control 9cRA cells and those transfected with 
TRPC1 siRNA followed by 9cRA treatment will be referred to as TRPC1 knockdown 
cells. 
 
Following transfection of cells and the subsequent knockdown of TRPC1 protein, Ca
2+
 
add-back experiments were performed to measure SOCE and DIC images were taken to 
determine the extent of morphological differentiation. 
  
Ca
2+
 add-back experiments performed on the cells revealed that there was no significant 
difference in store depletion between control EtOH (12.56±1.89µMs), control 9cRA 
(11.75±0.76µMs) and TRPC1 knockdown (12.87±0.94µMs) cells, P>0.05. SOCE was 
down-regulated in control 9cRA cells (13.25±1.77µMs) compared to control EtOH cells 
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(21.52±1.11µMs), P<0.05 (Figure 7.5). This result shows a similar relationship to 7 day 
EtOH and 9cRA treated cells N-type cells (Figure 4.4), confirming that following 3 
days 9cRA treatment SOCE becomes significantly down-regulated. However, SOCE 
measured in TRPC1 knockdown cells (19.39±2.35µMs) was not significantly different 
compared to control EtOH cells (P>0.05). Knockdown of TRPC1 prevented 9cRA-
induced SOCE down-regulation which suggests that TRPC1 does have a role in SOCE. 
 
DIC images of the cells were taken to correspond with the Ca
2+
 add-back experiments 
performed in order to determine any effects on morphological differentiation (Figure 
7.6). Images of control EtOH cells revealed cellular differentiation to be 1.21±0.12% 
compared to control 9cRA cells which were classed as 6.95±0.52% differentiated; 
P<0.001. This confirmed that the transfection procedure did not affect the ability of the 
cells to differentiate as the extent of differentiation was comparable to 3 day 9cRA 
treated cells (Figure 3.2). TRPC1 knockdown cells were determined to be 5.35±0.53% 
differentiated, significantly higher than control EtOH cells, P<0.001. Notably however, 
the extent of differentiation in TRPC1 knockdown cells was also significantly lower 
than control 9cRA cells (P<0.05). This suggests that knockdown of TRPC1 in N-type 
cells affects the ability of the cells to differentiate in response to 9cRA and that TRPC1 
may play a role in the switch from proliferation to differentiation.    
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Figure 7.5 Knockdown of TRPC1 in N-type cells prevents SOCE down-
regulation induced by 9cRA treatment 
N-type cells were transfected with either control siRNA or TRPC1 siRNA for 48 hours, 
followed by EtOH or 9cRA treatment for 3 days. Ca
2+
 add-back experiments were 
performed on cells following treatment. Store depletion in response to the addition of 
TG was not significantly different between control EtOH, control 9cRA and TRPC1 
knockdown cells, P>0.05. SOCE in response to the addition of Ca
2+
 was significantly 
down-regulated in control 9cRA cells compared to control EtOH cells (P<0.05
*
). SOCE 
in TRPC1 knockdown cells was not significantly different compared to control EtOH 
cells (P>0.05). For control EtOH cells n=3, control 9cRA cells n=5 and for TRPC1 
knockdown cells n=9.  
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Figure 7.6 Knockdown of TRPC1 in N-type cells followed by 9cRA treatment 
affects morphological differentiation 
Cells were transfected with either control siRNA or TRPC1 siRNA for 48 hours and 
then treated with EtOH or 9cRA for 3 days. DIC image of N-type cells transfected with 
a) control siRNA followed by EtOH treatment, b) control siRNA followed 9cRA 
treatment and c) TRPC1 siRNA followed by 9cRA treatment. Scale bars represent 
50µm. d) Quantification of DIC images; differentiated cells (neurite extensions ≥50µm) 
were counted and expressed as a percentage of the total cell population. The percent 
differentiation in control EtOH cells was ~1% (88/7399 cells), n=8, in control 9cRA 
cells ~7% (330/4674 cells), n=10 and in TRPC1 knockdown ~5% (174/3514 cells), n=9. 
Morphological differentiation was significantly higher in control 9cRA and TRPC1 
knockdown cells compared to control EtOH cells P<0.001
***
. However, morphological 
differentiation was significantly lower in TRPC1 knockdown cells compared to control 
9cRA cells, P<0.05
*
.  
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7.3 Discussion 
A down-regulation in SOCE was observed in 9cRA-differentiated SH-SY5Y and N-
type cells (Chapter 4). SOCE down-regulation in these cell types was accompanied by a 
down-regulation in the levels of STIM1 (Chapter 5) and of Orai1 (Chapter 6), consistent 
with the involvement of these proteins in the SOCE pathway. A key finding in the 
present chapter is that, unlike STIM1 and Orai1 which have decreased expression, the 
level of TRPC1 protein expression increases in 9cRA-differentiated SH-SY5Y and N-
type cells (Figures 7.1 and 7.2). This suggests that TRPC1 does not form a SOC in 
9cRA-differentiated SH-SY5Y or N-type cells and instead points to a potential role in 
proliferating cells and/or in the 9cRA-induced switch between proliferation and 
differentiation. TRPC1 was not detected in S-type cells (Figure 7.1) and therefore does 
not form a SOC in S-type cells. 
 
To investigate a potential role for TRPC1 in proliferating N-type cells, TRPC1 was 
knocked down. Knockdown of TRPC1 in proliferating cells did not affect SOCE 
(Figure 7.3) or itself induce morphological differentiation (Figure 7.4), suggesting that 
resting levels of TRPC1 do not form a SOC in proliferating N-type cells or themselves 
influence differentiation. 
 
To investigate whether the increase in TRPC1 levels seen in response to 9cRA-
treatment plays a key role in the 9cRA-induced switch from proliferation to 
differentiation, TRPC1 was knocked down in proliferating cells. These cells were then 
induced to differentiate by addition of 9cRA. Knockdown of TRPC1 in proliferating N-
type cells prevented the level of down-regulation in SOCE normally seen following 
9cRA treatment: SOCE in TRPC1 knockdown cells was comparable to that of control 
EtOH cells (Figure 7.5). In addition, knockdown of TRPC1 affected 9cRA-induced 
morphological differentiation: the extent of differentiation was significantly lower in 
TRPC1 knockdown cells compared to control 9cRA cells (Figure 7.6). All these data 
suggest that, although not a SOC in these cells, the increase in TRPC1 expression 
observed following 9cRA differentiation is necessary for cells to display a fully 
differentiated phenotype. TRPC1 seems likely therefore to play a role in the switch 
from proliferation to differentiation.  
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The reasons as to why increased expression of TRPC1 favours differentiation in N-type 
SH-SY5Y cells are unclear. In hippocampal neurons a dramatic increase in TRPC1 
protein expression was observed following differentiation, though this was also 
associated with an increase in SOCE (Wu et al., 2004). Results from TRPC1 
knockdown studies indicate that the role of TRPC1 in SOCE is variable between cell 
types. For example, in ECs (Abdullaev et al., 2008) and VSMCs (Potier et al., 2009) no 
effect on SOCE was observed following knockdown of TRPC1, however a decrease in 
SOCE was observed in myoblasts (C2C12), (Louis et al., 2008). The up-regulation of 
TRPC1 in differentiated N-type and SH-SY5Y cells could be due to an increase in the 
expression of the protein to act as a ROC in order to compensate for the loss of the 
down-regulated SOCE pathway. The function of TRPC1 as a SOC has been found to be 
regulated in a STIM1 dependent manner where STIM1 heteromultimerizes TRPC1 
channels to determine their function as SOCs (Yuan et al., 2007). Furthermore STIM1 
has been found to covert TRPC1 from a ROC to a SOC by inserting TRPC1 into LRDs 
where TRPC1 functions as a SOC only when inserted into LRDs (Alicia et al., 2008).  
 
The relationship between 9cRA-induced TRPC1 up-regulation and 9cRA-induced 
STIM1 (Chapter 5) and/or Orai1 (Chapter 6) down-regulation is unknown. 
Overexpression of TRPC1 in myoblast (C2C12) cells has been shown to suppress 
STIM1 expression (Louis et al., 2008), providing a potential molecular mechanism by 
which TRPC1 could indirectly influence the level of SOCE. Certainly TRPC1 has been 
shown to interact with STIM1 and Orai1 (Introduction 1.6.3). These studies determined 
regions of interaction that would indicate the involvement of TRPC1 in SOCE through 
ternary complexes with STIM1 and Orai1, these sites of interaction may also be how 
TRPC1 could mediate inhibitory affects (Ong et al., 2007; Ambudkar et al., 2007b; 
Liao et al., 2007, 2008, 2009).   
 
Perhaps STIM1 is down-regulated prior to TRPC1 and the removal of STIM1 inhibition 
allows TRPC1 expression to increase. TRPC1 has been shown to only act as a SOC 
when in the complex and with both STIM1 and Orai1and otherwise is not involved in 
SOCE (Jardin et al., 2008a).  
 
Clearly, whether the increase in TRPC1 expression observed in 9cRA-differentiated 
cells occurs before or after the down-regulation in STIM1 and/or Orai1 expression 
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needs to be investigated. TRPC1 overexpression studies may also be informative. 
Overexpression of TRPC1 in proliferating cells may promote a switch towards 
differentiation which would further support a key role for TRPC1 in controlling 
differentiation in these cells. Lack of availability of a reliable TRPC1 antibody and lack 
of time prevented completion of these experiments. 
 
In summary, TRPC1 does not appear to form a SOC in either proliferating or 
differentiated N-type cells. The increase in TRPC1 expression observed following 
9cRA differentiation appears may be important in allowing cells to obtain a fully 
differentiated phenotype. Decreased expression of TRPC1 seems to favour SOCE and 
proliferation whereas increased expression seems to favour down-regulated SOCE and 
differentiation. 
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8.1 Summary of Findings 
The aim of this study was to investigate the role of Ca
2+
 signalling in differentiation of 
neuroblastoma cells. N- and S-type cell populations enriched from the SH-SY5Y cell 
line were characterised both morphologically and biochemically. 
 
Morphologically N-type cells are small cells with many short neurite-like processes 
emanating from their cell bodies, whereas S-type cells are slightly larger and flatter and 
do not exhibit neurite extensions (Figure 3.4). Following 9cRA-induced differentiation 
both N- and S-type cells change morphology, with N-type cells becoming more 
neuronal-like, with neurite-like extensions of ≥50µm in length and S-type cells 
becoming more epithelial-like with increased cytoplasmic content and transparency 
(Figure 3.6).  
 
 β-Tubulin III was detected in both proliferating and differentiated N- and S-type cells 
(Table 8.1). The expression of β-Tubulin III remained unchanged following 9cRA-
induced differentiation of N-type cells. β-Tubulin III does not distinguish between 
immature and mature neuronal cells and therefore appears to be a indicator solely of 
neuronal cell type, in N-type cells at least. Surprisingly β-Tubulin III was present in S-
type cells, as a neuronal protein this was not expected. However both N- and S-type 
cells are immature cells derived from the neural crest, precursors of multipotent lineages 
that are still able to transdifferentiate into one another. It is therefore possible that the S-
type cells have not fully moved toward a non-neuronal cell type. Consistent with this 
notion is that following 9cRA-induced differentiation, as the cells become more 
epithelial-like, β-Tubulin III decreases. Due to variable expression of β-Tubulin III 
between N- and S-type cells it was still deemed a suitable marker to distinguish between 
the two cell phenotypes. Vimentin was not detected in N-type cells by western blot, 
which was expected as the protein is specific to non-neuronal cell types. Though 
immunofluorescence studies revealed that vimentin was occasionally detected in 
developing neurites of N-type cells (Figure 3.9), however a temporary role for vimentin 
has been identified in neuritogenesis. Vimentin was expressed in both proliferating and 
differentiated S-type cells (Table 8.1). Vimentin was deemed a suitable marker to 
distinguish between N- and S-type cells. Bcl-2 was expressed in proliferating and 
differentiated N-type cells, but was barely detectable in S-type cells (Table 8.1). Bcl-2 
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expression increases following RA-induced differentiation of N-type cells, as 
previously observed in SH-SY5Y cells (Hanada et al., 1993; Lasorella et al., 1995; 
Riddoch et al., 2007), Bcl-2 was therefore used as a biochemical marker of 
differentiation in SH-SY5Y and N-type cells. 
 
SOCE was characterised in N- and S-type cells by measuring changes in [Ca
2+
]i in fura-
2 loaded cells (Chapter 4). Differentiation of N-type cells toward a more neuronal-like 
cell type following 9cRA treatment was associated with a down-regulation in SOCE. 
Excitable cells have other means of Ca
2+
 signal generation, such as through VOCs, it 
has been proposed that as cells become more neuronal-like they rely less on SOCE as a 
means of generating Ca
2+
 signals and to replenish depleted stores (Berridge, 1998). In 
SH-SY5Y cells 9cRA-induced differentiation resulted in an increase in voltage-
dependent Ca
2+
 entry (Brown et al., 2005). S-type cells however showed no change in 
SOCE, though they adapted a more epithelial-like appearance following 9cRA-induced 
differentiation. As non-excitable cells, S-type cells likely rely on SOCE as a major 
pathway to generate Ca
2+
 signals and replenish depleted ER Ca
2+
 stores. It had 
previously been observed in this laboratory that 9cRA-induced differentiation of SH-
SY5Y cells resulted in down-regulated SOCE (Brown et al., 2005). This response can 
now be attributed to N-type cells and not S-type cells.  
 
The level of expression of the three key Ca
2+
 signalling proteins, STIM1, Orai1 and 
TRPC1, was measured in the 9cRA-induced switch from proliferation to differentiation 
by western blot in N- and S-type cells (Table 8.1), to determine the relationship between 
expression and SOCE as these proteins have been implicated in SOCE in numerous 
studies. In N-type cells STIM1 and Orai1 were associated with down-regulated SOCE 
as both STIM1 and Orai1 became down-regulated following 9cRA-induced 
differentiation (Figures 5.1 and 6.1). However, TRPC1 became up-regulated (Figures 
7.1 and 7.2), suggesting that TRPC1 does not form SOCs in N-type cells. 9cRA-induced 
differentiation of SH-SY5Y cells up-regulates a non-SOCE pathway (Brown et al., 
2005). Whether TRPC1 represents the non-SOCE channel protein in differentiated cells 
needs to be elucidated. In S-type cells the expression of STIM1 and Orai1 following 
9cRA-induced differentiation remained unaltered, consistent with no change in SOCE. 
TRPC1 was not detected in S-type cells and therefore S-type cells do not mediate SOCE 
through TRPC1 channels.    
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N-type cells 
 
S-type cells 
 Proliferating Differentiated Proliferating Differentiated 
β-Tubulin III ↑↑ ↑↑ ↑ ↓ 
Vimentin ×
*
 ×
*
 ↑ ↑ 
Bcl-2 ↑ ↑↑ × × 
STIM1 ↑ ↓ ↑ ↑ 
Orai1 ↑ ↓ ↓ ↓ 
TRPC1 ↓ ↑ × × 
 
 
Table 8.1 Summary of proteins expressed in N- and S-type cells  
Protein expression measured in proliferating and 9cRA-differentiated N- and S-type 
cells. ↑; protein was detected, ↑↑; protein was detected at an increased level than 
previously observed, ↓; protein was detected but the level of expression was low ×; 
protein was not/barely detectable. 
*
 Vimentin was not detected in proliferating or 
differentiated N-type cells by western blot (Figure 3.12) but was detected in some 
neurite extensions in immunofluorescence experiments (Figure 3.9).  
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The absolute level of STIM1 and Orai1 expression was variable between N- and S-type 
cells. S-type cells had similar levels of STIM1 compared to proliferating N-type cells, 
yet Orai1 protein expression was reduced compared to proliferating N-type cells. 
Although expression of Orai1 in S-type cells is low, a role for Orai1 as a SOC remains, 
though perhaps there is another SOC functioning in these cell types. S-type cells 
showed no changes in SOCE or Ca
2+
 signalling protein expression following 9cRA-
induced differentiation and therefore S-type cells were not studied further. The 
expression of STIM1, Orai1 and TRPC1 was however manipulated in N-type cells to 
determine a role for these proteins in SOCE and differentiation. Data obtained 
throughout this thesis was consistent with a role for STIM1 and Orai1 in SOCE and a 
role for STIM1, Orai1 and TRPC1 in differentiation. 
 
Knockdown of STIM1 and Orai1 in proliferating N-type cells resulted in down-
regulated SOCE (Table 8.2). Inhibition of SOCE by knockdown of STIM1 has 
previously been observed in SH-SY5Y cells (Roos et al., 2005), though down-
regulation of SOCE following Orai1 knockdown has not previously been reported in 
SH-SY5Y cells. Clearly STIM1 and Orai1 are involved in SOCE in N-type cells and 
appear to have similar role in SOCE down-regulation. However, Orai1 appears to have 
an additional role in the differentiation response of N-type cells. This conclusion was 
based on the observation that knockdown of Orai1 alone induced differentiation of N-
type cells and that knockdown of Orai1 followed by 9cRA treatment enhanced 
differentiation compared to 9cRA treatment alone (Table 8.2). In N-type neuroblastoma 
cells Orai1 therefore appears to be a negative regulator of differentiation. Consistent 
with this role is that overexpression of Orai1 in 9cRA-differentiated cells reduced the 
level of differentiation compared to 9cRA control cells. In contrast, knockdown of 
STIM1 alone did not induce differentiation or enhance differentiation induced by 9cRA, 
arguing against an addition role for STIM1 in regulating differentiation. However, 
overexpression of STIM1 in 9cRA-differentiated cells reduced the extent of 
differentiation (in addition to restoring SOCE) (Table 8.2). This raises the possibility 
that down-regulation of STIM1 in 9cRA-differentiated cells is required to maintain the 
differentiated state. Knockdown of TRPC1 in proliferating N-type cells had no effect on 
SOCE or on differentiation but reduced the extent of SOCE down-regulation and 
differentiation induced by 9cRA. TRPC1 expression may therefore be required for a 
fully functional differentiated phenotype. 
  
 
 
 
Expression 
 
Knockdown 
 
(in proliferating cells) 
Overexpression 
 
(in 9cRA-differentiated cells) 
Protein 
Proliferating 
cells 
Differentiated 
cells 
SOCE 
Induction of 
differentiation 
9cRA-induced 
differentiation 
SOCE 
9cRA-induced 
differentiation 
 
STIM1 
 
↑ ↓ Down-regulates No No effect Restores Reduces 
 
Orai1 
 
↑ ↓ Down-regulates Yes Enhances Restores Reduces 
 
TRPC1 
 
↓ ↑ No effect No Reduces - - 
 
 
Table 8.2 Summary of the results obtained from Ca
2+
 signalling studies using N-type cells in this thesis 
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Based on these results, a model of Ca
2+
 entry pathways in proliferating and 
differentiated N-type cells can be hypothesised (Figure 8.1).  
 
In proliferating N-type cells activation of a G-protein-coupled receptor in the PM results 
in Ca
2+
 release from the ER via the phosphoinostide signalling pathway and in some 
cells via ryanodine receptors (Riddoch et al., 2005). Depletion of ER Ca
2+
 causes 
redistribution of STIM1 to ER-PM junctions where STIM1 interacts with Orai1, which 
forms the SOC in proliferating N-type cells, to allow extracellular Ca
2+
 to enter the cell 
cytosol to replenish depleted ER stores (Putney, 2009). Proliferating cells do not 
express TRPC1.  
 
In differentiated N-type cells STIM1 and Orai1 are not present (or are expressed at very 
low levels) and TRPC1 is upregulated. Depleted ER stores are replenished through Ca
2+
 
entry via a non-SOCE mechanism. The non-SOCE mechanism may constitute a 
diacylglycerol-activated Ca
2+
 entry pathway (Tesfai et al., 2001) that has been 
postulated to involve members of the TRP protein family (Ma et al., 2000). An 
alternative possibility is that the non-SOCE pathway represents a form of the 
arachidonic acid-activated Ca
2+
 entry pathway (Broad et al., 2009) or the arachidonate-
regulated Ca
2+
 current  [IARC, Mignen & Shuttleworth, 2000]  (Luo et al., 2001; Peppiatt 
et al., 2004). In differentiated N-type cells Ca
2+
 release from the ER is propagated along 
neurites (Riddoch et al., 2007). A non-SOCE pathway provides a potential mechanism 
whereby more remote neuritic elements of ER can refill with Ca
2+
 in readiness for a 
subsequent stimulus.  
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Figure 8.1 Ca
2+
 signalling and the switch from proliferation to 
differentiation in N-type SH-SY5Y cells 
Schematic diagram showing how the results presented in this thesis contribute to the 
understanding of Ca
2+
 signalling in N-type SH-SY5Y cells. In proliferating cells, 
depletion of ER Ca
2+
 stores activates SOCE via a complex involving STIM1 in the ER 
membrane and Orai1 in the PM, enabling the ER to refill with Ca
2+
. In differentiated 
cells STIM1 and Orai1 are down-regulated, replaced by an up-regulation of TRPC1. 
Depletion of ER Ca
2+
stores activates a non-SOCE pathway via TRPC1 channels. 
 
 
 
 
 
 
 
 
 
 
 
Proliferating Differentiated
ER membrane
ER lumen
PM
Cytosol
Extracellular
STIM1
Orai1
SOCE
Ca2+
ER membrane
ER lumen
PM
Cytosol
Extracellular
TRPC1
non-SOCE
Ca2+
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8.2 Future Studies 
The key results from this thesis have revealed that following 7 day 9cRA-induced 
differentiation of proliferating N-type cells the expression of STIM1, Orai1 and TRPC1 
are altered. Due to time constraints, the sequence of change in protein expression was 
not determined. Measuring the expression of these proteins throughout the 7 days of 
9cRA treatment will be required to determine the relationship between STIM1, Orai1 
and TRPC1. For example, the up-regulation of TRPC1 may precede STIM1 and Orai1 
down-regulation and therefore TRPC1 may be a negative regulator of STIM1 and 
Orai1. This could be tested by overexpressing TRPC1 in proliferating cells and 
determining the effect on STIM1 and Orai1 expression, SOCE and differentiation. 
 
Interestingly, non-SOCE (IARC) and SOCE pathways have been reported to operate in a 
reciprocal manner, such that in the absence of SOCE, non-SOCE becomes the 
predominant pathway for Ca
2+
 entry (Mignen et al., 2001; Luo et al., 2001; Moneer & 
Taylor, 2001; Peppiatt et al., 2004). The notion that non-SOCE could be actively 
attenuated by SOCE (Mignen et al., 2001; Luo et al., 2001) would be consistent with an 
alternative protein expression profile in which STIM1 and/or Orai1 down-regulation is a 
driver for TRPC1 up-regulation. STIM1 has been shown to determine the function of 
TRPC1 (Alicia et al., 2008); a decrease in STIM1 expression may therefore allow 
TRPC1 to increase. Orai1 has been found to mediate the interaction between STIM1 
and TRPC1 (Ong et al., 2007; Cheng et al., 2008), perhaps down-regulation in Orai1 
expression is the enabling step and this then affects STIM1 and TRPC1 expression. This 
would be consistent with the suggestion in this thesis that Orai1 is a negative regulator 
of differentiation in these cells. Ultimately there are many possible interactions between 
the three key Ca
2+
 signalling proteins that could result in down-regulated STIM1 and 
Orai1 and up-regulated TRPC1 expression. Determining these interactions and their 
timelines will be key to understanding the molecular mechanisms involved in the switch 
from proliferation to differentiation. 
 
The increase in Bcl-2 expression observed in differentiated SH-SY5Y cells is associated 
with an increased resistance to apoptosis (Lasorella et al., 1995). Bcl-2 expression is 
high in neuroblasts which show low rates of spontaneous apoptosis and low in 
substrate-adherent cells which show high rates of spontaneous apoptosis (Piacentini et 
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al., 1996). Overexpression of Bcl-2 has been reported to down-regulate SOCE (Pinton 
et al., 2000; Vanden Abeele et al., 2002). It will be interesting to know whether the 
increased expression of Bcl-2 following 9cRA-induced differentiation plays a role in 
down-regulating STIM1 and/or Orai1 in N-type cells. 
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8.3 Conclusion 
Neuroblastoma tumours are predominantly composed of continually proliferating 
neuroblasts. RA induces differentiation and inhibits proliferation of neuroblastoma cells 
(Sidell, 1982). This effect underlies the use of RA in the treatment of neuroblastoma 
(Matthay et al., 1999, 2009; Reynolds et al., 2003). In the treatment of cancer, three key 
considerations are inhibition of proliferation, induction of differentiation and induction 
of apoptosis (Bergner et al., 2008). Understanding changes involved in the switch from 
proliferation to differentiation are therefore essential in the treatment of neuroblastoma 
as this provides further understanding of how to move proliferating cells towards a 
differentiated state (i.e. neurons) to enable the conversion of malignant tumours into 
benign tumours. The results obtained in this thesis have revealed that changes in Orai1 
and TRPC1 expression are involved in the switch from proliferation to differentiation 
and that changes in STIM1 expression may act to stabilise the differentiated state. 
 
In airway smooth muscle cells SOCE mediated by STIM1 and Orai1 was identified as 
playing a key role in proliferation. It was proposed that STIM1/Orai1 could represent a 
new drug target in the treatment of chronic asthma patients to attenuate proliferation and 
subsequent airway remodelling (Zou et al., 2011).    
 
Likewise in the treatment of neuroblastoma, Orai1, STIM1 and TRPC1 could represent 
new drug targets in the induction of differentiation. Drugs designed to inhibit Orai1 and 
stimulate TRPC1 expression would promote differentiation. Furthermore inhibition of 
STIM1 may further help the cells retain a differentiated state. On the contrary drugs 
designed to stimulate Orai1 and STIM1 expression and inhibit TRPC1 expression could 
be used to promote differentiation if so required. 
 
Further understanding of the relationship between these proteins as discussed (8.2 
Future work) is required to reveal priority drug targets (e.g. Orai1). Certainly in the 
proliferating airway smooth muscle cells mentioned above a much higher increase in 
Orai1 mRNA than STIM1 mRNA was associated with increased proliferation (Zou et 
al., 2011).  
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